var title_f29_2_29728="Urticaria 1";
var content_f29_2_29728=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F72519&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F72519&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Urticaria",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 252px; height: 384px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Urticaria is characterized by circumscribed, raised, erythematous, and extremely pruritic lesions. They typically appear in one area, resolve over the course of several hours, and then reappear elsewhere. Individual lesions may enlarge and develop central pallor before fading.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Andrew Samel, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_2_29728=[""].join("\n");
var outline_f29_2_29728=null;
var title_f29_2_29729="Thumb extension against resistance";
var content_f29_2_29729=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F83561&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F83561&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Thumb extension against resistance",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 405px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGVAhwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDmLJ8oua0Y+lYmnSAoOecVswuCo5rx5rU9eL0LSdKlA461EnWpqzNBh4pM80snAqJetAFmOrC1XiFWVHFJjJVFSoKjXpTwelSA/pTKeOab39qAAU9aZipFFTYB68nrUyiokHFTx0mBNEvFW4VqCIVZjGBVIlkjdBVeY4qZzgVSnehsSRWmOT1piDmlPLVPElQzQkjXAq3EtRRrx7VZShEMmXgUhJzTS3FN5xVXJsEhqDPzU+Vj0BqFTlqlspIvpnyTVWAZlOatL/x78+lQ265c1b2JRaHApje1PPSmjrzSAYV4pMVIefxo280mFyMDNKRilxtzQeRSGAFHTHNJ0pyjJ9qAAjNKB6U4jAp0dMQRr0xUwWmKKeWxTWgmIwpDxSFsnmmk5IoCwvPWlAyevFKKVaAGMeabtqYLuNLtosBGq+vWgLzT8c1Ii0JAJFHk81r2kG2PcfrVSKPkVoB/LjwcV004pamcmU7lv3gAqldPuOKsTyAMWzzVKRt74qKkhxQ3GaeE9BSonBqeNOc+lZqNymxqIAOacMBsnGKlCH8Ka6ndkGtLWJuJgHFNkX5eOtSKcHmnNyKYFMISeaegwehxUxjJBxTkTkA0lHUGMQZOcYFS54HFO2he1KMEc1okK45QMZJFNBUE+tMZyOlQM5ByTzQ5W0ESyygDFVGmOTzTJZMt1qBmyazlNstI+cLG+eMfP0xwa3tL1ETp+8IyOODXNtDsOzIx9KQQMj/uywJHY1q5KRahbY7+zuUfK7uRV9WGRyDXndre3NrI2csD61v2niCNowkq7XAxnFZuPYpPudHIeCOtRIfmqkNTheMEMCPrUttdxswwfzpWC5qRDvVpBxVa3ZWAwc1cUVLKCnd6COlKOlSA9elNPWkpR1oAeg9qkVcdqbGKnA4oAZnGKmiIOKqyNj6VNbNkikBoxDpVhc4qO36VMTihEPcrzPxVGVsmrNy3aqf3m4qWWth0a5PNXYkHaooY6txrgUgBRj1p2aXoBSUCAHNLnANKBio5DgUARTPzSW43MDTGOTVm0X5qAZdlG2DFV7XrVu5XEAzVS3zk1ctCFqWc00+vekagZxU3HYcKCe9NPFNJouFhzUlCjmnYpDGHrUiU3HApQeaAZIwzmheD7UinigUXJsPzzxS9utRZ5p4yadwYoHNKF4oAyfalpIBQOtPVCPxpVWrCLkZq0rktjFUKpqPPPWnSHtTQMU32BDkXJzU0a0yMY+lSrwacdBMsx4UZ6GormUbfemSSFVwKqu5arlPSyEkMkkLE5pEXmgDmpFHNZblkkajvU64AqAGpFY7q0iyWTbtoNR7smhmzwKaOvvVOQrC45qUJlc1GB0FW1ACdM8VUVcGQqO2KDhR0p6jHXNQSNyeab0EiXIK5PSonfHNDTBUA71WZ896TmOwSSZ6VCWyCKVuaFTnJ5FZvUqxGV4qMcdqsOMnimbcdqloLnzZg+Y3mD3qVAPMJXnjJHpW1JZL9pYlfkIGcdqiutKVJN0eQ2Mg561dzo2KbPGygOmPpVZokbPlHLZ6NxU91BPb4GwlSeDUDBxMoCEcZzTV0PRkK2rlsq7Ic9Ksw3t1ZMG++F6gimTTNGCcHpT0mEsIDH7wqlIlxXQ1LXxOm1Q8ZUg9RXQ2WtwTMAJQ27oK4c24wdoBHeqywlHPLKc8YqWkxWPVxcqVypBFKlypOCR+FeZ297dQElZS47gmte219FAMsRDeo70uXsB3YYHHIqRMHvXO2WrW0qCRZlz1Ksa1rS8gnAKOA31qGmBqInepCMCmW7b1Bp79DUgUZzyamsjkiqly3zVa08ZxTaA2oelLI+BTUOFqGZ+ai4rEEr5PvToEyc1Gqlmq5AmBQMmjQAVIKQCl6UCAjJpyrxzQKdQIRuKqTN1qxK3H0qlKc0mNAnar9ovzis+PrWrYDJFNbilsWL0/u6qW44q3f/cAqvb/dqpq7JjsPI5pCPantjNMzmoGBpuOc0rdelIoNIY4CkNJTc80DH9B3pVGTSDpSrQAue1KKaOaeKYgAqYY/GosVIOOTQtxMcOBilRcmmKcmp0GBTRLHqKfkqMU1OcU9zWiJIiO5oGKVjTKlsokzjpRvABpm4etMHzGi4rEhJYZNMHQ1I3CYqMjFMBB1p69TUYNPXpSuNkgOKcGFQjrmpFXiqQh6kUH2pBR2qhD0POe9WEJYE9qqofmqYPheDVxdhMJnxnGelUy5NSStknNQn681EpXGkKTml25X6UKAOtPpJAREUr5xxUm3uaMZOKYDEUntS7DzU4wq0zJ7GqsI8YS2dlCkD5lyahliI2iQfNH3z1FdBZ20bQqyDc5XB9j3qK6tIrm22nqp/I1nc6zJjQXE67xlR0PrSnTY2mZgvyt8v0pnklDiJykqH7h6GlN4xlQMGAbkj3ouOxDLoIlXEfUdT61nPoWxn2jAycexrsraeFnIdtoAz9au+TE8TfIB3+tHMFrHmcdhMATnjOMGq08MiA5X5vpXo0mmIZiDgIRuxjvVO80mJSHAyduM01ILHnqZXjYc96lEZkX0FdXNpUCxk8AnqSKy5NLKAkE464FPmuKxiSQDkLyfUU2KW6t8GGVxtrYhtigO4jJqzBbxD7w+WquKxWsfFV9ZYD/vU7g10lj4vt7ohZmMDHtWTJpVvcgGIDOKz7vw7cIwkjGR7UnysORnaNcpKNyuGHqK2tNHyKa8ohubvT22lXC+hrotK8Z/Zj5dxDuA7ik46aEnpGcLVdzmsO38XadOACzIfetK11GzuSPKnQ57ZrGzQF2Fc1bjFRRAY4Ofep/TikJjsUd6QGlFMQ7sOKCaO1NY0ARyniqbkZqxM3HWqv3jxSsNEkXJrasF71mW0eWHBrZtU2gVUVqTLYi1DOQKihPy80+/b5xUafdonuEVoObmko70vfNSPYSg8CnUw0hidRSd6KXOBQA4U/HFRqeaVTnigCQAUCkApec8UCJF6CpMZFRqOKkUZqkSNUYqwnpTNuKeTihCY4/KM00tSOeKYTxQ5DSFyTSZpoPFAGRmluPYRzk9aljG0fWogMvUo5/CmmJof1NMl4xil3AVE7ZaqvoJIBTxTF96kHWkgYueKePaoz2pV61SYE38I9aYxxQTikOTVX0EPXpxTgcDmmJ0FOIOcChCIWOTSLTmBU80oHGRSsAYzT1HIpFI29KeBxVAOYfLmo1XmnM5IxSqvy09xAoyaXYD2pyDFPCE9qtILnmMyeVPviPyyDeQO3vVeQxylmJCttyccbqeYLqKU5kR0JITjtSgb1MhQbosnp1rA60yokf2iJzgFxw271rIu7cQXpBDGNk+6eqn29q6Nowkm+Jc7xmQds1BqEIv0ZI8Fj909MUJlM52WGeDzETD5+Za29L1DhRLnfjmq9nC8YFvLjcVJB9RUVxbvvV4gAD1yaHYav1N1GWd+GPWp5oQzr8oKhc5rnbe4lt3ORjB5BPUVuadeiT5c/MvGDUtWGV57dWfYoyTzz2qjdWU28kEMo7V0XlhmDKAcjpUU8LoC2OOlCBM5SWAIADCMnrVP7OnzEEqxPC11RWKWMjAV/esye1aNy2Ac0+YfJczI4XhwfmB7Vu6aHcbWwazTceW4DitDTp43dcEDnmm3cLNGjLpMVwmHjGD3xWRd+DreVsxqVbsRXa6eylVDYxWksCuBsXrTVyeY8kuvBVzEC8DE+xrIltLm0bEqsh/vKa9wksniUsOVrC1jSIbuJyI13Drim5NbiVmefWOpanbKTb3DMAejc11Wl+JnYBb+BkP99elcreW76fdeXn5P4a37JxNa4KjpUtJjcL7nYWtxFcx74XDD2NWOlcHHBc2kpltZSmTnb2rYsvE0ZUJeKY3HBPY1FjN030OkLVFI1QxXkNwmYnVgfQ0134NBAyV80QruemD5jV61i6HFMC1bR4xWjEDjkVXhUACrsOMVcTNszb8EP7VHGflqbUTmSoUHyionuXHYdnmnZ9qZ0pVqCh1NalpGoEIfWmHk8UUopAKOKelIBzTo+tAEijjNSKvOcU1alUVSJF21Fc3MVpC0s7BUH6/SrC8iuTuZG1TXJo35gt22Ko7nuatK7HCPMyzL4kkYk21mWjHdjgmpLfxNbu4S6je3J6Fun51ObJQgwuOPSs3ULFZUIKg1pKlobKMWdOrq6gqQQehHeg9K43Q7+TTLsWlwxa2c4Un+A12INYNW0ZlKPKxelJnFIxpOc0XJHDinqQBzUYND/dpiFZsnikHWmdqFpNjsTqMil70qcJTTVPYkUcmnrTBxTkoQMUjFOTpTTSpVpiH9xinMcUi01jzVXsIjkOWpR0ApOtPAqOoxQAKkA4pvcVLjjitEIQR8UoGKevNPCcc9K0S7CI05fpVxY+OKrIMNx1q0jnbzVxRDPKHklRyXX50QFifu1nRyvNGQjqCwIxVi61CSRfs0CKzv/rD1wOwqfStJn80OyBHAzvfqPoK57HbsiaK2McUayFmIxkDrn3psypEk3OHUl0A9fStGWP7MWiB3SSKXU98+9VIrZpEjMp3SzHjI4z3qbDjLuURbhlgljX5lBJB7Z7VTu3KhQke75ug7fWtuSPysQL8zKc8HsarypHAV8wh5HbhRSsUmYtzCmB5hG8+lMeKSKQOnXHA7mtG9tvJiZyn3249qrSFoguMSP2OaClcs2F+rOqt1HXJ5FbyTJL8uVJ+lc0lqkjZBPnHqVFa1lE8OC53DoAKQO25dbTA5Ddu4qwNHjdQAuSfWtCyjLAZPXpmtS1gAwDkH3rSMbmUqjRwWq+Hcq23Ib0xXJypJaTeXKdjL91uxr3K6tYpoQpH+NefeMNH+V2CA+lTODiaUqvNoyPQLwyxICck8AGu00xg4yeCory7wvcyJcmJx90jBr03TRhAf4qI7hVVjVwGU5xjvXP3SCOdiB8p966AOPLJGCG/SsnUFBJIA4pz2MoaM8/8Z2QCmVQMr82aq6NlrcOmSpGeK6bxFD5lkw4I2mub8DtuSSBuqkgZ9KlbG7dlc1NrPHgLgmqk+nGVdpUe9ddbWCuvTGPQU5rDB6VJPOcGdJmik/0aR0x6Hil+06panaWEinua7oabuUmon0gYOV3D3HSi4XizkYNauoeZbck+1alh4ttcBblXi98cVoT6MMhsdO1ZVzoQIZkQFO4ouLlizo7PXLC5bEdxHn3OK0o7uIgFZUOf9oV5zJoa87Vwe2KzbjSLzdshmlU9uTQiHRR6fctvfIOR9acv3RXnUdtr1jCsdtdPKxPO7nFblne6/bxKt3bRzHPUHFEk2LksdTSDrXLXHiDULOYG4tFMZ7L1FWYPFunMB53mRE/3hjFTysOVnRnpUTVVi1SymAMdzEc9PmqcSxvjbIp+hpC1HClFAx9afjHNIQnoKkTrULOi/edR9TUsTKxO1lP0NAFhOalFQg9KUyKv3mC/U0ySdTjFc1oNoTqN7IcZaVjWxNf20UbMZo8gEgZqPQIdkQdhln+Y/jW9FXZcNE2bE0CC3DYxxzWBeIA5IPSukumXyyBkHrWBOgbd6111EioPQ5vU4kk3A4BPQ1ueG71rmw2yHMsR2MfX0rI1ONgcjtUfhq48nVXiJwsq/qK46i6lyjeJ15OTSk8VGCc80E81iYDs81IxyKhzUv8ADzQhMjPanKKQCpAvFG4yZemKaaOlIKokXBNPHFNHSlz1poQpFIvFLSd6YEmeKYx/OnDmo5Kb2EAqVOajU8U9aIgSgc08cUwEU9SK1RI5QcipnbaOSKhDc02VtxHYVadhE8fA5xThJx2qv5vygDrTuPWmmJo5DSNLhhc7lUfKGz6mpbt2NzA6qFUgox9Md61fIaMYwGXsao6pZNcwnAMbg5yDyfWs2zWLu9SosSC2mJJknkIAPtmp5LcM4AOPLTsOhqKxjKJy2WyFBPpWlaxthgRknJ+tJdi3oZS25Yl8YYZznvVa2st87zSAbjwvHSunSNHgBwMHjpUUcKiXeRyOOKOUfOYd1ponh+ZeM81jXOm7JEAQnaeOOCK9BkSN1HGeOgqq1kMsSC2fwwKXJYqNTucYkPAKfyxVu1IEuWHC8D61uXOmKSzKCrexrFu4vsxYms3oa3UtDctpFJXoARz/AI1rRNu24Ocdc1xmnX25wldRbTfcPtzWkJGFSNjQkKnpxisbxAqvandjOOK0JJScAH8TWPq5LQnJ4pzd0FNao4DT4ymuyxp90EGvRtOOUCnjiuJ0iPdqk8nfOK7SyJCjtjrWcTes9TSZsLyBj2qpcgMOOuPzqy4+TI5NVmXAOOlU9TFOxhaymbNwRXE+Hc22qnBxlsfrXe6qheFwD29K4lYvIvd/Qhs81KOhaxPTtL2yQjH41dMQAziszw23m2obua2ihwcZxVWuc70ZV2KF6UgCmpNhNNdCnKjJo5SSOSMYycc1WkgUDGOfpVwEE89RQVLDIGaTjqUmZTWit/D19qYmmAybsDCe3WtiNB6GptuEwQaFAfMzBESLKSI2z0OKmaMkbm644ArXhgGemc+tWVgT+6PamoMUpI5GbSTMfMmGWPqKxNT8NLdOGIAC9gK9LNpkZPSoZLNSMY/Sl7Noaqanl6+GURflTBHQimvoTxLlJJF78Ma9JlsBjIHSqE1luY8UmmUp3PN5rXVYh/o93MBnoTnFWIoNYvcItxNsHVjxXeLpgY8rgd+K1bexiRAFUflTjG4Smkedr4cmZQJpZZGHcsaSXRri3Q+RNMp/3q9MNomMYFM+wow5AIrVU0CqrsebWP8AbEbbHuXKdMmtu00gz/NcPLITyea66HToQ+RGvX0rUt7SFBlgAPShUmRUqRWx55q+lwwxwKItpZxjPU10mlQgquO1V/EVyl1q0FtEBshBPHqa1NMiEYHGa1pRXNoJP3CS6TIPHAFY1xFhTxXQ3AGCeayrwZB+laVCoHNajF5iE1z1t+41e1b/AG8GusuAFQ5rlLw7bqEjr5g/nXJNG+trHcE4JpKAc4NFcpyiqOaexwMUiYyKc3JoQCCpF5NNUZp6jBprcQ49KTvSv1pveqe4kOB4oz70lJRcLDyeKQGjtSYoAmTvSPzSJQTV9CRKch59aTANKOKAJOtGe1NVu1IzVSYrDy+KYZOetQu59aaDzScilEsBu5pwkPc1CentSU7k2LBZetUJJTLKQvA9ainusttXqetT2UZOABknrRdydkCVldieSAwwMjucU4Dy3DBSM+lXRGFU549jVSUh2O3gZxVPQpO4+IgHK5w2f+A04/TB/pTFcDA6ipGO4Z6A9PrTTARCFYDPFT+ZhdpGT65qpJ8g3Yzxziq8lx3B60nKxoo3LrSKoJbBGOlcn4jnCQue3WtZ7ncK4jxVfF5fJX15rKTub0oWZLoEhluB6A13dqw2ADkCuL8LRhYg5HJ6V2MA2Rr79apaMiq7snmI29qytVlHkEj0q/Mc8HjvWVqOWQ9MYobCmjD0lSszP3LV19iQ0efSuRtD5U4U9zxXU2X+rUevFJaFVFdmkrZ59KiuBgZHQelWI1G3b+tRXKHbg8VdtDnvZmZcDOfeuU1S2KyMQK6uUFW5rLv4RIm7GeKzOiOxqeCn32fqVOMV1yp8pLccVwngyRor+SI8BhkD3FehQyCRNrAcV00kmtTnqXUij5ab+tNkAyQOauTRKOQOaijQd+hrRqxN0UZIAcEdakjjZRzzVxkUHqMUuUA6iptqJyII4h36GpDGOgORUqugHzEVG80Q6MAafKhczESPDCkWXazAkHBqnd6gscbEOM1j22o/v2Ehznmk3FaFxi5I6kzDPAxT0fc2SBmsUXiZGGBFTLfKO9S5IVmaMihicnr2qF4h2AqmdSRerDNQyarGOrj86lyTBKRccKvLDiniRQOB+Fc7qWtRxx7lcH8aZBr8EsfDrn60k0jVU21ex0YlycVMHUL1rmf7XRRlnXH1qndeJLeEczAfU01Oweyb2Ote5EeWBrJ1TX0tYWJfLHhRnqa5G48Tvc5Wyjkmf/ZFYkY1G713y7sDCqGwpzt+vvSlUeyNI0V9o7fR1eYtPJ80kh3E11Oncg/SsjTIjFCgx0Fa9plG45rSjpYiWo+4brnpWdc8jpxWlcpjrWVcthCBWs2VFGJfckls49K5i8UNf2yDkmUdPrXS6gfkJz0rl4n365Bk8IS1ck2b2djuTjAxSLTYTuQE88U8VzHISoOKTPNSJ9ymYBzmmIBT1PFMHalFIdiQnmkJ5phPNHencVh2aWmU5aAHZ4oBpKO9O4rD0OBR/FSdqOlNMVh4pN3FNY0wnihyCw/dimls9DURNIG5pcw7EjcmlA9aapzUgPNNCJF5AFBXng0inDClZua1WxJzkUv74sfWtHTNWikneJD869RXF22qiTcwbgiodE1FE16UEjLgH601Fp6Gjgmj0q4uMqT+VRbljhy/Hfmq8EiyoGJ4FQ3cnnSiNeVHJqZNkQV9C1E/m8n61aGNnrVWIhEyaekgZuuB7URdhvUdMdi5IAArOlnKnI2kVemYbccY96ybuTGQQo9xRLc0psytWvvLQ7P9Z1zXGnfd3e92yxNb2szjyn6fWs3w/b75RPOMAn5R60JHTeysjrtDtPLiQtwcdK6CJOear2EQKhgK1FjAXgU1G7OWcijcHnnpWTdyKy7RzWveLhSB1rAdCJCG/SpaNaaujM3H7WMDvXVab87gDnaO9cgzbNURe2M11uhsDFuznJ60RKmbsa/KMim3Kbl9TT4mBIxU6gFfrW0Ujkk3c529jIGP1rLuG3JtLbQP1rpNQjzniud8sJNIzjPYZ7VjJWZ0U3dFS3m+w6lBOG+TcA30rsdU1600uETXNwkceM5JrjdVRfIwOv8AKvnnx5qmpz61Pb3l1I8cTbVXPGK2oXleCJq2XvM9413416Lalo7UvcMvHyjiuZk+O8YXEdjJntk14Jk+1BNdXsE92c3teyPbZfjpcMTixIHb5qrt8brth/x6Y/4FXjNOAo+rwGqr7HsS/Ge5b/WWzAexpT8Y3I/493z9a8exxSN0qfYQH7Vnpd98WNRmkAigUJnoTVG6+Jury4KKiMBgEVwA6807NV7GC6B7aZ6Bb/FLWo1wwjY+tSN8VdZb+BK87zxSil7GHYPazO8k+JWsP1ZFz6Cmf8J5qUp/eXbL/urXD88dKcB7UvYwGqsjv4PFiS/8fdxcSeozgVbPijTwn7pZUPqrmvOVUjmpVFQ6UTVVZHaT+KQchJ7rHpvpbTxPaxybpInkbuZGJriyRREryyLHEu52OABS9kh+0kewaL41a6kW2sYlDkcADGK7/wAL2AQGSTLTyHc7GvOfh94aNptmkGZWGTXs2jW3lRrgde9c7S5rIt3Ubs2LUL+FXICI+aoxJJExHG3qDT/PyMenUV0KVtyEr7E93KCCc4rDvJODzxVqa4B4zisu5lHPOaiczaCMrUZSUOM1ysFxjWAuRuNbev30VpaSSyMFVQSc15z4W1JtR1qW4/hZsKPasPi1LqSsrHtlk26EVYXrVHSzmBa0Y8VijlYpOBigHA5pr/epR0oELuzQWpjcU3NJsZLmkBpoPFGcii4DxyakFRA08GmIfmk703NBPPNAhwNKTTA2KazZBp3CwrH3qMvTWY5qMg4pXGkSb6UHJqEHmpVpoLEoOKfkcVCTSbjTTJLG6kLVDvpdwp3FY+XNO8U3MaZUiQfWpX8UTi6huEQq0ZyfcV5/FK8JBQkVpW2oqflnXn1Few6UdzmjVex9A+F/GKapCiI4BA5B612FndIULE8nk18y6bdtb3C3FlLtcc4z1r1Twjf6jrUWZF8mAcbgeWrjrUbao6Kck9Gd5Jqr3FyYbblVPJ7VtWYIUFicmsrTLeG3UALtPv3rY85VABIFcsVqbTfRC3JIAKnDfzrIvpC5+Yjb61cvJTuXbj69qzLiQOSCAKoIqxzmuNuVYhy0hCD86t6chfU0iT/UQKF+prA1vUoYNVj8xhiIE/jVjwPeXtzfTyOVa1d8p6irS901vqeraenyACtBV+Xmqmn8KOMmr7DII7VcVZHJJ6mddpuDCsC6XaSwI+tdBfOIoySccda5u7IkT5uIz0FYz3N6TOdvZgupRydsEZrS0HV1dY4kPzMa5fxvONPszcRqThsYFVvhvfnUb64lkiMRXAUGnGN1c2lbY9rsSWXJrRVAMHBzWRpbkxgVswnp6itYu5ySVmV7tQV6VzWpRbZckfLnJrr5UBFYmrQb1K0qkdLhTlZnH6i4aJjjqMD6V4P8U7P7ProlGcSrmvdtVyqthRjNeQ/FiIvFbynBIJGaVB2mjaquamzzImk/CnUAZr0jztxPSpFGcGhR0p+KlstITpTGNK7VGTmhITdhQadUY608dKbQkxfagD0pVHFOA9BU3KAVIgpFWplFQ2aJAop/QUh4qzYafc6hMEtoi3v2FS+7LW+hVVWkcJGCzE4AHevT/Afg4xhbq7TMzYIH90VpeB/AqWxS4ul8yY45PQV6nY6aIgqqv5CuapVv7sTaMeXVlbRtNEWwBeK6+xgCgZ4GKjsbQRgcfWtDGAMdKKcLGdSbYjYAOKo3SB+c7W9RVxmIBAqrKAAc/lWktQg7GZcbwMDDcdcVh3+UVm5WuguHA5OBXn/xB8QR6Vp0ku4bzwi+prBq7sdMZHmXxP1x5bkafFKSo5kwf0qT4dKfOU4rgbieS7unmlJaSRtxNenfDq2OUODWlRckLGXM5zuey6VxAM1oKcCqVj8sKire75cVwkvcd1Jopu6kL4FFwFfmm96Ac0YpDHDpSj6UgFKOtMQ4dKKTmkJoAfnFIeTTN2KFamKxIelMPQ0bs04UAR4pjdKmYVBJwaBgCMgU/NRClBzQgJQeKQnikFKelMBqnrmnBh603FL+FID4nApwXOABmnRxtJIqIMsTgCvSfCfg1Qiz3i7nPIU9q92U1FXOGnTc3ocHZ6deyMhijkCkgZxX0R4QtUs9Mt4jxhRn64rDvNOjtrMBI1ALAcD3rrdKjCRrnBwB1rkrT5onVClyM24v9X2I+tIAVZygyaImTHCipHmC9M8Vy2NCtNIxUgqAPU1QvJx5LlCMgcVYu7mKPl3IbrisLUr4GNyhwByeOtJmsUeYeKIn1LxJHbREkAgHB/OvWPC+mraQxoq4wAK878KWEtx4iuruc5DncgI6DNewaam1V4rabskiU73Z0unjYoz2q8T3xgVStT8tWmG9Oe3b1pRfQwluUb1wwzyQM1zd46ocMM/3QvY1v6nLsAQDk+naudunIRj0yePespm1I5zVokuriGKVdyk5INS6Tax22syxRoFBAPAoTEmtwKDnkk+1WtRU23iWJhwHjFa017hpP4kdxpi7FHpit2BuciucsJPu56Ct6GQcYNETCaLvVOSKyNUHDBTzWoH3DBqjfpwcirnqjKO557rat9pji52g5PvXmnxOgMmjlgPut2r1LWwTdH0rj9fsxexi3cDDnFc0XyyudrV4Hg8NnPL9xCauxaNdsP8AVN+Ve26X4TtoUXdGM+9bkWgWqgAIv5V1SxRxKikfPy6BeHpE35U4+Hb3/nm35V9Dro1qP4FNI+k2wH3B+VR9ZZfs0fOjeHrzOfLP5VJH4WvpOkTflX0GNJts/cX8qv2mlWwU4Raf1pk+yifPlr4KvJCNyGtSH4fXL4yDXuQsYEbhFq5FBGMfKtRLFSGqcTwgfDu49DTl+Hdx6GvehDH/AHRS+Smfuis/rEilGJ4Uvw8n75qZPh5LXuDRJj7orD1a4Msv2K14P/LRx29qSrSbLjFPoeS2/gtZrvyY8tGhwzevtXo/hzwrBbKgSMKBXTaRpEcESgICa6OyswvRe9U5SloXdQ2Kun6XsVRtHFbMVoIwPl5q5DGFAGOalkAA/Cto07amDk2yuqKOCMUyTg/L0p0jc+9RO2BnNW9BWI5HIHNUZnyeDz3NWpHDCs+4KgHHFZyZrFGVrN2ltBJI7AIgJJzXzT458QNruruyt/o0ZKxjPX3r0D4x+JzGh0mzc+Y/MpHYeleNhHOPlb8qulH7TCpK3uos2UfmXCAete3+ALLZAhxXlHhewa4vEBHGa988MWfkW6DGOKxxEugoLQ6SFdqCpG9qanSnCuMBuTR1NONNHWgY4cdKeOlNUU/OBihCCkPWgnFMLUxji2BTS+elM5P0p23A5oAQmhc+tBxinLQBIOlLmk7UmTimIVmqGU05jyKjfkigA/hoWmHORUqLkUAOHSjBx0pNuKepGMUCG0oHFOI9KKYHyb4FsVudaUyAMF5wa90tLVRCu0DIFeX6NpUukXhmCk/hXcxa4BbbY8mUjCivTlLm1FTjyaDtan3yR2sQ3FXBc+ldDpRLKNw4461iaVbgRs0vLt1J9a3bPbGFBasJs1Svqam8IcsOKgmnLZIO38KlcDYCDuP0qpMNykk7TnpWbGkROoZS7HOOmawdWDTusCABpW21szuI4Tnk+tVvDdv9u1lpX5SIYH1oSu7FN2TZWtNPFlqyKBgeWBXX6cOgJ4qLVrDbexuRjIxn3qaxwgwwwwNVN3kZJ+6btucAVYMqohLckfpVOE/Lw30pHXcrcMyk04mT3MzUZshmLcn+VYF04kBZic/XtWtexq5dipGOKxtSKpbkn8KzkdFNaFPw8BP4jVY+VRSTWt4tg8rUrOUjhgVz71V8AQCTVbmTpgAV0vjezMulrKo+aFg34V004fuwnL3xulyhokBIyBit21cn3rkNHkZ40JrqrVxgY61hsyZo2I26fypl8o2568dKjjlYAbTmnzkCPoSxH41qndGD3OB8Qoxucj8q5jUm2zRSd0YZ+ldhqsbSzPu7dq5HVYF2SAE7hXK9zugvdOhhIZAR0NWF6Vm6HL52mwseu2tMcCs3uc73AtULvTnPFVyctTQE0YyavwDANUrcZrRiXCUdSWVjkyYqzGKrgfvatKOlKQxwpwpB1pScCkBn63fLYWbSdZG+VB6mqeg2jogklX94/LH1NZd1OdW18KvNvbnA9CfWuxsIgoQY4rWMbFr3UadgECKO9bVsowMdKz7eIMBxitKIADAreETOTROJFDY4JpXZdvNMEMYBOMk85qG7k2qOOBXTayItroQSMNx5qq8gORUo5H1pkkSqMAcnrWcrs0jYpTvg4U/WsLXryaO38u1TMz/KCeg966hYFIIRB9TXJeOHktfsq2q7nV8sPUVjJO1zaFrpHGReFLf7S7akvmyyHJkb1qxc/D+0aLfboufTFd9p1tHeWas6gswyeOlOgiezk2Nyh6VDvuD0Z5cvhFrWUYQoc9RxW/Dpmq2sAaC6bA7EZr0R7GK5izgZ+lVpoRbhYyMlj0pOPcXOn0PP5LvXov8AlonH+zTV1PWQfmlX/vmu3vLYMCCgA+lU/wCzY9vzKB+FJ0x3izkzqurKc+YG+q0q+JtSg/10KOPbit27sEUEoKxrq3Uggrg1DVtxqKZYs/GcbEC4tmX3Wti18QWF0wVZdrHs3FcRcWWMmPg+lQIFDASLRyroLkR6hvDDKnINKBXE6RqsljKqu++2Y4Of4a7MMGUMpyDzmoaaM3HlHluaQtTaM+tSIduoBplOXmmBYTpyaDTFNP4xQSRtUT1MxqBjlqYxQKlj4FRrUqjpigQppAKcaBQAoNLxTQMGjNMLHlmpSW1uuCoeQ9FHWqmjWv2qVriSMKc4CjtU2kWbzyG4n5duea27S2W3LDuTmu23KVe4QIEcL2qeY+UuSeDStHnBHFQ3gLQ7c1m9TVFqPUDEu0yHOOKY97IwG/DA+9YhuvIO2Rc4rM1LWrWzjaSaQoB2J603FsaaRua/qAhssd+2a2fBsZtrESyD55TuNeU22sx6zqakzAW6HKqT1r0Ox1RY4VUMNnb2qlFx3MpTUtEdxest1ahoyC8ZzTBsaJW43EVy0ermJwyPx3HrWjHqccq5UgP1xWb1EoWN6CQEgZ9s1bYsEwA2AOtc7DeKz5DEZq8uoHaQXPp1qotIlwbZUvd0kpwpCjrWBrkh8grt6nrW7POHVjuAUck561y2u3KrGDu4HNQ9TogjV8COIZrkg5JbGa7S/mjn06dJcbChzXm/guci3aVj95s10s12b5hb25ygP7xq6oS5Y2InG7uUPDkzxDyZxhgflJ7iushc8BR9aox2KccfMOOnWtKCMqAQckDoa55bibuWreQZ5PPrVx5QsLMoP1PNZ/y444NV7i7ZIyhYY+tUnYzcbmZfsDOx3qPWuU1tURXOdoIroLkxeZvYgCuJ8Q3Mck5SMks3ABNY7s6o6I3vDB/4lcPGBWuzcVl6LiO0jQdFGKvu/PWoa1Odu7EkbNQqCWoLbj1qaFOaYizbKRitBR8lVoB0zVo4CGo6iZUHMhqwvAquv36sLSY0OBrF8Vap/Z2nER/6+X5VHpWyzLGjO5woGSfSvO7+6fWtbMnPkRnCiqgrsaV2bPhG38uLc/3ycknrXeWartHPNYGjWi+WuevtXQwW6qowT71stXoObRqW8iqBnFTrOgJzVBYBtHJxUyW4JB3EV0RTMtO5c+0bRxgj2qtM+889u1XYvIEOzZ8/97vTZFiK/KAK2cbrcSauUYgz8heB3qXbj73GakVgPlU4qQoCBkVnaxqtBUjUIT0xXLX1qL+4nk4Ow7V/CusnQmBtvBxWJpaAiRQO5z9aiortIqDtdi6Zb+Ui46HrVjULYSQ5H3hyKsww4GPSpxHuBBpxpXViJS1uZ+jyb1KsOR2qDUyDqCKpHAzU9mht74sB8ucGql0c6vNz6YrPaFmPTmCRQVLN0FZk85YkqOOg960tRfaFiXuMmo7Gz82RSe/QUpb2Q07aszksJrgEvwprM1DTTyYTnHWum1ST/Sks4vlCjLkfyqvNEFj2p0qJR6Fc5wVypjJD8HvWTKUDHccCux1ax8xTgfNXH31sYnZWGRWaNFZjHwqFScqfSu18NXJudJhZuWX5SfXFeeGVkBXrj9a6vwHdia3uYs/cbIFE1pciWqOtzSdabThxWRmHINSRj1qLPNSIfWgCYYFBPFJngZppOaBCO3BqActUjdaXGBTAValWol6CpRxQIdSUZozTAO1GfWkJozSA8406URKFPTFWnlG4c1zCX6qeTz6U9tXVQD6etehKDbHGUTqPtgQYPpWbeahGgZi4Fcze+J7SMHzZFHsK47X/ABWJw0dmDzxuNJU2+gOUUbviXxXDbFlibzJT29K851LUri/mZ53J9u1V5pGkcs5JJphrqp01A5qlVyBHeNg0bsreoNbFj4n1O0wFnLqOzc1iHg0hFatJ7mN2jtIPHl5GoEkakfWrkfxBZWyY2H0NefNUTZqVRg+gOtNdT2HSfiXa7gtyXT/arprfx1pVwwP2uMNjucZr53Bpw61EsLF7GkMXJbo+gdV8fadHER5yE/7Nef8Aibx1JfbYbFdsQPzE9WrgMnPWtDR7GTU9RgtYQS0jYPsKUcPCGrLeKlLSKPYvAGsS6zZrb28bIy4DNjgV6zomnLbQ7F5PrWJ4E8Ow6Tp0aRIAcAE45rsrdNsmK55O70Oi7UbMlVAhU45xzSSEdR0qwycjHpVS5X5Mg1hIE7lSa4KKRnrWFqV9hWyQBVzUZAin3rgvEd6Ylcl9qj3qL3N4pDNf1+O2ictNgD3rirDV/t+pblJ2Z4zXK+JdWN3MyIx2A07w1cbJlBPeuqNG0eZnPVr3fKj3nRpd0C89RWi5z3rm/DtzvgQA9q6NOa5ZLUYsS5NXYVqGFeRV1BxzWdwJIx0qZjiOohRIcxmlcLEUbZerAqjE37zFGrXwsLJ5z2HA9TRa4zF8aasY4lsLZv3kn3iOwqLwxp4jjG5axLSGS9umupzudznntXb6VEUQd+K1SsrFPRaGxaW2xQY2xWnCHC/MAfpVe0b5QKuooreEDByZIkgxg8VNG2R1qJNuOlOUAH2rVCLC4xnNIWyCM02PnvSMeeladNS0T2yguNo59TU8nDgdeKhhbbTJZT53FRLRDvqXSwML564rE0U7pJQvZzVp5zllGelVdHjMV04b+I7qzlK8ki1pFm/CiODgYanvFjDenFV5n2NvQ4PfFTLPvXrxXRzJaGNnuZbgJdyI3RuVNYjOz6w544xWvq77ZYpR2OK51pcanNz9K5JPobU43dy6QZrp3bpnitW1At4WlYgbFzzWZaEl+e9HiK68jT/LU4aQhacbatinduxnwyNcXEkv8Tnk+1XwMLycmsyz+6FHT0FaJX5c8AfzrO45blG6wc81zOrWwdWKr15rp7hSVJyDWLfuVRsdDweKxZpE88vQ0MjE84rY+H91HFe3McrhWfBXPeq+tW5cMRxmuet0YXigMQyjqK05eZWCR7QDnkGn5xXC6TrV5ZhRPmaE9+4rsLO7jvIRJCeD2zWDVjNqxZXrUq1Gox1p6mkIkH1prHGTmlB9KY5ytCENU5Oad1qJWwaeDTCxKPqaUmot3FIZKAsSl8U0yVWeXFQmbFA7F8SZpdw9azhPzVhX4ouFjz240YjOAhHrXLeI7Ly4WVWxxziuk1vXEtkYbua8413xC07MFPFehGUpbkuKRzGpR7ZG5J/Gs4jFWrqcysSe9Vq64aI5p6vQbSEU7Ge1BAqiLDD+lNqUrxTSvFO4rEZFMYcVKR75ppGaaZMkQYINC9akYV1XgrwjPrV0jyqVtweuOtOU1FXZEKblKyM7w/4dvdamC20Z2Z5c9K9k8C+BY9Hvo55AXm29fSuw8M+H4NPt0jiiCgD0rpzahApAwa46lVyPRp0Y0/UtWUKpGAOKubMEEdaggB2r6VNLLHGuCcVzuQN3HySbV96zby62gkVHd3agbtwxXJ65rkUMbfPjHWspMuEGLrmopGrF3wB714j448Rm7na3tn+QHBOetWPGni97t2t7Rzt6FhXBMxYlick11UKH2pEVq1vdiBOTz3rS0Zys4x61melaOjoTOK6p/Cckdz2TwjIWjWu7gX5RXC+Dom8teK763GEFeXUep2omjXpVlBxUca/lUo6ViAGkcgRnNRyTKuctisLV9citgUyCRQk2PoaIcLLy2B9a5rxDfHUb1bSH5oY+pHc1h6h4jd2KKfmPAxWt4btDtDuCWbkmtlTtqwRtaRaARDK4NdNZQmPGOhqhbW+FG3NbFscABhVpXZMpF+ADFT42jG7ioosDpU/Ddq2itCLioTmnnJ6VHnnilUkn2prQolXI6kVKCMdahXGfm6U8NnpzVDJFOOarvIPO54qUt2PFZt/LtK7euazm9Coq5bsJA95ICehqyy+XdZArnLW5e3v2Zs7WIrakuA21881nF6FyjZmg0oIwaijm2uRu4qi84K9ahWb5gxzVOetyFE0NSXzLZsdhmuI84m6kJPzDiu0MgeAjrkVw+rMscwKcNkg+9RN3dzSl2Og0+UM6H0FUPEEpm1SCIdEXdim6POWUY6jpWdqN2Rrku1WYgAcU7+6O15G/ZxALkdav+TlOoNc9bzXrY8uLAx/Ea1LN78Ovmxrtzjg81nzWIlF73HT2zbTxmsLUIyinjFdu0f7rPTiuZ1i2DH5c89qUo2VxU53ZwOrDAPNc+if8TCEgck4NdVr1qY1ZgrAd65TcY72L1DCiJrJaHRRxDBGeKsaNO1nfKMnY5wRTECnnGM1HGu+9iQZB384oewbndg5FPSol4A+lLurnMrE4Ipkh+U0zf9aikkpisN3fPT91VC+CaYbg5FMdi40lRM5qAMTUmKYbDJGJPepI4yetCpk1OgxxSHcRYQTTymDipEXHWmO2DQSfMniDU3mmYbic1zkjFiSTVm8JMpzVbZ7V68EoowqNtkePWjb7VL5ee1WbWzkmYAKapySEo3KaxluAKuW+nySnhTXU6P4bkmwWWuz03w4kYGUFYyrWNY0kzzFdClK52mqlxpMsXVTXt39lRKvKiqF7o0Uin5RWXt2maexTPEZLZ06rVdkweleo3/h1GLbRXP3mgYbgdTit4YhMwlh2UvBXh5tXvFeRT5Knn3r3/wANaRHaQosaBVUdK57wJogs7KL5OSMmvQ7KEIAMUpy52bU4KnEv2UQCAmp7hkVQM5NU5ZBGBiqlxeIOWIrGcrbC5XJmg94FXArH1TUdiMCwyKyL3VCsjHeAnaue1jXIhEzOwOBzmsG3I2jTS3E13xG0EbLuz9K8l8T+JZr2Voo3IQHn3pninXzdTulscIepHeuXOSSSck12UKFvekc1av8AZiOJJJ7mkzSZpyAscV1nHuKg3EYrq/DGnNLOp296oaJpT3Mi/Ka9Y8M6ILaJWZea5a1RJWN6UO5u+HLPyIUBGK6aPAArOgaOFOuMVSv9dgtgcyDP1rgd5PQ6bHQmZY1yx4qld6xBFGSGB9hXB6n4vQxuEPPNcc/iC4d3G48+9XGk2S5JHe614hxna+OegrjdQ1V5nLAk4rMjW4vJzljzzV9LAxqd/Wt4wURasqac7XGrQb843dK9n0KILGo7YryKxj8vU4GIIANev6QD5CtGQRjpU1Og4nRRpgArV+PBAJHFZ1rPkYIrThIYYFKKIZLwqgqfwqWNsrwfxqB0wM0RHGcitbgkWTkHtUkeMDNVwS3OelSjJWgZKxy2e1KCAc1Dvx1ppbnIqblIsnpzWZegc455q15mc1Un/izUzehpHQl+xC4tScYbqDWeryxOY5M8V0Fm6C1H071zus3sPn4tz5kg6gdKhpWTQRk27FzeHA28GknmURfeCge9Yqy3kw+8I19FqWPT9/32Zj7mlY05bas0LXUohlHkTPuawdfQMPOi+clu3etX+yIz/AKfZ6Ii3RcZwOgzxSswTitTK0qwumiALFAewrds9KRADjJ7561sQWoTGBirMcPPtVKD6kSqdipBahQMCrkMYBGelTeWFAxgmkeRYx2HbmrUUjG9x03AAH6Vi3cO6TocVoR3CyOVLYIORinzFfLLFgQp7DrRJKSFF8rOO1yzM0ZwuR2ryzXoDa3sTgYXd09K9z1KBOWX7pGQM9q8n8ewLkSJxk1glaVjohLmVh6v+7DDpjNWPDsf2nVDI3SIZxWXJIUt4z/s1qeErlR5p/iZuDRPRD6HXk9aaTTA+RmmPJXOQPaTGeahaSoXc5oClu1A7EcrkniiOMk5qbywpx3p+QoqhiomKd3wOKizk8GpYh7U0QyaNeOanUCmKOKdnFBI89OBUTLzS7xTSxzxSBHzfqPh2cTNhT+VJZ+F7iVhuU17TJp0Ln5lBqSLT4o8YUV2qq7D5Ty+08FsSCymuh03wpHCQWSu4SJF6KBQ2B2qXNsqxmWmnRwLwoFWiiqOBUrGoZG7Cs2y0iCXvWfctgGrszYz61h6pcCNW5/CklctOxUv7hEB6Vgx3In1KKP1YVBqd2zsQtZ9q7RXccpP3WBreELGM5nuujIqWqeuK0xOiAlmC49a5zQ79Z7JGjI+YcVrskOxWkIPHc1V3exTKmoamMtzkdq5jWvEMNshMrhB6k0/xZrFrp0DyMygDt3NeGeItcn1W7ZmYiPPC040ucidVU1sdfrHjKLcwhYua4vVNcub8kM+1PQVlMSRTSK6qdGMDiqYicx+c8880Cm5I6dakRc1qzFMAM1r6RYNcSDjNUraDLAkV2egLFAFZsZrGrOy0Nqcbu7Os8MaXHborOBmurku4reMAEDFcNNriW6/Iw4rIvvEry8LnmuJ03J3Z0qaR0HiHxDJGWWFuK4i61Oe6c73NQ3FxLcscmmwQEnJreEFFGbk5McGbA3E4NW7C2NxcKqg1EIQDk10XhuFTLuxzRJ2QRV3qbtjp8cFuCQNwFFza8Akda02ixbbhk+woji84LWCZ0s5+9tPKhSVRgg5rtfC97vt0HtWRf23+jlWFV/DlyYJTA54zxVPVEbM9MtSeq8j0rUt2BUEjpXP6dISowa27eTcMYqIvUUkWhISRzU4Axk4zVMsG46Gp4+V4Oau6JtYkzzxShz05qI8NUydDQ2MCc8UxyU5qKV8Hjim+buHNQ5FpEqyjdx3qvKSWJPT3ojfb1ArP1e62QPtPJ44pPYrrZDby/luF8qElYF4JH8VMgiUr0ApLKEyW64IVfWpTbPHnEny+9VCN90aJpaBpUq3LSBVZNjlfmHXFbsMI24Fc5a3iwzsrcN/Oti11BWIGeaqTSFPXY1kiAHFWY0CLntWfFdB+hGKGvQOKnnSMWmzTaRcexpVmRRzWJ9twcdeaie8POTUe1FyGxNdhTkEfhWbeXm9WBPNUJLktwDUEkhPNS5X3Golhboo2QTU5vGkGOQDWO2Q3zdfWrcGOMnODUmmhK97hGQk5U9T6VwfjJXkUt0TrXbziNZdxK5PrXCeJbr7ffxWFvywbfIR/CBTS1KTS2KF0p+yrzghe9VNAuZI7zaTxntWjqONhGFO3isvSBvuzgcZpy2EeiW0m+IHvTmGarWfEQq0K5xsaseakAC0hcLTWfJFIAc4NQPLzjNOmbANUw2W681SAuoc4q3H0qlDzjNXY+lBDLCnilJz1pi89afjigljQpJz2p7LzQpx2pN1AGLjNGcdqAcCkNdBqDNUbHNDdabg0rjQ1m4qu+ecmpXqGQ/Ln0pMop30oRCTXH6vdFiRmtnWbngjIrkbuQu5raC6mc2VZCCTmoXIwRU3lluaZMnloTWqMGyfTfEtxo5Kj95F6E9KtXnxI3Q7UR1cdjXEapMcnHSsZmJJrWFJS1ZnKrKOxqa7rlzq0paZiF7LmscemRTj7UBcn3roilFWRyyk5O7EA9uaApJ4qeK3kkPAq/baec5YUOaRSg2Z6W5J6VNHFtPIrXa3EadKqsAWxUKpcbp2I1fy6njvZBwMikS1ZzntVhbQCk5JjUGQtNJIeWNWLWLP3v1oSD5xjirkce0jis5M0UR0duV+YDirsEKt0FWYI1a35FNgXbIQcAVFyyDytrkEd66Tw5b7fn/KsZULsDnvXU6OREgXHBpS2HHc2ygER9DUlggHbkUqDfECOlWrWLavHWsDVu5W1FQ0Z4rmGBhugw45rsLiE7CTXOX8Hzk9CKcWFmdXoV15sC+tdJbuNvzcGvOtGvGgYITXYWl3vAJOaT0YmjcUZ7/jU6HYetZyT9KlE+SAaQNMutIAetSq4x1rNZ8jrzQJwvelcLGjIyMtUpHCkjoKhe7APB/Wq0kpkJ2sKTLSZbecKnBrmdduXMTyLkhK1mRiMZpH00TW5j67uuaSZSSWrOd0rxNFJGqiRSRxjPIrbbWEeLoD+Nefat4Jm/tN2hm8sDng4qnLomtQkrFeSEDpzmtYzaRsoRaO9vLiN4TMj/vV9+1R2urKApDcV58+i68Mus8zN6GiE69ZEiexkmT1UYNKT5tQUOXQ9ctNWjP3XqaS8LNu3DHtXkg8RNbKftFrdQkdSUOKs2/j3TQnlvcMG7Daaz5JPYlpI9P+2kn+tOFwsgzuyRXBWmuXN6u6ztLmRTyDswD+dadta67cAFIY4Qe7nJ/Kpsw5NLnUPOi85qvNfRx5O9VHfJqgnhbVLls3WoOqnqsa4q1a+AhDJ5onlmb0mO4UWJ91bsil1ZJOAxYjjK81EmqygYWGZvcKa7DStLa3/dywRgDuo61ekslXkKAKVhOUVpY87ul1bUQFijaBP7z8Y/CpbDSINMibBMk78tI3VjXazWwCE8Vzep5i3EY/GqWhN+bQ5PWsxO+eVcYqj4ciPnNnHFWtXk3occ81DoDEE9+aHsWdhE4RAKVrg9jVKMO+KsxwHvWAMVGdj1qfnilSPbTwOvApCbK1znGKhjQ4qW4OTx2pY14qgJYcr1q3GciqyDFTocCgllyMZ61JuAqqslBk4oJsTsw5qPd6VGz1Ez89RQFjPUmnA+tR7ucUV0GoN1NIx4pDzSSEAUrAQyNx6Vm31xsQircz4U5rA1OcHIFNIL2MbVJi5PNY23e+TV665J5quq4roSsYyd2OCALxgVn6if3Zx6VoKpb1qpeWzMp+lMl3OI1HO81QxzXQ6lYvu6Gsz7DJu+7XVCasc04tspohY4A5rXsdML7WK1a03SySCRxXQRW3lhQBUTqdhwp9yjbaeqY4Gau/ZUVelWAuGxQ4yMZrBts3UUjJvLfIOBVWKx3NnFbMigrim25UNtwKaYOKZSWEIcYxUq226rc0YLFlxSxDAoFbUpCEKTxUsKK7bWq7Hb7zntT3s8EMvBouFiS3hCps60iwht3HSpoF4wetWI0yxobGloZ0CESkCuk0/wC4M1nm1wdwq1ZkqcUm7glZnT2jDYFNX48A46Vk2TdMmtbkpkGsZItaj35BDDis6/tBIuVHzfStAZZeacB8vNQaLY5EqYpx2rotLmJAyag1Cwz+9UcGmWavEwweKu5NrnTJKAAcVIJxk+tQ2J81ADg+1akFnG/Veagdu5RMrE98GmN5jdBW6mnxgZC1KtmgH3RS1KTiYCJkfN1NSpasTlRW5Bp6SP0wK0YrCJB8ozQotg5pGBBZM2CwqS+lWzjUBf3jcBa3mi8sHCiuUvpRca46SHhBhRVctiU+ZkEdpHM5km+Z2PNaMdhEACiL+VK1i2zcj4b0qBL4wyeXKCPetFG25XNf4SybJCPuj8qa2lx7MkAmr8M8UiL0zUoYYzSdiOeRz1zosEiMHhVs9iM5rHsPAWmLfteNZxGQ9MrwK7wRb2HSrKRAccVOvQPaPZmRa6PFGmAoGPQVpQWKIQSM/hVpI8N04q4iADsaajchzZSSDDY21OEx0FWcDGOhqJio4puBDlcaF4IHWo2iJJBpRMA5HFLFMrTfXgiiyFqVLiEKCAM/WuW1+1zC7DqB0ru7mFGUH1rlteUojB+QehqZx5TSnK7PINTcx3LL261c8MpvJ44zVHxXiO9DrxnrV7wcxx83rWcvhN3udhHCFA6ZqRUNLuyBgU5TgVjYm4EYHAphPJ4qUmmt0osK5SYEvmpkXA5oCgmpQMAUBcAKM4NIzACkY0AOMmBTS9Mz1JprNjvQVYlElNLjNQ5OaQt6UgsMIGaaaTdTSeDXUCYrHAzVaR8nrSSydqqzS4B9aVh3Ir6bahwa5u8cknmtG8m3Z5rHuXycZrSKJcii/LUiipTyad0WtTMYmBT2XK+1RBsvVjgpikIqG2jkbkD8qiOmRFs4/StCOM5yamVfrRcLGctssPQcU2VO4HNaLxhhnmoNg3EUXBIokNxQR61amwvaozH5i5FA7FfYByaglj2uSoqxyvynNW7aJWX5qBIy4wWyDU8KhUIIq/NaKoDLgVGY/l6c+tMVhtgPn2mtZLYOAemKr6Rb73JNbBt2UjHSpbGkZn2YifI6VO0O1s4NaIhA570ipufkZpXGQRxho8dagMRSUN0Faiw4yQKrzLltozTTJZZs2xg1qW83vmsuBNkfIqWKQq1ElccTXjfBwelSqQTgdKoed8mRVq0feAc1lYu5cUB4WjIrP8sxSAEdO9aa4HPpS3UQePcAM96m4aIWyKkjacVt2zMpBxXPWRCSAH1rprUZQGmU9C7G5YAYqzGmTzUcRCgcCrSOGp2M9ieKNQvHWpuAuehqKMkkVYOCvPXFapaaEPcgJyh7ivPNWnWDxKecE9K7/IGeuK85+JGmzkre2md6dcVLdkaUl71jfjvMpnIJrO1GQSwvtG5xyvsa86g8XmAbLnzEccHIzU0Xi+J3+STJPrxVKomrGkqUo6nb6ffkBc9e9bMV5leTwTXm9lrKMzfMMk10FnqiOiAtisZIq19zvYLxMEE9BUq3quMDqP1rljMpCMj9Rg1WW+eGbbvyAanmaIdNM7yK6XdgnPvVgXAzkEVxdtqPIOcitKO+DAelWpmLp2OhN1781WnuOpyOKxzecfeqJ7ssvXP1oc7i5DQludp+U89aW3ulznPPWsKS4IcHNRx3BSUZOQfWo5jSMDqpbxjGVB561g6vO9xFtXrVmGXzEzmqGsTpDbM5cAgUXvuNJJnmHjUeW0aj7zNV7woPlya57XNSTUtYPlHdHEOvqa6bwzgRD3on8JTd2dbH90U7NRIwwOaXNYCJN1DtxURemyScUBYepApxb1qrv560b8jrQOxOzD1qNpOcZ4qJmpu7mgdifdxTSecmo93vRmkMVm44puaXrTSKAIs015MVGz7R1qBpR6112M7iTOBk1mXExJIqe5lznmqEhzmqSBu5WuW4NZswyc1fl781UkGSRWiJuVdnenHpiptvGO1MxzTArhDuyKnQEHnpTgNp9qkfhaQh8WGOO9WVQCq1oKvJjBzSYyAxA5qF4NhyKtg4PA4pspyhzSAy5I89etLCgXqKc7ck471JCC681TArXcA+8tJaAgc1ovDuj6UlvAFOSOtK4yDBYgdqe6AJkdquiADkCmSx8cUhE2hqGB4rVmX2qhog2ucitWQZPTipluCKqqSelSJCQ2asLGDjirAiHalcCk/APHSq9tGZJ6vTxkD1qSxgwS2KpAxJYgq1Scc5rTuOOO1UMfvOe9MkiiJD47Gr0DeXxk1EIOpFSIuQV70mNGjBLkcmrsbboyvYisKOUo2D1rQgnJIrOxe5A0phnIPQGun0q5EkI5Fczq8e6PzF/GmaLqBjYRscU0N6nfRnIx3qeFypwayLK7WQDJzWkDvGR2p3J8jSD4XNPSUk+1Uo5DjFKHIPFVcViwZPmIFVb6EXERVwCD2phlIl571MrEipT6D5bHE3vg3TbyYl49pJrH1H4X27gtatg+lehXCbTuBqzZzBgATSilezLdSaV0z571rwbqmlMzwtJtHTaawo9ev7F9lyhYDuODX1HfWcd0hyoOeua898SeDLG8JxHsY9wKpq2441FLc4Gw8XgxqHZlPvWjH4ktWYuZRk+9VdR8IJYMEY5U9DU+n+DIp03RvuPUA1LiiuYuweKrVDy+MVoReLrXj94BVeDQorP5bqyGOm7HBrVt9N0tgD9miOfapskRcqnxZbHGJB+dRSeKYc8OT9K2otJ0vfkWsOfda0Vs9PRMLawgf7ooSTJcrdDkD4oTHy7zn0FNPiQt/yzkyP9k13UVrZugZIYht9FFW7dLZODFH1/uinZB7TyOGXxXIiYS3mZgOgU1ga5ca5rUbYhe2th1LcE17UfsvlkiOIcZ+6K5LxK6tFKFAxim4paijPmdrHkCQJYoYusjHk12WgORCufSuD1K9WTVnUfdU4rqNHvlEYANTUTsVE7ZJRgc1J5me9c+moLjipV1CsbFWNln55NMZ/essXuaU3RNKwGmGFG4VmC5bHAo+0vRYDSJGOtN3CqPmufWmM8pPANAzQ80UnnAd6oATHseaesErYzmkBaNwBSG5HY0yOxkbqDVpdMJHNAXMuRuDVKWXnrTp5cZqmWJau+xgPc5zVaU/hUrNxVeU5NFh3IJOufSoWxUzfWoXGKYrjTgikUZIp3OORSxDkUAK8fFIFyOas7cimFOSaAuNiQipueetLEvFWVUHoKQyqCRwaSRSVNWjGM0MnHSgDKaPPUVcsoxtFPEOc06KMxtxQCJHi+XilhTnBpy5JxU8cdSNDCoAwagkjwOO9XJE45psEW5hnpQDJbCHYucVeA55ohXaMYqQLzUsSFjUZxU2wjkU1V5qbkikBCU3cEVat4QF4pI17mpQQtMCtcRnJqukCs3PWtBzkVEEGc96pCsNSIAe1NkhHVeKec9P5VDKzK2MUMSQyWNCue9UJLhoW6H61qJErL82c1L9lidMMAfrUFq3Uy01FZI9j9DxWZPIYpNynvwa1LzTlQ7oxWZcKcFTQUrGxpOsqCqu1dfZXyyINrZryOaORSWjJyKs6b4ils3CXHC+tJlWPY45xkf41OJQSDmuE0/xBFcICsgNa0GrKCAzcUuYOQ6KVt3I60RT44NZsV+jAFWzTZrnDZXin5hY15mVo896pwzBZODzVFdS+XB6Vm3WqIk3ynBzzQ31BROzt70dG4qHUIVkjZlH5VzP9qr5YIIz61Ys9ejmBjZwG+tNS0syHB7oxvE0DSWjMo+ZKqeF58qM9ehrbv5EcOMjDCuFh1NNL1V4ZGCxs2QaHqUux65ZeTOqrIisoHQimXfhayustAzQSH+6eK5/SNVjfaUkBz3Brp7W/Vsc5pxktpIwnGUdUc3e+GNUtNzW5E6D0PNY0893a/JcwSJ9RXpsV6pGCabdPDMhEqIw9xmqcYPYSqS6o8yj1RlyEOQetaNpqe8AHrW5e+HNLu8lYzC5/iQ1zup+FdSsm32MyTR+h61DgzWNSL3NZrslR0xXHeNdajtLV/nHmEEAVW1RvEEUZxCka+pNea+IJZg7tdzb5ieBmiEbvUcrLVFGyV7q+LZOS1eg6RpbtGvWuL8LRF51J9a9f0SDEK8UqzFAyjpbge1LHabT81dYbYMORVWex44rDmNLmVDAmBk4q7BZxt3FVprd4zwKijnkiPtRuFzaFjHilWxj71Shv843Vcju0Y4zUgTfZIwDxTFt48/dp/mhhwaQOB1PNJgSrBHxhRUiog6AVEJB6mnBx2pi1JsDFAPHNRbz60wyAd6QWOHkbJ700dKG60wtjpXpdDEbIahbrzUrHmoXPNIQxhk00rxin0nU0xkWzPA61LGnanKOalVfagYgXAp6rn6U8DjmpUUY6UgK6xnIIqxGMAZFKq1KBxSHYhIBPNKBx708jJqUR4FAECoaRl4q3t+WmiPNArFaMHfzV2MDFQGP5qsoPl60h2B0DCnQxEGnLUqDJqQJUT609QOaci8ClIHpSYDVODzU3GAagY45p0b5+lFgLikbBTJvu5qJZMMBmpSwPBpWEVo5mIKntUZuFVsNxTbkeW+9cCqU86sCG4q0BqxzjOQQanMkci8gZrm0lKchs08agAvXDChjN4yxqMHiomuEx96uduNWKrhgCKx7zVzj5HK4pWCx2Ut8g4JGPrWPfarax5Dla4e/16QKQJOa5q/1OWYnc5pqncOZRO21TxHaRZ8s7j7Vxmq6/JcMQhwKwppmcn5j+NQ9a6Y0UtzCdZvY0rbWLy2kDwzMp+tdHYePLyOMJcLv9xXFmgdetU6cXuiFVlHZnpFr8RnicZRitbEfxPt8fOjZ714+PrQah4eJp9Ymevt8RrWQZG4fhWFr/AI6E6bbQfP8A3q89ooVCKYOvJo7Cx8eajAmyXEgqG58Z3zy+ZCfLPtXK0Zq/ZQ7Ee1n3OxX4gar5Wxip464rE1HXLzUJN0snNZIHNP7U1CK2DnkzqPDXiu50yRUmkZ4wfXpXrXh7xlbXSL++G70zXz8BzzUkMskTbonZW7EGsZ0VLVGkarWjPqy11dJEUrJV8amO7V8y6X4v1GyIDOZEHY9a7XR/H9vKVW7JQ+9YSpSiaJwke2R36nnINTnUAYyeeled2HifTpFBF1Hj3an3fi6xtoHZrqMjsARUJtMpwRb8a6qltpkkjsBgHivn3ULxr68Z2zgnit3xp4ok1uXy4ci3B/76rnrCIySgda6IR5Vdmcmr2R2vgy2LOvFewaTBtiWuF8FaeVRDivTLOLZGAK4qsrs1WiHbBjpUTxA1b28UhUVkK5nSW2eoqpNpwbnFbZFKIs0XKuctLpjjO0VCbSaPpmuxFtnqKeLJSOQKdw5jix5y9QacJpAOc12D6bGw6VVk0YN0WgamjmhdsODU0d0cVpzaG3OBVGbTZIs8Ux8yYqzsw4NNZmzUHmGLjFMNyc9KQznQc0xuvFIh4oavSOaxG5qByc1M/eoG+lAADmnYpoFSqM49aBAoIqeMHimAc9KlUcUix5FPX60wehpy0guPXNPFInNSoucUhpjduCDVhcFRTQvY1Iq4xQAY46cUkZ+apguRTAm1s0Ahjrg5pYwM1MU3LUaqVJ4pBYcRg1NDUa9KlXA6GkBNnApC2RxUbMCOtQiQjOaQWHytlfpTIZxu2k5poYMTmqEoaG43fw5ppAbDMAwOaJpcrlTzWclwDgE802afCnBosBJPOWU98VnSy7v8agluTuIz17VSkuDGfmxigdid5XiY85H1rPurxgxwaivLxApwaw7zURyF60WbHoaF5qO1cE1g3l+zZwcCqlzO0h+Y1m3M2MgHmtYQMpVLbC3FyWY85qnLIX70mCSaekDv90GuhJROdtsixzSjNalno1xOwCoTW7B4Punjz5Z/KolVigUGzjjSYrpb7wvd2+T5Z49qxprCeNiGQ8U1Ui9mDi10KdJUzQyA/dNN2Njoau6JsMPTNFPEbf3TU8VlNJ92Mn8KTkkNIq45oxV/+y7kf8sj+VOGlXTDiI/lS549x8rKABp2Kvf2Vdf88m/Kh9NuEGWQgfSlzx7jsyjSinvGyHDDFNpi1AUUUo60DHKzAfeI/GnEs3Uk02nLikykKo5rofDVp5tyvHGawoULuAO9eleBdKLujbawqysjSC1PRPDFkIoE47V1SphcVW0u18uJRjoK0dvtXnvU0bIMc0m2rGzJpRF7UhXK6x5NWEjqWOLtUwTApqIuYhCgdhShgeKWQVXc4NGwLUtqVA5p4kQdazjKexqNmJ6E0+cOW5qPNF3xVC7EUgOMVXIYnqaDEx5ocmxqNjNmsFc5AqlJp+Gxg/lW+U2qc1QmmxIRmkWpHmUT8dakqhDIB3q2snFekYXB+tRN9ae7e9MPNIq49OtSCo0welSqOlBJIo9alQcU2MDiplGBSK3Ap6U3kdKlU0FeTikOxGuc1Zjz65qLbg1NH9KB2JCcDNTRcioWGcVPD93FICRDTtuTUbnaRTlbIzRYCQrjHP6UyUYGalXmoZuBikA8DMdRjOeTSROOhpkx4JFAx8lQyttXimedxg1VnnAHJpAXAdwyOtVblg3DVAt2FXj+dVLm7DHrii47CSymGTrxSSXIZfvVRuLhSOT0rJurzb0NAF26n2uSGrKvL85xu6VRuL0sTgmqc0mTk00hNks9w0nUms+eVQT1pJ58cCoArSc4zWqiZSkRSSMxPpUaQSSPwDn6VrWmnPM2ApP4V2vhnwoZXVpE49xTdVRRKg5M43TtCmnYfIea7rQPBu/aZFP5V6FpfhuCFRlBn6V0NrYpCvAArknXb2NFBI5vSfC9vAq5jH4iugi0u3Rduxfyq/t2gAUGsHJsq5k3eiW84IKL+VYF74Ltpcny1/AV2tHWhSaC55rN4AgY8IB+FU5Ph5ETwn6V6tjPpShRnpVKpLuGh5XF8Oog3KD8q3tP8D20S/NGv5V3Sj0qQdKOeT0Ecj/wh9n/AM81z9KkXwjZgf6tfyrqsUUuZiuct/wiVpjiNfyqhqPg63eMhY16dhXcYo2g8Yo5ncfMeAeJvBbwlmiQ4+lcDfabNbSEOhGPavrO706K4Qh1FclrXgu3uQxCDn2rohXa0ZLSZ82FCDyMUAV6rrPw/kQkxqfyrjtQ8L3dqx/dtx7V0RqpkuDRzgFOAJPFWZbGeM4MbflVnT9MuLiYARt+VU5rcXKy/wCG9Na6uE+XvXufhPSBBCmVrnPA/hsxKjSJg/SvUrK1EUYAFcNWfM7GvwokhjwAKnCVIqYqUJUKJDkQrGKdsFTFaAtVyk8wwJgU1zUp4HWqszYoasNakcrdaqSNk+tSuSagYc1izVKw0cmp0jzTY1zVqJaSQNiJAKkeMKOlWI1plyQBWyjZXM73Mm7bapxxXO3Eh85q3b1hyK5u6kAmPNZm0VoeZQueKuRMTRRXpMwRI3Q0A4FFFIY+Pripx0FFFA0TR59amzRRSGhR7cVOBxRRSKDHFSDoKKKBki8gU9eKKKQCyHiliYnrRRQA9mKkc0jsSOaKKGIrgnJxUckhUUUUhlKRzVKeQ55zRRSKKkspA4qnPI23miimBkXVw65ANZskrN1NFFMgqSMRiqk0jbsZoorSJnIWCMO3JrpNH02KYjcT+VFFKoKG56BoWhWoKnGT9K7zTNPhhT5R+lFFcVRu5ozWVQEGKUUUVl1AUikxRRTAAKSiikwAdqcKKKAJEqQCiiqQmOA60hHFFFIQwjFOFFFMBy9aeQD1ooqkJkMtvG/3lBzWXe6LaTDDIOfaiigcWYFx4U0925Qc+wqzp/hewicFUHHtRRTu7FnT2VnFCg2AD8KvooxRRRHcye5KABTwOKKK0JFApSMZoopgV5GNVJjRRWMyokBqI80UVkbIfHV2EcUUVcdyWW0GVqneNjIoorZ7Ga3MG/YgE1y9wxaUk0UVgdK2P//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Resisted thumb extension can be used to assess radial nerve function and the strength of thumb extensors.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rebecca Bassett, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_2_29729=[""].join("\n");
var outline_f29_2_29729=null;
var title_f29_2_29730="Vasectomy";
var content_f29_2_29730=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Vasectomy (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?29/2/29730/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/2/29730/contributors\" id=\"au1903\">",
"       Christopher J Cutie, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/2/29730/contributors\" id=\"au1595\">",
"       Theodore J Ongaro, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?29/2/29730/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/2/29730/contributors\" id=\"se3217\">",
"       Jerome P Richie, MD, FACS",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?29/2/29730/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/2/29730/contributors\" id=\"de2771\">",
"       Kathryn A Collins, MD, PhD, FACS",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?29/2/29730?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Vasectomy is a safe, effective, and permanent method of birth control for men. It is also the most cost-effective form of birth control, costing half as much as a tubal ligation (having a woman's \"tubes tied\"). In the United States, one out of five men over the age of 35 has had a vasectomy.",
"    </p>",
"    <p>",
"     This topic reviews recommendations for men who are considering vasectomy, including the success and failure rates, as well as how the procedure is done. Topics discussing other methods of birth control are available separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/28/7620?source=see_link\">",
"      \"Patient information: Permanent sterilization procedures for women (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/32/22021?source=see_link\">",
"      \"Patient information: Hormonal methods of birth control (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?4/16/4355?source=see_link\">",
"      \"Patient information: Long-term methods of birth control (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/2/22563?source=see_link\">",
"      \"Patient information: Barrier methods of birth control (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      VASECTOMY DEFINITION",
"     </span>",
"    </p>",
"    <p>",
"     Sperm are produced in the testicles and then move into the epididymis, which sits on the upper surface of each testicle. Sperm are stored in the epididymis, where they mature and become capable of fertilization.",
"    </p>",
"    <p>",
"     At the time of ejaculation, the seminal fluid and sperm move from the epididymis through the vas deferens and are then expelled from the penis. The vas deferens are long, thin tubes that start in the scrotum and run behind the bladder and then return forward to empty into the urethra inside of the prostate gland; the urethra is the tube inside the penis that carries urine and semen.",
"    </p>",
"    <p>",
"     When a vasectomy is performed, the vas deferens are cut and sutured closed, preventing sperm from leaving the epididymis (",
"     <a class=\"graphic graphic_figure graphicRef69387 \" href=\"UTD.htm?19/52/20293\">",
"      figure 1",
"     </a>",
"     ). This way, no sperm are expelled from the penis at the time of ejaculation. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44712?source=see_link\">",
"      \"Vasectomy and other vasal occlusion techniques for male contraception\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      WHO SHOULD CONSIDER A VASECTOMY?",
"     </span>",
"    </p>",
"    <p>",
"     Vasectomy is for men who want",
"     <strong>",
"      ALL",
"     </strong>",
"     of the following from their birth control method:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Permanent, not meant to be reversed",
"      </li>",
"      <li>",
"       No preparation before or during sex",
"      </li>",
"      <li>",
"       A high success rate and low risk of complications",
"      </li>",
"      <li>",
"       No other children",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Men who are not sure that vasectomy is right for them can consider a number of other contraceptive options. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/60/9157?source=see_link\">",
"      \"Patient information: Birth control; which method is right for me? (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/28/7620?source=see_link\">",
"      \"Patient information: Permanent sterilization procedures for women (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      VASECTOMY SUCCESS RATES",
"     </span>",
"    </p>",
"    <p>",
"     Vasectomy is successful in more than 99 percent of men. A second method of birth control is necessary until testing is done to confirm that there are no sperm in the semen.",
"    </p>",
"    <p>",
"     The sperm count is checked, usually three months after the procedure, to ensure that no sperm remain in the ejaculate. A man needs to have ejaculated at least 20 times after vasectomy to clear the ducts of sperm before the follow-up sperm count.",
"    </p>",
"    <p>",
"     A sperm count requires that the man give a semen sample, usually obtained by masturbation. A man who continues to have sperm requires a second sperm count two months later.",
"    </p>",
"    <p>",
"     If the follow-up check shows sperm that do not move, there is a small chance that a partner may become pregnant. Another method of contraception should be continued until &ldquo;special clearance&rdquo; is given by the doctor.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      VASECTOMY PROCEDURE",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Consultative visit",
"     </span>",
"     &nbsp;&mdash;&nbsp;Men who are considering a vasectomy usually have a consult visit before the procedure. At this visit, the doctor will explain the procedure and answer any questions.",
"    </p>",
"    <p>",
"     Men frequently have a great deal of anxiety about vasectomy. Much of the anxiety is related to a fear of pain or damage to the penis or scrotum. The consult visit is an excellent opportunity to discuss the procedure, risks, and potential complications. It is preferable for the man to bring his partner to this visit.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      The procedure",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most vasectomies are performed in a physician's office and take about 30 minutes. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44712?source=see_link\">",
"      \"Vasectomy and other vasal occlusion techniques for male contraception\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       A local anesthetic is injected under the skin (not into the testicle) using a very small needle. Only the area around the vas deferens (vas or sperm duct) becomes numb. The injection of the local anesthetic will sting briefly.",
"      </li>",
"      <li>",
"       Once the area is numb, some men will still feel a pulling",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       cramping sensation during the procedure. The physician finds the vas deferens by feeling through the skin of the scrotum. A clamp is placed around the vas through the skin.",
"      </li>",
"      <li>",
"       To expose the vas, a small (less than one-half inch) incision is made with a scalpel. A no-scalpel technique can also be used. A loop of vas is brought to the surface and a small segment is removed (about 3 or 4 millimeters). The two cut surfaces of the vas are then either cauterized (treated with heat), tied off, or clipped. When one side is complete, the other side is treated.",
"      </li>",
"      <li>",
"       The skin edges are then closed with stitches or surgical staples. There will be a small scar from the incision, but this will be barely visible once healed.",
"      </li>",
"      <li>",
"       An athletic supporter (jock strap) is used to hold a bandage in place and apply pressure to the scrotum.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      After the procedure",
"     </span>",
"     &nbsp;&mdash;&nbsp;The man may go home a few minutes after the vasectomy is completed, but should have someone available to accompany him and assist with tasks (driving, heavy lifting, etc).",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The most important factor in a smooth recovery is rest. It is best to take it easy for two to three days after the procedure.",
"      </li>",
"      <li>",
"       Patients may be asked to limit their activities for about five days. Strenuous exercise or lifting should be avoided for a total of seven days.",
"      </li>",
"      <li>",
"       Patients should not bathe or swim for 24 to 48 hours after the procedure.",
"      </li>",
"      <li>",
"       Sexual intercourse can be resumed after a week, but a back-up method of birth control is necessary until testing is done to confirm that sperm are no longer present in the ejaculate (usually at six and eight weeks after the procedure).",
"      </li>",
"      <li>",
"       Men need to ejaculate at least 20 times to clear the ducts of sperm before the three month check. (See",
"       <a class=\"local\" href=\"#H4\">",
"        'Vasectomy success rates'",
"       </a>",
"       above.)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      PAIN CONTROL FOLLOWING VASECTOMY",
"     </span>",
"    </p>",
"    <p>",
"     After the vasectomy, there will be some cramping and discomfort at the incision site. This can be relieved with a pain medication such as acetaminophen (Tylenol&reg;). Ibuprofen and aspirin should be avoided for at least one week because these medications may increase the risk of bruising or bleeding around the incision. For more severe pain, a stronger pain medication may be prescribed. Most men find that they do not need the stronger medication.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      VASECTOMY COMPLICATIONS",
"     </span>",
"    </p>",
"    <p>",
"     Vasectomy is a relatively simple procedure to perform. Complications are unusual, although possible.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Bleeding &mdash; Excessive bleeding occurs in less than 5 percent of men who undergo vasectomy. Most bleeding problems occur within the first 48 hours after the procedure. Bleeding within the scrotum can lead to a hematoma, which is an expanding mass of blood within the tissues around the vas. This can grow to a large size if not treated promptly.",
"       <br/>",
"       <br/>",
"       Men can help to prevent bleeding by avoiding aspirin, ibuprofen, and other nonsteroidal antiinflammatory drugs (NSAIDs) for at least one week prior to surgery, and by following the instructions regarding rest and limited activity after surgery.",
"      </li>",
"      <li>",
"       Infection &mdash; Infection occurs in up to 4 percent of men who undergo vasectomy. This typically involves the scrotal skin around the incision. Occasionally, the epididymis will become swollen after a vasectomy. This is usually treated with a short course of oral antibiotics.",
"      </li>",
"      <li>",
"       Sperm granuloma &mdash; A sperm granuloma occurs in 15 to 40 percent of men who undergo vasectomy. A sperm granuloma is a mass that develops over time as a result of the body's immune reaction to sperm leaking from the cut end of the vas. It is typically treated with an anti-inflammatory medication, such as ibuprofen. The mass is not dangerous. There are instances, however, in which a sperm granuloma causes significant scrotal discomfort. This may be treated by surgically removing the granuloma.",
"      </li>",
"      <li>",
"       Post vasectomy pain syndrome &mdash; A feeling of fullness from sperm congestion occurs in up to 6 percent of men after a vasectomy. This is due to stretching of the surface of the testicle (epididymis) from stored sperm cells. The full sensation usually resolves after a few weeks and requires no treatment, but a very small number of men may develop chronic pain which might require vasectomy reversal or other surgery.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      HEALTH EFFECTS OF VASECTOMY",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Sex drive",
"     </span>",
"     &nbsp;&mdash;&nbsp;Having a vasectomy will not affect testosterone (male hormone) levels, sex drive, or the ability to have an erection.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Risk of cancer",
"     </span>",
"     &nbsp;&mdash;&nbsp;Although there have been some concerns regarding a link between vasectomy and prostate and testicular cancer, several large studies suggest that there is no increased risk of any cancer following vasectomy [",
"     <a class=\"abstract\" href=\"UTD.htm?29/2/29730/abstract/1-4\">",
"      1-4",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Heart disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;Similar to the situation with cancer, there have been some concerns about a link between vasectomy and heart disease; however, studies have found no such link.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      CHILDREN AFTER VASECTOMY",
"     </span>",
"    </p>",
"    <p>",
"     A man should not have a vasectomy unless he is sure that he does not want children in the future. However, about 5 percent of men who have a vasectomy eventually decide that they would like to have it reversed.",
"    </p>",
"    <p>",
"     Sperm antibodies develop in 40 percent of men after a vasectomy. These are formed when leaked sperm cells interact with the body's immune system. These antibodies cause no harm to the man, but can make sperm cells less effective if the vasectomy is reversed.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Vasectomy reversal",
"     </span>",
"     &nbsp;&mdash;&nbsp;Vasectomy reversal is called a vasovasostomy. This is a microsurgical technique that reconnects the vas deferens. The success rate of this procedure depends upon the condition of the vas. As more time elapses from the time of the vasectomy, vasovasostomy is less likely to be successful (ie, result in pregnancy) [",
"     <a class=\"abstract\" href=\"UTD.htm?29/2/29730/abstract/5,6\">",
"      5,6",
"     </a>",
"     ]. In one study, vasovasostomy resulted in pregnancy about 76 percent of the time when performed three years or less from the time of the vasectomy, but pregnancy resulted in 30 percent when the vasectomy was performed fifteen years or more before reversal [",
"     <a class=\"abstract\" href=\"UTD.htm?29/2/29730/abstract/5\">",
"      5",
"     </a>",
"     ]. If sperm antibodies have developed, fertility after vasovasostomy is further reduced. In the United States, vasectomy reversal is not covered by most insurance plans.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Sperm banking",
"     </span>",
"     &nbsp;&mdash;&nbsp;Sperm banking involves storing a collected sample of sperm with a preservative at a very low temperature. Sperm banking can be accomplished prior to vasectomy or collection of sperm from the ducts can be done at the time of vasectomy reversal surgery. The initial cost of storing sperm is about $500, with annual storage costs between $300 and $1000 per year.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      BIRTH CONTROL AFTER VASECTOMY",
"     </span>",
"    </p>",
"    <p>",
"     If the three-month check shows no evidence of residual sperm in the ejaculate, a second form of birth control (eg, condoms) is no longer needed to prevent pregnancy. However, vasectomy does not protect against sexually transmitted diseases (STDs) such as HIV. Men who have more than one sexual partner and men whose partner has other partners should consider using condoms to reduce the risk of STDs.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1804488796\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11568143\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/25/36242?source=see_link\">",
"      Patient information: Vasectomy (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/56/14211?source=see_link\">",
"      Patient information: Choosing birth control (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11568177\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/28/7620?source=see_link\">",
"      Patient information: Permanent sterilization procedures for women (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/32/22021?source=see_link\">",
"      Patient information: Hormonal methods of birth control (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?4/16/4355?source=see_link\">",
"      Patient information: Long-term methods of birth control (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/2/22563?source=see_link\">",
"      Patient information: Barrier methods of birth control (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/60/9157?source=see_link\">",
"      Patient information: Birth control; which method is right for me? (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39306?source=see_link\">",
"      Overview of contraception",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/61/39893?source=see_link\">",
"      Overview of vasectomy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44712?source=see_link\">",
"      Vasectomy and other vasal occlusion techniques for male contraception",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Planned Parenthood Federation of America",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.plannedparenthood.org/\">",
"      www.plannedparenthood.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Managing Contraception",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.managingcontraception.com/\">",
"      www.managingcontraception.com",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Vasectomy Information",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.vasectomy-information.com/\">",
"      www.vasectomy-information.com",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?29/2/29730/abstract/1-5\">",
"      1-5",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 6, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?29/2/29730?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29730/abstract/1\">",
"      Schwingl PJ, Guess HA. Safety and effectiveness of vasectomy. Fertil Steril 2000; 73:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29730/abstract/2\">",
"      Hewitt G, Logan CJ, Curry RC. Does vasectomy cause testicular cancer? Br J Urol 1993; 71:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29730/abstract/3\">",
"      M&oslash;ller H, Knudsen LB, Lynge E. Risk of testicular cancer after vasectomy: cohort study of over 73,000 men. BMJ 1994; 309:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29730/abstract/4\">",
"      Cox B, Sneyd MJ, Paul C, et al. Vasectomy and risk of prostate cancer. JAMA 2002; 287:3110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29730/abstract/5\">",
"      Belker AM, Thomas AJ Jr, Fuchs EF, et al. Results of 1,469 microsurgical vasectomy reversals by the Vasovasostomy Study Group. J Urol 1991; 145:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29730/abstract/6\">",
"      Fuchs EF, Burt RA. Vasectomy reversal performed 15 years or more after vasectomy: correlation of pregnancy outcome with partner age and with pregnancy results of in vitro fertilization with intracytoplasmic sperm injection. Fertil Steril 2002; 77:516.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f29_2_29730=[""].join("\n");
var outline_f29_2_29730=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           VASECTOMY DEFINITION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           WHO SHOULD CONSIDER A VASECTOMY?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           VASECTOMY SUCCESS RATES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           VASECTOMY PROCEDURE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           PAIN CONTROL FOLLOWING VASECTOMY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           VASECTOMY COMPLICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           HEALTH EFFECTS OF VASECTOMY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           CHILDREN AFTER VASECTOMY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           BIRTH CONTROL AFTER VASECTOMY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H19\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/52/20293\" title=\"figure 1\">",
"           Anatomy of vasectomy PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f29_2_29731="Fibrous dysplasia sites";
var content_f29_2_29731=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69064&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69064&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Skeletal distribution of fibrous dysplasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 247px; height: 605px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Yochum TR, Rowe LJ. Yochum and Rowe's Essentials of Skeletal Radiology, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_2_29731=[""].join("\n");
var outline_f29_2_29731=null;
var title_f29_2_29732="Trimethobenzamide: Patient drug information";
var content_f29_2_29732=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Trimethobenzamide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/63/4085?source=see_link\">",
"     see \"Trimethobenzamide: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/7/24692?source=see_link\">",
"     see \"Trimethobenzamide: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F231401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tigan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F231402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Tigan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10017044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691522",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat upset stomach and throwing up.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10017043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703084",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to trimethobenzamide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10017048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697320",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have Parkinson's disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10017049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10017051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699055",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shakiness, trouble moving around, or stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10017046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Capsule:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695985",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10017047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Capsule:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10017052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Capsule:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10017053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11125 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-189.2.19.178-294E67EF58-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_2_29732=[""].join("\n");
var outline_f29_2_29732=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231401\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231402\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017044\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017043\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017048\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017049\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017051\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017046\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017047\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017052\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017053\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?3/63/4085?source=related_link\">",
"      Trimethobenzamide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/7/24692?source=related_link\">",
"      Trimethobenzamide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_2_29733="Calcium citrate: Pediatric drug information";
var content_f29_2_29733=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"18\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Calcium citrate: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38628?source=see_link\">",
"    see \"Calcium citrate: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?24/15/24820?source=see_link\">",
"    see \"Calcium citrate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F144542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cal-C-Caps [OTC];",
"     </li>",
"     <li>",
"      Cal-Cee [OTC];",
"     </li>",
"     <li>",
"      Cal-Citrate&trade; 225 [OTC];",
"     </li>",
"     <li>",
"      Calcitrate [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F144543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Osteocit&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1002942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Calcium Salt",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Electrolyte Supplement, Oral",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Adequate intake (AI):",
"     </b>",
"     200 mg/day of",
"     <b>",
"      elemental calcium",
"     </b>",
"     ; requirements may vary on prematurity, postnatal age, and other clinical factors; serum calcium concentrations should be monitored closely to determine patient-specific needs",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hypocalcemia:",
"     </b>",
"     Dose depends on clinical condition and serum calcium concentration: Dose expressed in mg of",
"     <b>",
"      elemental calcium:",
"     </b>",
"     50-150 mg/kg/day in 4-6 divided doses; not to exceed 1000 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1002960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38628?source=see_link\">",
"      see \"Calcium citrate: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Adequate intake (AI):",
"     </b>",
"     Dosage expressed in terms of",
"     <b>",
"      elemental calcium:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-6 months: 200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7-12 months: 260 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Recommended daily allowance (RDA):",
"     </b>",
"     Dosage expressed in terms of",
"     <b>",
"      elemental calcium;",
"     </b>",
"     during pregnancy and lactation, requirements may change:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-3 years: 700 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-8 years: 1000 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9-18 years: 1300 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Females 19-50 years, males 19-70 years: 1000 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Females &ge;51 years, males &ge;71 years: 1200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hypocalcemia:",
"     </b>",
"     Dose depends on clinical condition and serum calcium concentration: Dose expressed as",
"     <b>",
"      elemental calcium:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;\">",
"     Children: 45-65 mg/kg/day in 4 divided doses",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;\">",
"     Adults: 1-2 g or more per day in 3-4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dietary supplement:",
"     </b>",
"     Adults: 500 mg to 2 g divided 2-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Adjunctive prevention and treatment of osteoporosis:",
"     </b>",
"     Adults: 500 mg",
"     <b>",
"      elemental calcium",
"     </b>",
"     2-3 times/day; recommended dosage includes dietary intake and should be adjusted depending upon the patient&rsquo;s diet; to improve absorption do not administer more than 500 mg",
"     <b>",
"      elemental calcium",
"     </b>",
"     /dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;25 mL/minute may require dosage adjustment depending upon serum calcium level",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F144531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cal-C-Caps: Elemental calcium 180 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cal-Citrate&trade; 225: Elemental calcium 225 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Granules, oral:  (480 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: Elemental calcium 200 mg [DSC], Elemental calcium 250 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cal-Cee: Elemental calcium 250 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Calcitrate: Elemental calcium 200 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F144518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F3429789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with plenty of fluids; may administer without regard to food when using to treat/prevent deficiency conditions; administer with food when treating hyperphosphatemia or when administering granule formulation",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F3429788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1002943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of  hyperphosphatemia in end-stage renal failure; dietary supplement; prevention and treatment of calcium deficiency; adjunctive prevention and treatment of osteoporosis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F144560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Citracal&reg; may be confused with Citrucel&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F144559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypercalcemia, hypophosphatemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, constipation, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild hypercalcemia (calcium: &gt;10.5 mg/dL) may be asymptomatic or manifest itself as anorexia, constipation, nausea, and vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     More severe hypercalcemia (calcium: &gt;12 mg/dL) is associated with coma confusion, delirium, and stupor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Thirst",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1002945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to calcium formulation; hypercalcemia, renal calculi, ventricular fibrillation",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F3429086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use cautiously in patients with sarcoidosis, respiratory failure, acidosis, renal or cardiac disease; some products may contain aspartame which is metabolized to phenylalanine and must be avoided in patients with phenylketonuria",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1002946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Multiple salt forms of calcium exist; close attention must be paid to the salt form when ordering and administering calcium; incorrect selection or substitution of one salt for another without proper dosage adjustment may result in serious over- or under-dosing. Some products may contain tartrazine which may cause allergic reactions in susceptible individuals.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F144526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aluminum Hydroxide: Citric Acid Derivatives may increase the absorption of Aluminum Hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral calcium supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Acetate: Calcium Salts may enhance the adverse/toxic effect of Calcium Acetate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Calcium Salts may diminish the therapeutic effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Calcium Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DOBUTamine: Calcium Salts may diminish the therapeutic effect of DOBUTamine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Calcium Salts may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any polyvalent cation (e.g., calcium-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estramustine: Calcium Salts may decrease the absorption of Estramustine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May increase the serum concentration of Calcium Salts.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Calcium Salts may decrease the absorption of Phosphate Supplements.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Calcium Salts may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Moxifloxacin (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Strontium Ranelate: Calcium Salts may decrease the serum concentration of Strontium Ranelate.  Management: Separate administration of strontium ranelate and oral calcium salts by at least 2 hours in order to minimize this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Calcium Salts may decrease the serum concentration of Tetracycline Derivatives.  Management: If coadministration of oral calcium with oral tetracyclines can not be avoided, consider separating administration of each agent by several hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Calcium Salts may diminish the therapeutic effect of Thyroid Products.  Management: Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Calcium Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Calcium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Calcium Salts may enhance the adverse/toxic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1002956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not give orally with bran, foods high in oxalates (spinach, sweet potatoes, rhubarb, beans), or phytic acid ( unleavened bread, raw beans, seeds, nuts, grains, soy isolates) which may decrease calcium absorption; minimize administration with dairy products (when treating deficiency state) as this will reduce absorption",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13333812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Calcium crosses the placenta. Intestinal absorption of calcium increases during pregnancy. The amount of calcium reaching the fetus is determined by maternal physiological changes. Calcium requirements are the same in pregnant and nonpregnant females (IOM, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F3429087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum calcium (ionized calcium preferred if available), phosphate, magnesium, heart rate, ECG",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F3429088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Calcium: Newborns: 7-12 mg/dL; 0-2 years: 8.8-11.2 mg/dL; 2 years to adults: 9-11 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Calcium, ionized, whole blood: 4.4-5.4 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1002957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Calcium moderates nerve and muscle performance via action potential excitation threshold regulation; it is necessary for maintaining the functional integrity of nervous, muscular, and skeletal systems and cell-membrane and capillary permeability. Calcium citrate combines with dietary phosphate to form insoluble calcium phosphate which is excreted in feces and reduces phosphate absorption",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1002958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: 25% to 35%; varies with age (infants 60%, prepubertal children 28%, pubertal children 34%, young adults 25%); decreased absorption occurs in patients with achlorhydria, renal osteodystrophy, steatorrhea, or uremia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 45%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Primarily in the feces as unabsorbed calcium",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F3429790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     1 g calcium citrate = 211 mg elemental calcium = 10.6 mEq calcium. Due to a poor correlation between the serum ionized calcium (free) and total serum calcium, particularly in states of low albumin or acid/base imbalances, direct measurement of ionized calcium is recommended. If ionized calcium is unavailable, in low albumin states, the corrected",
"     <b>",
"      total",
"     </b>",
"     serum calcium may be estimated by this equation (assuming a normal albumin of 4 g/dL); [(4 &ndash; patient's albumin) x 0.8] + patient's measured total calcium",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Elemental Calcium Content of Calcium Salts",
"     </caption>",
"     <col align=\"left\" width=\"200\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium Salt",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Elemental Calcium",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg/1 g of salt form)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mEq/g)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Approximate Equivalent Doses",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg of calcium salt)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium acetate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         12.7",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         354",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium carbonate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         400",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         225",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium chloride",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         270",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         13.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         330",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium citrate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         211",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10.6",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         425",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium glubionate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         64",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3.2",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1400",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium gluconate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         90",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1000",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium lactate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         130",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         6.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         700",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium phosphate (tribasic)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         390",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         19.3",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         233",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Dietary Reference Intakes for Calcium and Vitamin D",
"      </i>",
"      , Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium, Ross AC, Taylor CL, et al, eds, Washington, DC: National Academies Press (US), 2011. Available at",
"      <a href=\"file://www.nap.edu/catalog.php?record_id=13050\" target=\"_blank\">",
"       file://www.nap.edu/catalog.php?record_id=13050",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/2/29733/abstract-text/21796828/pubmed\" id=\"21796828\" target=\"_blank\">",
"        21796828",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12867 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-6C4A8C19E1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_2_29733=[""].join("\n");
var outline_f29_2_29733=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144542\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144543\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1002942\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442186\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1002960\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144531\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144518\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3429789\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3429788\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1002943\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144560\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144559\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1002945\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3429086\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1002946\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298939\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144526\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1002956\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13333812\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3429087\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3429088\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1002957\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1002958\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3429790\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12867\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12867|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38628?source=related_link\">",
"      Calcium citrate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?24/15/24820?source=related_link\">",
"      Calcium citrate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_2_29734="Ethinyl estradiol and norgestrel: Patient drug information";
var content_f29_2_29734=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ethinyl estradiol and norgestrel: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/0/16393?source=see_link\">",
"     see \"Ethinyl estradiol and norgestrel: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F168604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cryselle&reg; 28;",
"     </li>",
"     <li>",
"      Lo/Ovral&reg;-28;",
"     </li>",
"     <li>",
"      Low-Ogestrel&reg;;",
"     </li>",
"     <li>",
"      Ogestrel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F168605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Lo-Femenal 21;",
"     </li>",
"     <li>",
"      Ovral&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10027188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700856",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not smoke while taking birth control pills. Cigarette smoking raises the chance of very bad heart and blood-related side effects. This chance is higher with age (older than 35 years of age) and with heavy smoking (15 or more cigarettes per day). Birth control pills do not stop the spread of diseases caused by having sex.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10027190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691546",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop pregnancy.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691832",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat endometriosis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691841",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat women with hypogonadism.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691877",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat heavy bleeding during monthly periods (menstruation).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10027189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702082",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ethinyl estradiol, norgestrel, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Blood clots, breast cancer, diseased arteries in the brain, disease of a heart valve with problems, endometrial cancer, heart disease, high blood pressure, liver disease, liver tumor, very bad headache, tumor where estrogen makes it grow, or vaginal bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703789",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have surgery and need bed rest.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701021",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a heavy smoker (more than 15 cigarettes per day) and older than 35 years of age.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have not started your period.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10027194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696940",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use this drug if you have a history of endometrial cancer.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697169",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any blood flow problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697221",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have gallbladder disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698524",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), you will need to watch your blood sugar closely.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697308",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have migraine headaches, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a blood thinner, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698554",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do monthly breast self-exams and have a gynecologic exam every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696901",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort, dong quai, black cohosh, saw palmetto, red clover, or ginseng with this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid cigarette smoking. People older than 35 years of age and/or smoking more than 15 cigarettes per day have more chance for heart disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697712",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To protect from diseases caused by having sex, use a latex condom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10027195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697923",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Enlarged breasts.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, vaginal yeast infection. Report itching or discharge.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698231",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Period (menstrual) changes. These include lots of bleeding, spotting, or bleeding between cycles.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Gallbladder disease, blood clots, heart attacks, and other blood vessel problems may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10027197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698723",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you throw up within 1 hour of taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698615",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in how contact lenses feel in the eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698598",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A lump in the breast or breast soreness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698670",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10027192\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705508",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Stopping pregnancy:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694870",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to use as you have been told by your doctor or read the package insert.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698535",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you miss 2 periods in a row, take a pregnancy test before starting a new dosing cycle.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705507",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Stopping pregnancy after unprotected sex:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695923",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug within 72 hours after unprotected sex. Take it as soon as you can.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10027193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705508",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Stopping pregnancy:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696559",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696550",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Missed dosing facts may be found in the package insert or call your doctor to find out what to do.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705507",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Stopping pregnancy after unprotected sex:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10027198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10027199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12453 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-926874B457-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_2_29734=[""].join("\n");
var outline_f29_2_29734=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168604\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168605\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027188\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027190\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027189\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027194\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027195\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027197\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027192\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027193\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027198\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027199\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/0/16393?source=related_link\">",
"      Ethinyl estradiol and norgestrel: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_2_29735="Depression in pregnant women: Clinical features and consequences";
var content_f29_2_29735=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Depression in pregnant women: Clinical features and consequences",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/2/29735/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/2/29735/contributors\">",
"     Shaila Misri, MD, FRCPC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/2/29735/contributors\">",
"     Shari I Lusskin, MD, FAPA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/2/29735/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/2/29735/contributors\">",
"     Peter P Roy-Byrne, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/2/29735/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/2/29735/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/2/29735/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/2/29735/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy is generally considered a period of emotional well-being for the woman and her family. However, for many women, pregnancy and motherhood are times of increased vulnerability to psychiatric conditions. Longitudinal studies have shown that pregnancy does not protect against the development of new onset major depression or relapse of existing major depressive illness [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29735/abstract/1\">",
"     1",
"    </a>",
"    ]. Women who discontinue or reduce their doses of antidepressants are at particularly high risk.",
"   </p>",
"   <p>",
"    Epidemiological surveys indicate that the lifetime prevalence of major depression is two times higher in adult women than in men [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29735/abstract/2\">",
"     2",
"    </a>",
"    ]. Therefore, it is not surprising that depression is one of the most frequently encountered medical complications during pregnancy and postpartum [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29735/abstract/3\">",
"     3",
"    </a>",
"    ]. In spite of the high risk of this illness in women, many clinicians fail to recognize, diagnose, and offer appropriate treatment for depression during pregnancy. This may be due, in part, to the fact that somatic symptoms of depression during pregnancy, such as changes in sleep and appetite, may be attributed to normal pregnancy-related changes in maternal physiology [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29735/abstract/4\">",
"     4",
"    </a>",
"    ]. Even when women at risk for depression are identified, studies have shown that very few receive treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29735/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic reviews the clinical features and consequences of depression during pregnancy. Management of depression during pregnancy and postpartum depression are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28682?source=see_link\">",
"     \"Depression in pregnant women: Management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/11/20666?source=see_link\">",
"     \"Postpartum blues and depression\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although many women report experiencing negative mood symptoms during their pregnancies, the number of pregnant women who actually fulfill the diagnostic criteria for major depression is much smaller [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29735/abstract/5-11\">",
"     5-11",
"    </a>",
"    ]. The best estimate of prevalence of perinatal depression was reported by the Agency for Healthcare Research and Quality [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29735/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Point prevalence (ie, the measure of a condition in a population at a given point in time) of major depression alone ranged from 3.1 to 4.9 percent at different times during pregnancy and 1.0 to 5.9 percent at different times during the first postpartum year.",
"     </li>",
"     <li>",
"      Point prevalence for major and minor depression ranged from 8.5 to 11.0 percent during pregnancy and 6.5 to 12.9 percent during the first year postpartum.",
"     </li>",
"     <li>",
"      The period prevalence (ie, the measure of a condition in a population over a period of time; a combination of point prevalence and incidence) of depression at any time from conception to birth was 14 to 23 percent; the period prevalence at any time from birth to three months postpartum was 11 to 32 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These prevalence estimates were not significantly different from those of similarly aged nonpregnant women.",
"   </p>",
"   <p>",
"    The Agency for Healthcare Research and Quality also found that major and minor depression occurred more often during the second trimester and postpartum than at other times; however, the confidence intervals were wide and there was significant variation among study designs, so it is not certain that depression peaks at these times [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29735/abstract/12\">",
"     12",
"    </a>",
"    ]. Another meta-analysis found that depressive symptoms (as opposed to clinical depression) were more prevalent in the second trimester (13 percent) and third trimester (12 percent) than in the first trimester (7 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29735/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is unclear why pregnancy represents a vulnerable time for onset of depression in some women. Possible etiological factors that may interact with each other include hormonal shifts, neuroendocrine changes, and psychosocial adjustments.",
"   </p>",
"   <p>",
"    Many risk factors for developing depression during pregnancy have been identified. A systematic review of 57 studies (out of 1361 studies initially selected) found the strongest evidence for [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29735/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Life stress, including adverse life events",
"     </li>",
"     <li>",
"      Lack of social support",
"     </li>",
"     <li>",
"      Domestic violence",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other risk factors include history of depression prior to pregnancy, maternal anxiety, unintended pregnancy, ambivalence towards the pregnancy, lower income, lower education, smoking, single status (noncohabitation), poor relationship quality, public insurance (United States studies only), history of antepartum or postpartum depression, family history of depression (especially during pregnancy or postpartum), and discontinuing or decreasing antidepressant medication [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29735/abstract/1,6,8,9,13-16\">",
"     1,6,8,9,13-16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28682?source=see_link&amp;anchor=H6#H6\">",
"     \"Depression in pregnant women: Management\", section on 'Risks of suboptimal dosing and discontinuing therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Criteria for diagnosis of major and minor depression in adults are described elsewhere. The Edinburgh Postnatal Depression Scale (EPDS) can be used as a screening tool antepartum or postpartum [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29735/abstract/17\">",
"     17",
"    </a>",
"    ]. The PRIME-MD Patient Health Questionnaire is another option and has been validated in obstetrics and gynecology patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29735/abstract/18\">",
"     18",
"    </a>",
"    ]. The Hamilton rating scale can be used to rate the severity of depression in women diagnosed with the disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link\">",
"     \"Clinical manifestations and diagnosis of depression\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is substantial comorbidity between various psychiatric disorders. As an example, when making a diagnosis of major depression, consider that the patient may also have panic attacks (",
"    <a class=\"graphic graphic_table graphicRef73966 \" href=\"UTD.htm?37/9/38044\">",
"     table 1",
"    </a>",
"    ), generalized anxiety disorder (",
"    <a class=\"graphic graphic_table graphicRef55612 \" href=\"UTD.htm?28/54/29547\">",
"     table 2",
"    </a>",
"    ), or obsessive compulsive disorder (",
"    <a class=\"graphic graphic_table graphicRef78513 \" href=\"UTD.htm?15/1/15387\">",
"     table 3",
"    </a>",
"    ). In addition, unipolar major depression needs to be distinguished from bipolar major depression.",
"   </p>",
"   <p>",
"    The course of panic disorder in pregnancy is variable, but the condition almost invariably worsens postpartum. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/0/32776?source=see_link\">",
"     \"Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7305?source=see_link\">",
"     \"Pharmacotherapy for panic disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As in nonpregnant women, bipolar disorder should be included in the differential diagnosis of women with antenatal depression. Careful screening for a history of mood swings and a family history of bipolar disorder will help identify patients at risk (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19639?source=see_link\">",
"     \"Bipolar disorder in adults: Epidemiology and diagnosis\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of a psychiatric disorder does not exclude the potential coexistence of other medical and obstetrical conditions. Therefore, evaluation for mood and anxiety disorders in pregnancy should include an appropriate baseline medical work-up including a complete blood count and thyroid, renal, and liver function tests.",
"   </p>",
"   <p>",
"    We recommend sending a urine toxicology screen, given the high comorbidity between psychiatric disorders and drug and alcohol use. Self-medication with drugs, alcohol, and tobacco is a common complication of mood disorders, even in pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29735/abstract/19\">",
"     19",
"    </a>",
"    ]. Both prescription drugs (particularly in healthcare professionals) and illicit drugs may be used. In addition, the woman should be evaluated for use of herbal medications and over-the-counter remedies that may precipitate or exacerbate psychiatric disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5033?source=see_link\">",
"     \"Substance use disorders: Principles for recognition and assessment in general medical care\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CONSEQUENCES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Maternal",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the mother, consequences that have been attributed to antenatal depression include [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29735/abstract/12,20-24\">",
"     12,20-24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Impaired judgment leading to noncompliance with prenatal care",
"     </li>",
"     <li>",
"      Self-medication with tobacco, alcohol, and drugs",
"     </li>",
"     <li>",
"      Poor appetite and poor weight gain",
"     </li>",
"     <li>",
"      Insomnia",
"     </li>",
"     <li>",
"      Anxiety (frequently comorbid with depression)",
"     </li>",
"     <li>",
"      Worsening of depression (which may lead to development of psychotic symptoms)",
"     </li>",
"     <li>",
"      Suicidal ideation and suicide",
"     </li>",
"     <li>",
"      Impaired maternal-infant bonding",
"     </li>",
"     <li>",
"      Postpartum depression",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The overall risk of suicide in pregnancy is low; data are conflicting as to whether it is lower than or similar to the risk in age-adjusted nonpregnant females [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29735/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. The suicide risk is highest after a stillbirth, in pregnant adolescents, in women with a prior hospitalization with a psychiatric diagnosis, and in postpartum women [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29735/abstract/25,28\">",
"     25,28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10377?source=see_link\">",
"     \"Suicidal ideation and behavior in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In California, the rate of attempted suicide during pregnancy from 1991 to 1999 was 0.4 per 1000 pregnancies; 90 percent were by ingestion of a potentially harmful substance (eg, drug overdose, poison) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29735/abstract/29\">",
"     29",
"    </a>",
"    ]. Risk factors were young age, multiparity, African-American race, low socioeconomic status, and history of substance abuse.",
"   </p>",
"   <p>",
"    The Confidential Enquiry into Maternal Deaths 1997 to 1999 found that suicide was a common cause of maternal death in the first postpartum year [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29735/abstract/24\">",
"     24",
"    </a>",
"    ]. There were 378 deaths of women who were pregnant or up to one year postpartum; 28 of these deaths were suicides. Women committed suicide by violent means such as hanging or jumping. The majority of the women suffered from a serious psychiatric illness and nearly half of those had a history of a postpartum psychiatric admission. Nonetheless, it was rare for the treating psychiatric or obstetric services in the index pregnancy to be aware of the previous history or the risk of recurrence.",
"   </p>",
"   <p>",
"    These findings highlight the importance of screening for mood disorders during pregnancy, for obtaining a complete history of prior episodes, and for implementing preventive strategies, to minimize the morbidity and mortality associated with perinatal mental illness [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29735/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pregnancy and offspring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depression",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    its treatment may also have direct effects on pregnancy, but few high quality studies exist [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29735/abstract/31-36\">",
"     31-36",
"    </a>",
"    ]. The majority of studies in this area have not adequately controlled for severity of the maternal mood disorder, substance abuse (cigarettes, alcohol, illicit drugs), poor nutrition, and other confounders (eg, non-compliance with prenatal care, low maternal income, maternal weight and weight gain, maternal age) and have had small sample sizes. Therefore, the potential for direct adverse effects, such as miscarriage, teratogenicity, low birth weight, preeclampsia, preterm birth, fetal growth restriction, and hyperemesis gravidarum, has not been fully characterized. For example, an association between preterm birth and depression may be due to comorbid factors such as poor nutrition, smoking, use of other drugs, or elevated corticotropin releasing hormone [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29735/abstract/33-36\">",
"     33-36",
"    </a>",
"    ]; a link with SSRI use may be because women using SSRIs may be more depressed than other women.",
"   </p>",
"   <p>",
"    There are few studies that specifically assessed the short- and long-term effects of maternal depression during pregnancy on offspring. Research on fetal and child development is often hampered by methodologic limitations. These include using heterogeneous populations, nonstandardized control groups, small samples, incomplete assessment of maternal mental health, inadequate controls for exposure to perinatal mental illness in either parent, and inadequate controls for maternal substance abuse (including alcohol and tobacco) and use of medications.",
"   </p>",
"   <p>",
"    One study has found that depressive symptoms may reduce fetal growth. In a community sample of pregnant women with clinically relevant depression who were not treated with antidepressants (N = 570) and pregnant women with few or no depressive symptoms (N = 7027; control group), fetal growth was examined with ultrasonography each trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29735/abstract/37\">",
"     37",
"    </a>",
"    ]. Compared to the control group, fetal weight gain was reduced in fetuses from depressed mothers by approximately 4.4 g per week. Although growth of head circumference was initially reduced in fetuses from depressed mothers compared to controls, head circumference at birth was comparable. &nbsp;",
"   </p>",
"   <p>",
"    Numerous studies have suggested that offspring of depressed parents are at increased risk of psychiatric problems, and possibly non-psychiatric medical disorders, compared to offspring of nondepressed parents [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29735/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. Both environmental influences (the effects of living in a household with depressed individuals) and genetics (see below) probably play a role in outcome.",
"   </p>",
"   <p>",
"    The effects of antenatal anxiety have been more widely investigated [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29735/abstract/41-46\">",
"     41-46",
"    </a>",
"    ]. These studies are important, given the high prevalence of anxiety disorders in women (4.7 percent) and the high comorbidity between anxiety and depressive symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29735/abstract/41\">",
"     41",
"    </a>",
"    ]. The mechanisms by which maternal stress (anxiety and depression) actually affects fetal development are not well-characterized. The fetal programming hypothesis states that \"the environment in utero can alter the development of the fetus during particular sensitive periods, with a permanent effect on the phenotype\" [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29735/abstract/42\">",
"     42",
"    </a>",
"    ]. Different mechanisms may operate at different stages of development; gender also influences susceptibility. Antenatal stress may interfere with development of the hypothalamic-pituitary-adrenal axis, the limbic system, and the prefrontal cortex. Cortisol, which crosses the placenta, may be a prime mediator of these effects.",
"   </p>",
"   <p>",
"    Another proposed explanation is that maternal mental health may affect fetal development via the neuroendocrine,",
"    <span class=\"nowrap\">",
"     immune/inflammatory,",
"    </span>",
"    and cardiovascular systems in the fetus. Placental corticotropin releasing hormone may play a central role. Genetic predisposition",
"    <span class=\"nowrap\">",
"     (race/ethnicity)",
"    </span>",
"    may determine the degree of sensitivity to adverse effects of prenatal stress [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29735/abstract/47\">",
"     47",
"    </a>",
"    ]. However, an association between maternal anxiety and specific adverse perinatal outcomes (eg, preterm birth, low birthweight, low Apgars) has not been proven [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29735/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Offspring may have a genetic predisposition to depression. A family history of depression, particularly postpartum depression, is a risk factor for postpartum depression in the next generation. The role of genetics in the pathophysiology of depression is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/38/37481?source=see_link&amp;anchor=H8#H8\">",
"     \"Unipolar depression in adults: Epidemiology, pathogenesis, and neurobiology\", section on 'Genetics'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Effects of antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effects of maternal antidepressant medication on fetal and neonatal development are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28682?source=see_link\">",
"     \"Depression in pregnant women: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women should be screened for and counseled about their risk of developing a mood disorder. The point of this discussion is to increase the patient's awareness of the tendency toward depression so that early symptoms will be recognized, and appropriate intervention sought.",
"   </p>",
"   <p>",
"    The United States Preventive Services Task Force (USPSTF) recommends screening adults for depression in clinical practices that have systems in place to assure accurate diagnosis, effective treatment, and follow-up. The USPSTF clinical practice guideline for screening for depression, as well as other USPSTF guidelines, can be accessed through the website for the Agency for Healthcare Research and Quality at",
"    <a class=\"external\" href=\"file://www.ahrq.gov/clinic/uspstfix.htm\">",
"     www.ahrq.gov/clinic/uspstfix.htm",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Pregnancy provides an optimal time for screening, as women have frequent contact with healthcare providers. Early detection of depression during pregnancy is important because untreated illness has consequences for both mother and child, and may evolve into postpartum depression [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29735/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal tool for screening pregnant women for depression has not been determined. Many studies have used the Edinburgh Postnatal Depression Scale, which is an easily completed self-rating instrument available in many languages (",
"    <a class=\"graphic graphic_figure graphicRef67741 graphicRef81407 \" href=\"UTD.htm?33/20/34115\">",
"     figure 1A-B",
"    </a>",
"    ), although it was created for use in postpartum women [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29735/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/11/20666?source=see_link&amp;anchor=H11#H11\">",
"     \"Postpartum blues and depression\", section on 'Screening'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We also suggest that the clinician ask questions such as \"How have you been feeling?\" and \"Are you able to enjoy your usual activities?\". If the answer is concerning, then follow-up questions such as \"Do you feel overwhelmed? Sad? Depressed? Hopeless or helpless?\" will better define the patient's mood [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29735/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional screening tools, which are used in the general adult population, are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link&amp;anchor=H22#H22\">",
"     \"Clinical manifestations and diagnosis of depression\", section on 'Screening for depression'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of women planning pregnancy and pregnant women is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/25/16794?source=see_link&amp;anchor=H13#H13\">",
"     \"Preconception evaluation and counseling\", section on 'Psychosocial issues'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28682?source=see_link\">",
"     \"Depression in pregnant women: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest screening pregnant women for depression (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The somatic and emotional symptoms of depression during pregnancy may be misattributed to normal pregnancy-related changes in maternal physiology and temperament. Sad, blue, hopeless or helpless mood and suicidal ideation are distinguishing features of depression. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prevalence of depression in pregnant women is not significantly different from that in similarly aged nonpregnant women. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prevalence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major risk factors for developing depression during pregnancy are history of depression prior to pregnancy, history of antepartum or postpartum depression, and family history of depression (especially during pregnancy or postpartum). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Criteria for diagnosis of major and minor depression in adults are described elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link\">",
"       \"Clinical manifestations and diagnosis of depression\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pregnant women who are diagnosed with depression should have a baseline medical work-up (complete blood count and thyroid, renal, and liver function tests), urine toxicology screen (given the high comorbidity between psychiatric disorders and drug and alcohol use), and evaluation for use of herbal medications and over-the-counter remedies that may precipitate or exacerbate psychiatric disorders. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most serious consequence of maternal depression is suicide; this risk is particularly high in adolescents and after stillbirth. Noncompliance with prenatal care and substance abuse are additional concerns. Women with antenatal depression are also at high risk for postpartum depression. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Consequences'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Offspring of depressed mothers are at risk for numerous consequences. Genetic factors may influence the offspring's susceptibility to environmental stressors (eg, maternal anxiety and depression, maternal medication use).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29735/abstract/1\">",
"      Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006; 295:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29735/abstract/2\">",
"      Weissman MM, Olfson M. Depression in women: implications for health care research. Science 1995; 269:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29735/abstract/3\">",
"      Hendrick V, Altshuler L. Management of major depression during pregnancy. Am J Psychiatry 2002; 159:1667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29735/abstract/4\">",
"      Altshuler LL, Hendrick V, Cohen LS. Course of mood and anxiety disorders during pregnancy and the postpartum period. J Clin Psychiatry 1998; 59 Suppl 2:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29735/abstract/5\">",
"      Marcus SM, Flynn HA, Blow FC, Barry KL. Depressive symptoms among pregnant women screened in obstetrics settings. J Womens Health (Larchmt) 2003; 12:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29735/abstract/6\">",
"      Llewellyn AM, Stowe ZN, Nemeroff CB. Depression during pregnancy and the puerperium. J Clin Psychiatry 1997; 58 Suppl 15:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29735/abstract/7\">",
"      Watson JP, Elliott SA, Rugg AJ, Brough DI. Psychiatric disorder in pregnancy and the first postnatal year. Br J Psychiatry 1984; 144:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29735/abstract/8\">",
"      O'Hara MW. Social support, life events, and depression during pregnancy and the puerperium. Arch Gen Psychiatry 1986; 43:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29735/abstract/9\">",
"      Kumar R, Robson KM. A prospective study of emotional disorders in childbearing women. Br J Psychiatry 1984; 144:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29735/abstract/10\">",
"      Evans J, Heron J, Francomb H, et al. Cohort study of depressed mood during pregnancy and after childbirth. BMJ 2001; 323:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29735/abstract/11\">",
"      Bennett HA, Einarson A, Taddio A, et al. Prevalence of depression during pregnancy: systematic review. Obstet Gynecol 2004; 103:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29735/abstract/12\">",
"      Gaynes BN, Gavin N, Meltzer-Brody S, et al. Perinatal depression: prevalence, screening accuracy, and screening outcomes. Evid Rep Technol Assess (Summ) 2005; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29735/abstract/13\">",
"      Lancaster CA, Gold KJ, Flynn HA, et al. Risk factors for depressive symptoms during pregnancy: a systematic review. Am J Obstet Gynecol 2010; 202:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29735/abstract/14\">",
"      Josefsson A, Berg G, Nordin C, Sydsj&ouml; G. Prevalence of depressive symptoms in late pregnancy and postpartum. Acta Obstet Gynecol Scand 2001; 80:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29735/abstract/15\">",
"      Beck CT. A meta-analysis of predictors of postpartum depression. Nurs Res 1996; 45:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29735/abstract/16\">",
"      O'Hara, MW, Swain, AM. Rates and risk of postpartum depression&mdash;a meta-analysis. Int Rev Psychiatry 1996; 8:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29735/abstract/17\">",
"      Buist A, Condon J, Brooks J, et al. Acceptability of routine screening for perinatal depression. J Affect Disord 2006; 93:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29735/abstract/18\">",
"      Spitzer RL, Williams JB, Kroenke K, et al. Validity and utility of the PRIME-MD patient health questionnaire in assessment of 3000 obstetric-gynecologic patients: the PRIME-MD Patient Health Questionnaire Obstetrics-Gynecology Study. Am J Obstet Gynecol 2000; 183:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29735/abstract/19\">",
"      Kelly R, Zatzick D, Anders T. The detection and treatment of psychiatric disorders and substance use among pregnant women cared for in obstetrics. Am J Psychiatry 2001; 158:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29735/abstract/20\">",
"      Yonkers KA, Ramin SM, Rush AJ, et al. Onset and persistence of postpartum depression in an inner-city maternal health clinic system. Am J Psychiatry 2001; 158:1856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29735/abstract/21\">",
"      Larsson C, Sydsj&ouml; G, Josefsson A. Health, sociodemographic data, and pregnancy outcome in women with antepartum depressive symptoms. Obstet Gynecol 2004; 104:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29735/abstract/22\">",
"      Bonari L, Pinto N, Ahn E, et al. Perinatal risks of untreated depression during pregnancy. Can J Psychiatry 2004; 49:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29735/abstract/23\">",
"      Kurki T, Hiilesmaa V, Raitasalo R, et al. Depression and anxiety in early pregnancy and risk for preeclampsia. Obstet Gynecol 2000; 95:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29735/abstract/24\">",
"      Oates M. Suicide: the leading cause of maternal death. Br J Psychiatry 2003; 183:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29735/abstract/25\">",
"      Appleby L. Suicide during pregnancy and in the first postnatal year. BMJ 1991; 302:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29735/abstract/26\">",
"      Marzuk PM, Tardiff K, Leon AC, et al. Lower risk of suicide during pregnancy. Am J Psychiatry 1997; 154:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29735/abstract/27\">",
"      Oates M. Perinatal psychiatric disorders: a leading cause of maternal morbidity and mortality. Br Med Bull 2003; 67:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29735/abstract/28\">",
"      Comtois KA, Schiff MA, Grossman DC. Psychiatric risk factors associated with postpartum suicide attempt in Washington State, 1992-2001. Am J Obstet Gynecol 2008; 199:120.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29735/abstract/29\">",
"      Gandhi SG, Gilbert WM, McElvy SS, et al. Maternal and neonatal outcomes after attempted suicide. Obstet Gynecol 2006; 107:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29735/abstract/30\">",
"      Lusskin SI, Pundiak TM, Habib SM. Perinatal depression: hiding in plain sight. Can J Psychiatry 2007; 52:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29735/abstract/31\">",
"      Hemels ME, Einarson A, Koren G, et al. Antidepressant use during pregnancy and the rates of spontaneous abortions: a meta-analysis. Ann Pharmacother 2005; 39:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29735/abstract/32\">",
"      Mian AI. Depression in pregnancy and the postpartum period: balancing adverse effects of untreated illness with treatment risks. J Psychiatr Pract 2005; 11:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29735/abstract/33\">",
"      Suri R, Altshuler L, Hellemann G, et al. Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. Am J Psychiatry 2007; 164:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29735/abstract/34\">",
"      Hoffman S, Hatch MC. Depressive symptomatology during pregnancy: evidence for an association with decreased fetal growth in pregnancies of lower social class women. Health Psychol 2000; 19:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29735/abstract/35\">",
"      Wisner KL, Sit DK, Hanusa BH, et al. Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am J Psychiatry 2009; 166:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29735/abstract/36\">",
"      Orr ST, James SA, Blackmore Prince C. Maternal prenatal depressive symptoms and spontaneous preterm births among African-American women in Baltimore, Maryland. Am J Epidemiol 2002; 156:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29735/abstract/37\">",
"      El Marroun H, Jaddoe VW, Hudziak JJ, et al. Maternal use of selective serotonin reuptake inhibitors, fetal growth, and risk of adverse birth outcomes. Arch Gen Psychiatry 2012; 69:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29735/abstract/38\">",
"      Weissman MM, Wickramaratne P, Nomura Y, et al. Offspring of depressed parents: 20 years later. Am J Psychiatry 2006; 163:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29735/abstract/39\">",
"      Kim-Cohen J, Caspi A, Rutter M, et al. The caregiving environments provided to children by depressed mothers with or without an antisocial history. Am J Psychiatry 2006; 163:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29735/abstract/40\">",
"      Deave T, Heron J, Evans J, Emond A. The impact of maternal depression in pregnancy on early child development. BJOG 2008; 115:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29735/abstract/41\">",
"      Field T, Diego M, Hernandez-Reif M, et al. Pregnancy anxiety and comorbid depression and anger: effects on the fetus and neonate. Depress Anxiety 2003; 17:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29735/abstract/42\">",
"      Van den Bergh BR, Mulder EJ, Mennes M, Glover V. Antenatal maternal anxiety and stress and the neurobehavioural development of the fetus and child: links and possible mechanisms. A review. Neurosci Biobehav Rev 2005; 29:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29735/abstract/43\">",
"      Connor, TG, Heron, J, et al. Maternal antenatal anxiety and children's behavioural/emotional problems at 4 years. Report from the Avon Longitudinal Study of Parents and Children. British Journal of Psychiatry 2002; 80: 502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29735/abstract/44\">",
"      O'Connor TG, Heron J, Golding J, et al. Maternal antenatal anxiety and behavioural/emotional problems in children: a test of a programming hypothesis. J Child Psychol Psychiatry 2003; 44:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29735/abstract/45\">",
"      Van den Bergh BR, Marcoen A. High antenatal maternal anxiety is related to ADHD symptoms, externalizing problems, and anxiety in 8- and 9-year-olds. Child Dev 2004; 75:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29735/abstract/46\">",
"      Van den Bergh BR, Mennes M, Oosterlaan J, et al. High antenatal maternal anxiety is related to impulsivity during performance on cognitive tasks in 14- and 15-year-olds. Neurosci Biobehav Rev 2005; 29:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29735/abstract/47\">",
"      Federenko IS, Wadhwa PD. Women's mental health during pregnancy influences fetal and infant developmental and health outcomes. CNS Spectr 2004; 9:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29735/abstract/48\">",
"      Littleton HL, Breitkopf CR, Berenson AB. Correlates of anxiety symptoms during pregnancy and association with perinatal outcomes: a meta-analysis. Am J Obstet Gynecol 2007; 196:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29735/abstract/49\">",
"      Ryan D, Milis L, Misri N. Depression during pregnancy. Can Fam Physician 2005; 51:1087.",
"     </a>",
"    </li>",
"    <li>",
"     Cox, J, Holden, J. Perinatal psychiatry. Use and misuse of the Edinburgh Postnatal Depression Scale. Glasgow: The Royal College of Psychiatrists 1994; 275.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29735/abstract/51\">",
"      Jesse DE, Graham M. Are you often sad and depressed? Brief measures to identify women at risk for depression in pregnancy. MCN Am J Matern Child Nurs 2005; 30:40.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1718 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-D8E5382BBA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_2_29735=[""].join("\n");
var outline_f29_2_29735=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CONSEQUENCES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Maternal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pregnancy and offspring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Effects of antidepressants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/1718\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/1718|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/43/34495\" title=\"figure 1A\">",
"      Edinburgh depression scale 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/61/34783\" title=\"figure 1B\">",
"      Edinburgh depression scale 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/1718|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/9/38044\" title=\"table 1\">",
"      Dx criteria panic disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/54/29547\" title=\"table 2\">",
"      Dx criteria generalized anxiety",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/1/15387\" title=\"table 3\">",
"      Diagnostic criteria for obsessive-compulsive disorder",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19639?source=related_link\">",
"      Bipolar disorder in adults: Epidemiology and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28682?source=related_link\">",
"      Depression in pregnant women: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/0/32776?source=related_link\">",
"      Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7305?source=related_link\">",
"      Pharmacotherapy for panic disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/11/20666?source=related_link\">",
"      Postpartum blues and depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/25/16794?source=related_link\">",
"      Preconception evaluation and counseling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5033?source=related_link\">",
"      Substance use disorders: Principles for recognition and assessment in general medical care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10377?source=related_link\">",
"      Suicidal ideation and behavior in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/38/37481?source=related_link\">",
"      Unipolar depression in adults: Epidemiology, pathogenesis, and neurobiology",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_2_29736="Parentage testing using DNA";
var content_f29_2_29736=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"36\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Parentage testing using DNA",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/2/29736/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/2/29736/contributors\">",
"     Elizabeth S Panke, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/2/29736/contributors\">",
"     Alan E Donnenfeld, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/2/29736/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/2/29736/contributors\">",
"     Louise Wilkins-Haug, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/2/29736/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/2/29736/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/2/29736/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The number of parentage test cases processed by laboratories in the United States is rapidly increasing due, in part, to advances in DNA and information technology. The AABB (formerly the American Association of Blood Banks) reported that 414,843 paternity tests were performed in 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29736/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Physicians should become knowledgeable about DNA parentage testing, as they will undoubtedly face situations where they need to understand the process, results, accuracy, limitations, and implications of testing. Court-ordered parentage testing is becoming more common. In addition, patients will ask for these tests or for help with interpretation of test results since DNA testing is now directly available to the general public.",
"   </p>",
"   <p>",
"    Regulation of DNA parentage testing laboratories is limited; external oversight and accreditation of these laboratories are voluntary. As a result, the quality, thoroughness, interpretation of results, and admissibility of the information in court from DNA parentage testing laboratories vary from laboratory to laboratory. In this environment, it is important that the physician and the patient abandon the pervasive belief that all DNA tests produce extremely accurate, totally conclusive, and irrefutable answers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     APPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;From a historical perspective, the primary objective of parentage testing was to determine whether a man accused of paternity (ie, alleged father) could be accurately excluded as the biological father of a given child. More than 99 percent of falsely accused men can be excluded of paternity by using systems of red cell antigens, serum proteins, red cell enzymes, and HLA [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29736/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Actual proof of paternity is not possible with any laboratory test because there is always a chance that another man could have the same test results as the alleged father since the number of markers tested is limited. However, advances in DNA technology have made it possible for DNA parentage testing to produce highly conclusive evidence of parentage or absence of parentage.",
"   </p>",
"   <p>",
"    The most common situations in which parentage testing may be performed include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Court ordered DNA analyses to determine responsibility for child support and custody rights. If the father is deceased, the test may be used to obtain Social Security, veteran's, or insurance benefits or settle an inheritance dispute for the child. Court ordered DNA analyses are also performed in criminal cases involving sexual abuse of a minor resulting in pregnancy.",
"     </li>",
"     <li>",
"      Determination of a child's biological parents. These cases usually involve adoption, immigration, and citizenship issues. They may also be related to assisted reproduction procedures (eg, in vitro fertilization) or, rarely, newborns misidentified in the hospital or kidnapped.",
"     </li>",
"     <li>",
"      Prenatal paternity testing for pregnant women who are unsure who has fathered their child.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Occasionally, laboratory test results reveal the unexpected finding that the father is not the biological father of a child. Management of this situation can be complicated, and is addressed below (see",
"    <a class=\"local\" href=\"#H22\">",
"     'Disclosure of false paternity'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     COST",
"    </span>",
"    &nbsp;&mdash;&nbsp;The laboratory fees for DNA paternity tests typically range from $400 to $600 in the United States; most insurance plans do not cover these costs. The cost of ultrasound examination plus amniocentesis or chorionic villus sampling adds to the cost of prenatal paternity testing (by about $2000) and is not covered by insurance unless these tests are performed for standard indications, such as increased risk of Down syndrome or presence of a congenital anomaly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SAMPLE COLLECTION AND PROCESSING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since DNA is present in most cells of the body, a variety of cell types may be collected for DNA parentage testing. Samples are usually obtained from the inside of the mouth with a cotton or a Dacron swab due to the ease of collection. Blood samples may also be submitted for testing; just a few drops of blood from a finger or a heel prick are sufficient. For prenatal DNA parentage testing, a fetal sample is collected from amniotic fluid (5 to 10 mL) by amniocentesis or by chorionic villus sampling (CVS); thus, prenatal DNA paternity testing can be performed as early as the late first trimester. The fetal cells can be submitted directly to the DNA testing laboratory, or they can be sent to a cytogenetics laboratory for culture before they are forwarded for paternity analysis. Noninvasive prenatal diagnosis using cell free fetal DNA in maternal blood is possible, but remains investigational (see",
"    <a class=\"local\" href=\"#H1786280\">",
"     'Noninvasive prenatal paternity testing'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Sample collection procedures are an integral part of the DNA parentage testing process. The legal ramifications of DNA parentage test results require that sample collections conform to strict chain-of-custody procedures. These collection procedures dictate the:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Selection of the person collecting the samples",
"     </li>",
"     <li>",
"      Documentation of the identity of the tested individuals",
"     </li>",
"     <li>",
"      Tracking of the sample during the collection and testing process",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Unfortunately, thousands of sample collections are performed for DNA parentage tests that do not conform to the documentation of identity and chain-of-custody procedures described below. As an example, numerous laboratories offer home testing kits that allow for anonymous testing and for sample collections without the involvement of laboratory personnel or other professionals. These tests are sometimes referred to as \"curiosity testing\" as opposed to \"court-approved tests.\"",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Collection personnel",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important first step in the proper collection of samples is the selection of the individual(s) performing the sample collection. The Standards for Parentage Testing Laboratories published by the AABB state: \"all biologic samples for testing shall be collected by persons with no interest in the test outcome\" [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29736/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Identification of test subject",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tested individuals must be properly identified and the method of this identification must be documented. The AABB's Standards for Parentage Testing Laboratories procedures require that the tested individual must present government photo identification",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the tested person's photograph can be taken at the time of sample collection. Since government photo identifications do not always reflect the most recent and accurate appearance of the tested individual, identity is best documented with a photocopy of government photographic identification accompanied by the tested individual's photograph taken at the time of sample collection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Specimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each collected sample must be clearly identified through an affixed label containing a unique identification for the collected sample, the date of collection, and initials of the person collecting the sample. The person who provides legal consent for the collection of the sample must verify the accuracy of the affixed label in writing [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29736/abstract/3\">",
"     3",
"    </a>",
"    ]. Strict chain-of-custody procedures also apply. Samples may never be left out of sight. They must be sealed in a tamper-evident package immediately following sample collection. Test participants may not package or transfer the samples to the testing laboratory.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Prenatal testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;A request from a pregnant woman to determine the identity of the father of her fetus is becoming a more common event. Some women may use the test to terminate pregnancies that have arisen from a sexual assault or from an extramarital relationship. Others may use the information in legal proceedings, such as custody, child support, and inheritance rights.",
"   </p>",
"   <p>",
"    Whatever the motivation for requesting prenatal paternity testing, an obstetrician is under no obligation to perform or become involved in such testing if it violates his or her moral, ethical, religious, or professional beliefs. The obstetrician can notify the patient that",
"    <span class=\"nowrap\">",
"     he/she",
"    </span>",
"    does not participate in prenatal paternity testing and refer her to another physician who may be able to assist her.",
"   </p>",
"   <p>",
"    To perform prenatal paternity testing, biologic samples from the mother, fetus (by amniocentesis or CVS), and at least one suspected father are required. Testing may only be performed if a court order or informed consent of all adults involved has been obtained. The principle of autonomy and the confidentiality established by the doctor-patient relationship mandate that there is no obligation to inform the patient's partner (or husband) that paternity is an issue in the pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1786280\">",
"    <span class=\"h3\">",
"     Noninvasive prenatal paternity testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noninvasive prenatal paternity testing is possible [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29736/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. In 2011, a non-invasive prenatal paternity test became commercially available [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29736/abstract/6\">",
"     6",
"    </a>",
"    ]. This test can be done as early as 9 weeks of gestation, requires only a blood sample from the pregnant mother and alleged father(s), and costs $1625 in the United States. Cell-free fetal DNA isolated from the plasma of the mother&rsquo;s blood is analyzed using a dense microarray chip that examines 317,000 genetic markers known as single nucleotide polymorphisms (SNPs). An informatics algorithm is used to compute the similarity of genetic markers between the fetal DNA and the alleged father&rsquo;s DNA, as well as to unrelated random individuals. Although the methodology appears sound, results of peer reviewed clinical trials are not available, and there are no AABB professional guidelines for the use of such parentage testing, methodology standards, and proficiency testing. We do not endorse the use of such tests prior to comprehensive scientific and medical review [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29736/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PATERNITY TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the extent of misattributed paternity is unknown, estimates are surprisingly high and generally range from 5 to 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29736/abstract/8\">",
"     8",
"    </a>",
"    ]. A series reported by the AABB and including over 300,000 tests found that the average paternity exclusion rate for laboratories reporting exclusions was 27.4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29736/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    DNA parentage testing typically analyzes nuclear DNA. Although each individual has a unique sequence of nuclear DNA (except identical twins), more than 99.9 percent of the information present in the human genome is shared by unrelated individuals. Parentage testing using DNA analysis identifies variable regions of DNA (DNA polymorphisms) in the remaining 0.1 percent of our genetic material and then compares these sequences for different individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     DNA length polymorphisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the most useful types of polymorphic DNAs in parentage testing is length polymorphism. Length polymorphisms occur when small sections of DNA sequences are repeated numerous times in a row at a specific locus. The number of times these tandem DNA units are repeated produce alleles that are shorter in some people and longer in others. Two fragment lengths can be identified in each individual at the specified locus, one from each chromosome of the pair.",
"   </p>",
"   <p>",
"    These tandemly repeated regions of DNA are typically classified into several groups depending on the size of the repeat region. Minisatellites (also called \"variable number of tandem repeats\" [VNTRs]) have core repeats with 9 to 80 base pairs, while microsatellites (also called \"short tandem repeats\" [STRs]) contain 2 to 5 base pair repeats. Paternity testing laboratories have moved primarily towards the analyses of tetranucleotide STRs, which may be amplified using the polymerase chain reaction (PCR). Millions of copies of DNA fragments of interest are rapidly produced using this technology. These PCR-generated fragments are then sorted by size through electrophoresis and the specific fragment lengths are identified.",
"   </p>",
"   <p>",
"    At any specified genetic locus, two fragment lengths can be identified in each individual, one from each chromosome of a homologous pair. When reading DNA test results, it is important to first compare the allele sizes of the child and mother. One of the alleles in the child must match one of the alleles in the mother since the child must have received one-half of its DNA from the mother. The child's remaining allele can only have been inherited from the biological father and it is called the \"obligate paternal allele.\"",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Paternity index",
"    </span>",
"    &nbsp;&mdash;&nbsp;The paternity index (PI) is the ratio of the chance that the alleged father will pass a marker gene to the child compared to the chance that a random man will pass the marker gene to the child. The frequency of distribution of individual marker genes for a randomly selected man is determined from a database.",
"   </p>",
"   <p>",
"    If the tested man does not have the child's obligate paternal allele, the observed pattern is inconsistent with paternity (",
"    <a class=\"graphic graphic_table graphicRef70179 \" href=\"UTD.htm?29/46/30444\">",
"     table 1",
"    </a>",
"    ). The observed inconsistency at the specified locus is documented by a PI of zero (",
"    <a class=\"graphic graphic_table graphicRef82594 \" href=\"UTD.htm?26/52/27468\">",
"     table 2",
"    </a>",
"    ). An opinion of nonpaternity should not be rendered on the basis of a genetic mismatch at a single DNA site, or even when the mismatch involves two sites, especially when all remaining tested systems yield a large combined paternity index (discussed below). Most such occurrences merely reflect de novo genetic mutations that occur naturally in normal people. In cases where there are only one or two mismatches, the PI value at a single or double mismatching genetic site is not documented as zero, but calculated using equations that incorporate the mutation rate at the specified genetic site. For typical DNA-RFLP and -STR systems, average mutation rates range from 0.005 to 1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29736/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    DNA family relationship testing laboratories usually require that a minimum of three genetic mismatches between the alleged father and the child be present prior to rendering the diagnosis of nonpaternity, as three or more de novo mutations would be exceedingly rare (",
"    <a class=\"graphic graphic_table graphicRef82594 \" href=\"UTD.htm?26/52/27468\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    When a genetic match is identified between the tested man and a child, a PI is calculated to determine the likelihood of a coincidental match (",
"    <a class=\"graphic graphic_table graphicRef77866 \" href=\"UTD.htm?36/52/37708\">",
"     table 3",
"    </a>",
"    ). The PI utilizes information on the frequency of any one particular allele in the general population. When the paternal allele seen in the child is abundant in the population at large, a coincidental match (or a match by chance) is not unusual so the PI is low.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Combined paternity index (CPI)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The final analysis combines all of the genetic evidence and is a product of all of the individual PI values for both mismatches and matches. This is the bottom-line result of the DNA paternity test and it is called the Combined Paternity Index (CPI). The CPI is a ratio of the chance that the tested man, given his entire analyzed genetic makeup, is the biological father compared to the chance that a random man is the biological father.",
"   </p>",
"   <p>",
"    At what percent of probability does one feel reasonably secure in concluding that the tested man is the child's biological father? Currently, a CPI of 100 is the minimum required to establish parentage for legal purposes in most states. What does this level of test result really mean?",
"   </p>",
"   <p>",
"    A CPI of 100 means that the tested man is 100 times more likely to be the biological father than a random man in the general population. For a CPI of 100, the Random Man Not Excluded (RMNE) statistic value would also equal approximately 100 and it would be expressed as \"one individual in 100 has the same genetic pattern as the tested man,\" and the probability of paternity that the tested man is the biological father would be 99 percent. At this level, which is the minimum legal standard, 1 out of approximately 100 individuals in the population has the same genetic pattern as the tested man, and therefore could be the biological father.",
"   </p>",
"   <p>",
"    A number of laboratories believe that the minimum CPI required for legal establishment of parentage should be raised from a CPI of 100 (probability of paternity 99 percent) to a CPI of 1000 (probability of paternity 99.9 percent) to determine the biological father with a reasonable degree of certainty and to decrease the rate of false positive paternity results (",
"    <a class=\"graphic graphic_table graphicRef67221 \" href=\"UTD.htm?25/13/25819\">",
"     table 4",
"    </a>",
"    ). The following examples illustrate cases of incorrect attribution of paternity:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study used a 9- or 15-genetic STR loci test to test 249 men known",
"      <strong>",
"       not",
"      </strong>",
"      to be the child's father [",
"      <a class=\"abstract\" href=\"UTD.htm?29/2/29736/abstract/11\">",
"       11",
"      </a>",
"      ]. Among the 249 non-fathers, one matched the child on all nine genetic sites and had a CPI of 298 and 99.66 percent probability of paternity. Another man had a probability of paternity of 99.72 percent (CPI of 353) when 15 genetic sites were tested.",
"     </li>",
"     <li>",
"      A case reported at the Twelfth International Symposium on Human Identification involved a man accused of sexual assault whose DNA paternity test result showed a 99.3 percent probability of paternity [",
"      <a class=\"abstract\" href=\"UTD.htm?29/2/29736/abstract/12\">",
"       12",
"      </a>",
"      ]. Only with additional testing was this man excluded as the biological father of the child resulting from the sexual assault.",
"     </li>",
"     <li>",
"      Another report at the symposium was a case from the Arizona Public Safety Crime Laboratory that identified a match between two unrelated offenders, one Caucasian and the other African-American, who shared both alleles at nine genetic loci [",
"      <a class=\"abstract\" href=\"UTD.htm?29/2/29736/abstract/13\">",
"       13",
"      </a>",
"      ]. The Florida State Crime Laboratory has also reported a nine-genetic loci match between two unrelated individuals [",
"      <a class=\"abstract\" href=\"UTD.htm?29/2/29736/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A CPI of 1000 (probability of paternity &ge;99.9 percent) is possible in virtually all cases when the child, the child's mother, and the alleged father are tested at 13 independent genetic sites that include the CODIS loci. If testing is limited to samples collected from only the child and the alleged father (the mother's sample is not tested), a CPI of 1000 is not reached in up to 10 percent of cases. The need to collect and test the mother's sample in these cases to reach a CPI of 1000 increases testing costs. If the mother is absolutely unavailable for testing, the laboratory would be required to test several additional genetic sites between the child and the alleged father before a CPI of 1000 could be reached in most cases, which also increases testing costs.",
"   </p>",
"   <p>",
"    Evidence suggests that gains in adopting a minimum standard CPI of 1000 outweigh the costs, as reflected by several states increasing their standards for the presumption of paternity. Hawaii and Illinois increased the established presumption of paternity to a CPI of 500 (probability of paternity &ge;99.8 percent); Louisiana has increased the established presumption of paternity to a CPI of 1000 (probability of &ge;99.9 percent).",
"   </p>",
"   <p>",
"    Another significant benefit of an extensive DNA test is that it is more reliable in excluding falsely accused men who are relatives of the biological father, such as a brother, father, or son. This is important because laboratories are often given the opportunity to only test one of the alleged fathers.",
"   </p>",
"   <p>",
"    In an ideal world, laboratories would provide extensive testing in all cases and would test to a level of certainty of at least 99.9999999 percent, thereby removing any doubts of paternity. Technology is available to provide that level of certainty in every case. Paternity testing laboratories, however, have an economic incentive to keep the level of testing as low as possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Probability of paternity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Probability of paternity is another statistical means of describing the likelihood that the alleged father is the biological father of the child. It incorporates both genetic (CPI) and nongenetic (prior probability) information. Prior probability assigns a numerical value from 0 to 1 to the non-genetic evidence used in evaluating paternity; a prior probability of zero is impossible paternity, 0.5 is considered neutral, and 1 is certain paternity. When prior probability is 0.5, the formula for calculating probability of paternity is",
"    <span class=\"nowrap\">",
"     1/[1+1/CPI].",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Random man not excluded",
"    </span>",
"    &nbsp;&mdash;&nbsp;An",
"    easier way of expressing these figures is the RMNE statistic, which closely approximates the CPI. The RMNE is the frequency with which men selected at random from the same racial group as the alleged father would not be excluded as the biological father of the child by the given DNA paternity test.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Alleged fathers who are brothers",
"    </span>",
"    &nbsp;&mdash;&nbsp;A DNA testing laboratory must always be informed about situations in which two alleged fathers are related as brothers. DNA paternity tests cannot distinguish the true biological father in cases where two alleged fathers are monozygotic twins because monozygotic twins have identical nuclear DNA. When two alleged fathers are related as full siblings, they share half of their genetic makeup. In such cases, the most conclusive DNA paternity test results are obtained when both alleged fathers undergo DNA paternity testing: the DNA testing laboratory continues testing until one of these alleged fathers shows at least three genetic mismatches with the tested child.",
"   </p>",
"   <p>",
"    Sometimes the two alleged fathers are related as brothers and only one alleged father is available for DNA testing. In such cases, the DNA testing laboratory typically performs extended DNA testing analyzing a minimum of 15 to 24 genetic sites and the child's mother's sample is also tested (unless her sample is unavailable). Such extended testing and testing of the child's mother allow DNA testing laboratories to exclude a falsely accused brother from paternity in most cases; however, absolute certainty of exclusion in such cases can only be achieved when both brothers are tested.",
"   </p>",
"   <p>",
"    Additionally, upon request, the DNA testing laboratory can provide the avuncular index calculation along with the paternity index calculation on the DNA test report. Such reports will show how much more likely it is that the tested man is the biological father of the child versus the child's uncle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     OPTIONS WHEN THE FATHER IS NOT AVAILABLE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Grandparent testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;In cases where the alleged father is deceased or missing, both of his parents can be tested to determine the likelihood they are the child's paternal grandparents. The deceased alleged father received his genes from his parents; therefore, the child's paternal alleles will match the alleles in the alleged paternal grandfather and grandmother in cases where the deceased man is the true biological father of the child and true biological child of the grandparents.",
"   </p>",
"   <p>",
"    If the child's paternal alleles do not match the alleged grandparents' alleles on at least three different genetic sites, the DNA test for grandparentage proves conclusively that the tested grandparents are not the paternal grandparents of the child. In such cases, we can presume the deceased alleged father could not be the child's biological father. This presumption is only valid when the tested paternal grandparents are true biological parents of the deceased alleged father of the child.",
"   </p>",
"   <p>",
"    If the alleged paternal grandparents' alleles match the alleles of the child, the probability of grandparentage is determined. The calculations for the probability of grandparentage are based on gene frequencies of the matching alleles. The DNA test for grandparentage has the ability to reach probabilities of grandparentage far in excess of 99.9 percent. However, there are some limitations to this testing. As an example, the DNA test for grandparentage cannot resolve paternity if two potential fathers are related as full brothers, and therefore, have the same parents.",
"   </p>",
"   <p>",
"    If only one alleged grandparent is available, testing is problematic. As a couple, the two paternal grandparents collectively match the child on one half of the child's genes, while a single grandparent only matches 25 percent of the child's genes. Therefore, when only one alleged grandparent is tested with the child, it is impossible for the testing laboratory to conclusively prove that the tested alleged grandparent is not the child's grandparent. True and false grandparentage relationships in these cases cannot be distinguished using the DNA test result interpretation criteria described above for DNA parentage tests. Evaluation of these cases is complicated and beyond the scope of this topic review.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Family reconstruction test",
"    </span>",
"    &nbsp;&mdash;&nbsp;A DNA family reconstruction test is another means of determining paternity when the alleged father is deceased or missing. Such DNA testing is possible because the genes of the deceased or missing alleged father are present in his known biological family members (siblings, known children, parents).",
"   </p>",
"   <p>",
"    The deceased or missing alleged father can be excluded with absolute certainty as the biological father of the child by the DNA test for family reconstruction. Alternatively, the DNA test for family reconstruction can demonstrate greater than 99.9 percent probability that the deceased or missing alleged father is the biological father of the child. Such probabilities of paternity can be reached only if a sufficient number of family members with known relationships to the alleged father is available for testing.",
"   </p>",
"   <p>",
"    Extended family studies should only be ordered in consultation with experienced DNA laboratory scientific professionals. The capacity to achieve conclusive DNA test results in extended family DNA testing depends on thorough understanding of the alleged family's clinical information, in depth knowledge of genetics, and expertise in the most current DNA testing technology. Testing large, genetically diverse DNA sites is labor intensive, time consuming and costly for the testing laboratory.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Sample case",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consider the following example where the alleged father is deceased. The deceased man's wife and their two known biological children are available for testing. Another child whose biological father is in question, and this child's mother, are also tested.",
"   </p>",
"   <p>",
"    The first laboratory tested 17 DNA sites and also performed HLA testing (",
"    <a class=\"graphic graphic_table graphicRef81614 \" href=\"UTD.htm?14/56/15246\">",
"     table 5",
"    </a>",
"    ), and their results showed a relatively low probability of paternity of 57.2 percent (CPI 1). An inexperienced observer can easily become impressed with the shear number of tested genetic sites and be convinced that the best possible DNA test was performed. Notice, however, that the first laboratory limited their testing to genetic sites very commonly present in most individuals within the population. DNA testing of these common genetic sites is done through a highly automated system, and therefore is the most cost effective method of testing for the laboratory.",
"   </p>",
"   <p>",
"    The second laboratory performed DNA testing on the same individuals. However, the second laboratory chose to test large, highly diverse genetic sites that are not commonly shared by many individuals within the population. As a result, the second laboratory produced highly conclusive probability of paternity of 99.999 percent (CPI 99,807) (",
"    <a class=\"graphic graphic_table graphicRef54923 \" href=\"UTD.htm?20/56/21388\">",
"     table 6",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Sibling test",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the DNA sibling test, two children are tested to determine whether they share the same biological parent or parents. Each of a child's genes matches genes of a biological parent. Since the mother and the father have two copies of each gene, they may donate different copies to different children.",
"   </p>",
"   <p>",
"    True full siblings who share the same mother and father have about a 25 percent chance of not sharing the genetic information at any one genetic site in a DNA sibling test. True half siblings who share one parent have a 50 percent chance of not sharing any markers at any one genetic site in a DNA sibling test. Therefore, the DNA testing laboratory cannot report with absolute certainty that two individuals are not related as siblings when only two alleged siblings are available for testing.",
"   </p>",
"   <p>",
"    DNA tests for determination of biological sibling relationships between two tested individuals have their own criteria for test result interpretation and for determination of the likelihood of a sibling relationship. The criteria as to whether the two tested individuals are true",
"    <span class=\"nowrap\">",
"     full/half",
"    </span>",
"    siblings or unrelated individuals claiming to be siblings are derived from studies of cohorts of true siblings and from studies of cohorts of matched unrelated individuals. The data generated from these DNA sibling studies are classically summarized with the Combined Sibling Index (CSI) statistic. The CSI indicates the likelihood that the tested alleged individuals are siblings versus being unrelated. For example, the CSI of 64,236 indicates that the likelihood is 64,236 to 1 that the tested alleged siblings are true siblings versus being unrelated.",
"   </p>",
"   <p>",
"    When only two individuals are tested, DNA sibling tests often show very high CSI, and such DNA sibling test results are easy to interpret since the data are statistically pointing toward a positive full sibling relationship. However, true full siblings can have \"single digit\" CSI values. In fact, studies of cohorts of true full siblings and studies of cohorts of matched unrelated individuals have shown that when only two individuals are tested, the statistical evidence supports the conclusion that the two individuals are related as true full siblings when the CSI is equal to or is greater than 1 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29736/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. In one study, less than 1.61 percent of true full sibling pairs had CSI values of less than 1 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29736/abstract/15\">",
"     15",
"    </a>",
"    ], but another study reported that 1.6 percent of random, unrelated pairs were found to have a CSI between 1 and 3 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29736/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When only two individuals are tested, studies of cohorts of true half siblings and studies of cohorts of matched unrelated individuals have shown that a combined CSI of approximately 30 or higher is characteristic of individuals who are related as half siblings [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29736/abstract/19\">",
"     19",
"    </a>",
"    ]. Another study found that up to approximately 13 percent of CSI values are less than 1 in those individuals who are half siblings and that up to 13 percent of CSI values are greater than 1 in those individuals who are not related [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29736/abstract/15\">",
"     15",
"    </a>",
"    ]. Studies of cohorts of true siblings and studies of cohorts of matched unrelated individuals suggest that CSI of less than 0.1 is fairly characteristic of unrelated individuals who claim to be siblings [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29736/abstract/16,19\">",
"     16,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In cases where DNA sibling test results are uninformative, the conclusiveness of DNA sibling test results can be greatly improved by testing additional known family members. For example, testing known biological parents of one (or both) of the siblings in addition to testing the two alleged siblings greatly improves the ability of the DNA testing laboratory to provide definitive sibling answers. Also, the DNA testing laboratory has the ability to reconstruct the complete genetic makeup of biological parents (ie, genetic makeup of entire family) when DNA specimens are available for study from several known siblings in a family.",
"   </p>",
"   <p>",
"    An alternative strategy is to investigate the paternal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    maternal lineages of the tested alleged siblings by performing supplemental DNA testing using sex-linked DNA polymorphisms on the Y chromosome or in mitochondrial DNA, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Y-STR DNA test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Y-STR paternal lineage DNA test can be used to determine whether two or more males are related through their paternal lineage. The Y chromosome is passed from father to son and has a relatively infrequent mutation rate, thus, it remains the same through many generations. The Y-STR paternal lineage DNA test examines specific sites on the Y chromosome and yields a unique Y-STR profile for each male tested. Males who are related through their fathers tend to have the same Y-STR profiles, and males who are not related tend to have different Y-STR profiles.",
"   </p>",
"   <p>",
"    It is important to remember that the Y-STR paternal lineage DNA test does not differentiate who the child's biological father is in cases where the two alleged fathers are paternally related. However, the Y-STR paternal lineage DNA test can be particularly useful for excluding males from an alleged biological relationship. As an example, in cases where the alleged father is missing and cannot be tested, Y-STR profiles of a male child and his alleged uncle (brother of the alleged father) are compared. If the two Y-STR profiles do not match, then the alleged father is very likely not the biological father of the child.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     DISCLOSURE OF FALSE PATERNITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occasionally, laboratory test results (whether complicated molecular genetic tests or relatively simple blood typing) reveal that the alleged father is not the biological father of a child or fetus. In 1994, the Committee on Assessing Genetic Risks of the Institute of Medicine (IOM) recommended that in such cases, only the mother should be informed, as \"genetic testing should not be used in ways that disrupt families\" [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29736/abstract/20\">",
"     20",
"    </a>",
"    ]. This report has received widespread support. Among a sampling of more than 500 genetic counselors, 98.5 percent stated they would not inform the father if misattributed paternity was revealed as a serendipitous finding on a laboratory test result [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29736/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An alternative (and proactive) approach is to raise the issue (as a hypothetical case scenario) prior to testing and inform parents that false paternity might be identified in the performance of a laboratory analysis. Raising the issue prior to testing allows the physician to obtain guidance as to how to handle actual test results that may identify false paternity. Several ethicists have argued that this is the optimal approach when false paternity is accidentally discovered [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29736/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     FINDING AN ACCREDITED TESTING FACILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regulation of parentage testing is limited. External oversight of laboratories is voluntary or comes about because laboratories offer other services that are regulated. More than 160 laboratories are advertising DNA parentage testing on the internet, but only about 44 of them are accredited by the AABB (a list of AABB accredited laboratories can be viewed at",
"    <a class=\"external\" href=\"file://www.aabb.org/\">",
"     www.aabb.org",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The AABB is the primary organization that has established national procedures and standards for DNA parentage testing and performs on site laboratory inspections for the purpose of accreditation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29736/abstract/3\">",
"     3",
"    </a>",
"    ]. The AABB also directs an external proficiency testing program for DNA parentage testing laboratories and provides this testing program in conjunction with the College of American Pathologists (CAP).",
"   </p>",
"   <p>",
"    Accreditation refers to the qualifications of the DNA testing laboratory. Certification refers to the qualifications of the DNA laboratory personnel. In the United States, only the State of New York requires mandatory certification by the New York State Department of Health (NYSDOH) for all doctoral level professionals performing DNA parentage testing. The State of New York is also the only state that requires DNA testing laboratories to have a physician's prescription or a court order for each DNA parentage test they perform. The NYSDOH further requires accreditation of all DNA laboratories performing DNA testing on individuals from the State of New York. The NYSDOH has established procedures and standards for DNA parentage testing, performs on site laboratory inspections, and has an established proficiency testing program [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29736/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since DNA laboratory accreditation is voluntary outside of the state of New York, the patient must be cognizant of the laboratory accreditation process in order to select an accredited testing facility. The patient should also be aware that AABB accredited laboratories may retain and proclaim their accredited status while offering some testing that does not meet standards [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29736/abstract/24\">",
"     24",
"    </a>",
"    ]. Additionally, DNA parentage tests are often marketed and sold by brokers. Brokers frequently work with a number of contracting laboratories. The contracting laboratories are often not identified by name, making it impossible to verify their accreditation status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     ETHICAL CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The advances in today's technology summon us to redefine the process of parentage determination. For countless generations, parentage rights were easy to assign. The woman who gave birth to the child was the child's mother. In large measure, paternity has been based on social, rather than biological factors. Widespread availability of highly accurate DNA tests raises questions about whether genetic parentage testing should replace social and childrearing tests for parenthood. In some states, statutes have been passed that allow a genetic test to upset paternity judgments at any time in the child's life. Legal initiatives have been proposed to allow a man to stop paying child support if a DNA paternity test shows he is not the father [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29736/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. On the other hand, men with infertility problems may use donated semen to create a child and consider this child to be theirs despite lack of a genetic connection. In fact, assisted reproduction techniques create situations where a child may have several \"parents,\" such as an egg donor, sperm donor, gestational carrier, and the couple who intend to raise the child. Clearly, we need to reanalyze our definition of parentage.",
"   </p>",
"   <p>",
"    The process of parentage determination also raises a number of other issues. There are questions about who should be able to order DNA parentage testing, and under what circumstances. Should an individual be able to use a hair follicle from a comb, or collect a buccal swab from a minor child and test the child's DNA without their custodian's knowledge or consent? Should presumed fathers be allowed to surreptitiously test children without maternal consent? Should divorced fathers and lovers use DNA testing to reopen previously agreed-upon child support responsibilities?",
"   </p>",
"   <p>",
"    Genetic testing has the potential to be highly disruptive to families, and to children who may find themselves cut off financially and emotionally from the persons they consider parents. To address some of these issues, a collaborative project was initiated between The Hastings Center and the Institute For Bioethics, Health Policy and Law at the University of Louisville, supported by a grant from the National Human Genome Research Institute of the National Institutes of Health [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29736/abstract/27\">",
"     27",
"    </a>",
"    ]. The objective was to develop a public policy framework to address the difficult ethical and legal issues raised by technology used to determine parentage. The following recommendations resulted from this research [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29736/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Parentage testing should only be performed by accredited laboratories and all testing should be done in accordance with accreditation standards.",
"     </li>",
"     <li>",
"      There should be a flat prohibition on parentage testing without consent or court order.",
"     </li>",
"     <li>",
"      Laboratories should be required to obtain documentation of authority. In cases where the DNA parentage test is performed by order of a tribunal, the court order for DNA testing is providing consent to testing. For cases where there is no court order for DNA testing, the specimen collector must obtain written informed consent, according to applicable law, from each tested individual prior to specimen collection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The AABB \"Guidance for Standards for Relationship Testing Laboratories\" states: \"testing may be ordered by a physician or attorney without a court order [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29736/abstract/29\">",
"     29",
"    </a>",
"    ]. Each physician or attorney is responsible for informing his or her clients as to any risk involved in relationship testing. The laboratory should provide the physician or attorney with guidance. For cases where there is no court order and the persons being tested are the laboratory's clients, the laboratory is required to obtain consent for all participating individuals to indicate that they had knowledge of and granted consent for the test. Written authorization should be obtained prior to or at the time of sample collection. Laboratories should be familiar with the applicable state laws and regulations governing",
"    <span class=\"nowrap\">",
"     consent/competency.\"",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Standards for parentage testing should be complemented by a criminal law covering unauthorized testing. Adoption of such legislation at the federal level would ensure that all DNA parentage testing is performed in accordance with uniform standards of technical proficiency and ethical principles.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      DNA parentage testing is primarily used to determine whether a man can be conclusively excluded as the biological father of a given child. There are legal, financial, and social indications for obtaining this information. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Applications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Biologic samples for DNA parentage testing must be obtained and processed using a strict chain-of-custody protocol. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Sample collection and processing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Parentage testing uses tandemly repeated DNA length polymorphisms to compare DNA samples between individuals. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'DNA length polymorphisms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Samples from the child, mother, and alleged father are used. Alleles not shared by mother and child represent obligate paternal alleles. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'DNA length polymorphisms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When the alleged father is not available, DNA grandparentage testing can produce highly conclusive results. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Grandparent testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Alternatively, family reconstruction by DNA analyses can provide highly conclusive results if a sufficient number of family members with known relationship to the deceased is available for testing and if a sufficient number of highly diverse genetic sites is tested. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Family reconstruction test'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The combined paternity index (CPI) is the ratio of the chance that a tested man, given his entire analyzed genetic makeup, is the biological father of the child in question, compared to the likelihood of a random man producing the child. A CPI of 1000 (equivalent to a probability of paternity of 99.9 percent) means that odds are 1000 times to 1 that the tested man is the biological father in comparison to a random man in the general population. A combined paternity index of 1000 should be utilized as a minimum requirement to establish paternity. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Paternity index'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Random Man Not Excluded (RMNE) statistic closely approximates the CPI. For a CPI of 1000, the RMNE statistic value would also equal approximately 1000 and it would be expressed as \"one individual in 1000 has the same genetic pattern\" as the tested man. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Random man not excluded'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Y-STR paternal lineage DNA test can be used to determine whether two or more males are related through their paternal lineage. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Y-STR DNA test'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An opinion of non-paternity should not be rendered on the basis of a genetic mismatch at a single DNA site. A minimum of three genetic mismatches between the alleged father and the child should be present prior to rendering the diagnosis of non-paternity. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Paternity index'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prenatal paternity testing requires informed consent from all adults involved in testing, samples from the mother, one of the potential fathers, and the fetus (by either CVS or amniocentesis). In other situations, legal standards for consent may not exist, but experts believe parentage testing without consent or court order is unethical. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Prenatal testing'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24\">",
"       'Ethical considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Regulation of DNA parentage laboratories is voluntary. The AABB (formerly the American Association of Blood Banks) is the primary organization that has established national standards for DNA parentage testing and performs on site laboratory inspections. Parentage testing should only be performed by accredited laboratories and all testing should be done in accordance with accreditation standards. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Finding an accredited testing facility'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Association of Blood Banks (AABB), Annual Meeting; New Orleans, October 24, 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29736/abstract/2\">",
"      Walker RH. DNA probe technology in parentage testing. Immunohematology 1989; 5:31.",
"     </a>",
"    </li>",
"    <li>",
"     American Association of Blood Banks (AABB), Standards for Parentage Testing Laboratories, 7th ed, 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29736/abstract/4\">",
"      Wagner J, Dzijan S, Marjanovi D, Lauc G. Non-invasive prenatal paternity testing from maternal blood. Int J Legal Med 2009; 123:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29736/abstract/5\">",
"      Guo X, Bayliss P, Damewood M, et al. A noninvasive test to determine paternity in pregnancy. N Engl J Med 2012; 366:1743.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.natera.com/non-invasive-prenatal-paternity-test.html. (Accessed on March 13, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29736/abstract/7\">",
"      Benn PA, Chapman AR. Ethical challenges in providing noninvasive prenatal diagnosis. Curr Opin Obstet Gynecol 2010; 22:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29736/abstract/8\">",
"      Le Roux MG, Pascal O, David A, Moisan JP. Non-paternity rate and screening in genetic disease analysis. Lancet 1993; 341:57.",
"     </a>",
"    </li>",
"    <li>",
"     American Association of Blood Banks. Annual report summary for testing in 2003 - Prepared by the Parentage Testing Standards Program Unit, October 2004.",
"    </li>",
"    <li>",
"     American Association of Blood Banks (AABB), Standards for Relationship Testing Laboratories, 9th ed, 2009.",
"    </li>",
"    <li>",
"     Twelfth International Symposium on Human Identification. Genetica DNA Laboratories, Inc., October 9-12, 2001.",
"    </li>",
"    <li>",
"     Twelfth International Symposium on Human Identification. Bio Links, Lima, Peru, October 9-12, 2001.",
"    </li>",
"    <li>",
"     Twelfth International Symposium on Human Identification. Arizona Department of Public Safety Crime Laboratory, October 9-12, 2001.",
"    </li>",
"    <li>",
"     Florida State Crime Laboratory, personal communication.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29736/abstract/15\">",
"      Pu CE, Linacre A. Systematic evaluation of sensitivity and specificity of sibship determination by using 15 STR loci. J Forensic Leg Med 2008; 15:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29736/abstract/16\">",
"      Reid TM, Wolf CA, Kraemer CM, et al. Specificity of sibship determination using the ABI Identifiler multiplex system. J Forensic Sci 2004; 49:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29736/abstract/17\">",
"      Wenk RE, Traver M, Chiafari FA. Determination of sibship in any two persons. Transfusion 1996; 36:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29736/abstract/18\">",
"      Tzeng CH, Lyou JY, Chen YR, et al. Determination of sibship by PCR-amplified short tandem repeat analysis in Taiwan. Transfusion 2000; 40:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29736/abstract/19\">",
"      Allen RW, Fu J, Reid TM, Baird M. Considerations for the interpretation of STR results in cases of questioned half-sibship. Transfusion 2007; 47:515.",
"     </a>",
"    </li>",
"    <li>",
"     Institute of Medicine, Committee on Assessing Genetic Risks, National Academy Press, Washington, DC 1994. p. 276.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29736/abstract/21\">",
"      Pencarinha DF, Bell NK, Edwards JG, Best RG. Ethical issues in genetic counseling: a comparison of M.S. counselor and medical geneticist perspectives. J Genet Couns 1992; 1:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29736/abstract/22\">",
"      Lucassen A, Parker M. Revealing false paternity: some ethical considerations. Lancet 2001; 357:1033.",
"     </a>",
"    </li>",
"    <li>",
"     New York State Department of Health (NYSDOH). Standards for Parentage Testing Laboratories: Wadsworth Center. www.wadsworth.org/labservices.htm (Accessed 3/7/05).",
"    </li>",
"    <li>",
"     American Association of Blood Banks, 2002 Annual Meeting, Parentage Testing Special Group Session I, audiotape available from Audio Archives International, Inc.",
"    </li>",
"    <li>",
"     Maryland Code Ann. Fam. Law. Section 5-1038.",
"    </li>",
"    <li>",
"     Ohio Revised Code, Section 3119.962.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29736/abstract/27\">",
"      Anderlik MR, Rothstein MA. DNA-based identity testing and the future of the family: a research agenda. Am J Law Med 2002; 28:215.",
"     </a>",
"    </li>",
"    <li>",
"     Anderlik, MR, Rothstein, MA. Genetic bonds and family law: The challenge of DNA parentage testing conference, New Orleans, March 27-28, 2003.",
"    </li>",
"    <li>",
"     American Association of Blood Banks (AABB). Guidance for Standards for Relationship Testing Laboratories. 9th edition, 2009.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 425 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-AA4CF5E739-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_2_29736=[""].join("\n");
var outline_f29_2_29736=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      APPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      COST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SAMPLE COLLECTION AND PROCESSING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Collection personnel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Identification of test subject",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Specimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Prenatal testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1786280\">",
"      - Noninvasive prenatal paternity testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PATERNITY TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DNA length polymorphisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Paternity index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Combined paternity index (CPI)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Probability of paternity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Random man not excluded",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Alleged fathers who are brothers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      OPTIONS WHEN THE FATHER IS NOT AVAILABLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Grandparent testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Family reconstruction test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Sample case",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Sibling test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Y-STR DNA test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      DISCLOSURE OF FALSE PATERNITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      FINDING AN ACCREDITED TESTING FACILITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      ETHICAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/425\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/425|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/46/30444\" title=\"table 1\">",
"      Paternity index example",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/52/27468\" title=\"table 2\">",
"      Mismatches consistent with nonpaternity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/52/37708\" title=\"table 3\">",
"      Likelihood of paternity sample case",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/13/25819\" title=\"table 4\">",
"      Probability of paternity by CPI and RMNE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/56/15246\" title=\"table 5\">",
"      Family reconstruction test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/56/21388\" title=\"table 6\">",
"      Family reconstruction test-2",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_2_29737="Blood pressure management in patients with atherosclerotic cardiovascular disease";
var content_f29_2_29737=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Blood pressure management in patients with atherosclerotic cardiovascular disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/2/29737/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/2/29737/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/2/29737/contributors\">",
"     Guy S Reeder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/2/29737/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/2/29737/contributors\">",
"     Juan Carlos Kaski, MD, DM, DSc, FRCP, FESC, FACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/2/29737/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/2/29737/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/2/29737/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/2/29737/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension is the most prevalent major risk factor for premature cardiovascular disease (CVD), being more common than cigarette smoking, dyslipidemia, and diabetes, the other major risk factors. In the INTERHEART study of patients from 52 countries, hypertension accounted for 18 percent of the population-attributable risk of a first myocardial infarction (MI) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29737/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37685?source=see_link\">",
"     \"Cardiovascular risks of hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The impact of hypertension on the risk of the development of a cardiovascular event such as myocardial infarction, stroke or cardiovascular death is directly related to the level of blood pressure. In addition, the majority of individuals with hypertension have one or more other risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29737/abstract/2,3\">",
"     2,3",
"    </a>",
"    ], which augment the cardiovascular risk at any level of blood pressure (",
"    <a class=\"graphic graphic_figure graphicRef55353 \" href=\"UTD.htm?24/31/25086\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29737/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The excess risk of a future cardiovascular event attributable to hypertension is greater in individuals with established CVD, diabetes mellitus, or chronic kidney disease compared to those at lower risk. The 2003 Seventh Joint National Committee (JNC 7) report on high blood pressure cited ischemic heart disease, heart failure, diabetes, chronic kidney disease, and cerebrovascular disease as \"compelling indications\" for the treatment of hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29737/abstract/5\">",
"     5",
"    </a>",
"    ]. Other considerations include peripheral artery disease and traditional major coronary risk factors such as cigarette smoking and family history (",
"    <a class=\"graphic graphic_table graphicRef81993 \" href=\"UTD.htm?18/25/18844\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    For those patients in whom a decision is made to lower blood pressure, the two most important issues are the choice of antihypertensive agent(s) and the goal blood pressure (BP). The goal BP in patients at increased risk for a cardiovascular event will be reviewed here. Goal BP in the general population and in the specific settings of diabetes, proteinuric chronic kidney disease, and heart failure are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33417?source=see_link\">",
"     \"What is goal blood pressure in the treatment of hypertension?\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=see_link\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29031?source=see_link\">",
"     \"Treatment of hypertension in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The choice of antihypertensive drugs, assuming that the patient does not have an indication for a particular class of drugs, is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=see_link&amp;anchor=H3#H3\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\", section on 'Importance of attained blood pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of BP reduction in patients at increased risk of a cardiovascular event has been investigated in a number of major clinical trials. Some of these trials compared an ACE inhibitor or ARB to placebo, while other trials compared two or more antihypertensive agents, at least one of which was usually an angiotensin converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB).",
"   </p>",
"   <p>",
"    Based upon trial design, inclusion criteria, and patient population, the degree of blood pressure lowering varied significantly in these trials. The findings in the major trials will be briefly reviewed followed by recommendations for the goal BP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Trials comparing blood pressure goals",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only three large trials, ACCORD BP, Cardio-Sis, and HOT have directly compared blood pressure goals to test the hypothesis that lower attained blood pressures (below the usual goal of less than",
"    <span class=\"nowrap\">",
"     140/90",
"    </span>",
"    mmHg) improve patient outcomes. ACCORD BP and Cardio-Sis, but not HOT, were limited to patients at increased cardiovascular risk other than hypertension itself. In addition, HOT did not achieve systolic pressures below the usual goal since the mean attained BP was",
"    <span class=\"nowrap\">",
"     140/81",
"    </span>",
"    mmHg in the lowest group. As a result, the HOT trial will not be further discussed here. The best data come from the ACCORD BP trial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33417?source=see_link&amp;anchor=H11#H11\">",
"     \"What is goal blood pressure in the treatment of hypertension?\", section on 'HOT trial'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\", section on 'HOT trial'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     ACCORD BP trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ACCORD BP trial randomly assigned 4733 patients with type 2 diabetes who had cardiovascular disease or at least two additional risk factors for cardiovascular disease to systolic blood pressure targets of either less than 120 mmHg or less than 140 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29737/abstract/6\">",
"     6",
"    </a>",
"    ]. The mean attained systolic pressures were 119 and 134 mmHg, respectively, compared to",
"    <span class=\"nowrap\">",
"     139/76",
"    </span>",
"    mmHg at baseline.",
"   </p>",
"   <p>",
"    After a mean follow-up of 4.7 years, there was no significant difference in the annual rate of the primary composite endpoint of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes (1.87 versus 2.09 percent, hazard ratio 0.88, 95% CI 0.73-1.06). Stroke as a secondary endpoint is discussed below. (See",
"    <a class=\"local\" href=\"#H271902655\">",
"     'Stroke as an outcome of interest'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Significant adverse events occurred in significantly more patients in the group assigned to the lower blood pressure goal (3.3 versus 1.3 percent). ACCORD BP is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\", section on 'ACCORD BP trial'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Cardio-Sis trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardio-Sis evaluated different blood pressure goals in 1111 patients with a systolic pressure &ge;150 mmHg and at least one additional cardiovascular risk factor, but without diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29737/abstract/7\">",
"     7",
"    </a>",
"    ]. The patients were randomly assigned to a systolic target of less than 130 mmHg (tight-control) or less than 140 mmHg (usual-control). The mean attained blood pressures were",
"    <span class=\"nowrap\">",
"     132/78",
"    </span>",
"    versus",
"    <span class=\"nowrap\">",
"     135/79",
"    </span>",
"    mmHg. Although the composite secondary outcome occurred significantly less often in the tight-control group (4.8 versus 9.4 percent; hazard ratio 0.50, 95% CI 0.31-0.79), the benefit was primarily due to a reduction in rates of new onset atrial fibrillation or coronary revascularization.",
"   </p>",
"   <p>",
"    Cardio-Sis has important limitations, including a short duration of follow-up (two years), a weak primary endpoint that assessed a risk marker (electrocardiographic left ventricular hypertrophy), not cardiovascular events, and a composite secondary endpoint that included unusual endpoints for a hypertension trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H271901243\">",
"    <span class=\"h3\">",
"     INVEST trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The INVEST trial compared the effectiveness of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    in 22,576 hypertensive patients with a mean baseline blood pressure of",
"    <span class=\"nowrap\">",
"     150/86",
"    </span>",
"    mmHg. Cardiovascular outcomes were similar in the two groups. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20218?source=see_link&amp;anchor=H13#H13\">",
"     \"Choice of therapy in essential hypertension: Clinical trials\", section on 'INVEST trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An observational secondary analysis included 6400 patients who were at least 50 years old and had diabetes and coronary artery disease; cardiovascular outcomes were compared in the patients who attained tight control (systolic BP 125 to 129 mmHg), usual control (systolic BP from 130 to &lt;140 mmHg), or were not controlled (&ge;140 mmHg or higher) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29737/abstract/8\">",
"     8",
"    </a>",
"    ]. The primary combined outcome of the first occurrence of all-cause mortality, nonfatal myocardial infarction, or nonfatal stroke occurred in 12.7, 12.6, and 19.8 percent of the three groups respectively. The rates in the tight and usual control groups were not significantly different from each other (ie, no benefit from attained systolic pressure below 130 mmHg), but were both significantly lower than the rate in the uncontrolled group. The clinical applicability of these findings is limited by their observational nature.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Placebo-controlled trials with a mean baseline BP less than 140/90 mmHg",
"    </span>",
"    &nbsp;&mdash;&nbsp;Placebo-controlled trials, such as HOPE, EUROPA, PEACE, CAMELOT, TRANSCEND, and NAVIGATOR evaluated the hypothesis that ACE inhibitors or ARBs might have a direct and clinically-significant cardiovascular benefit in patients with a mean baseline BP less than",
"    <span class=\"nowrap\">",
"     140/90",
"    </span>",
"    mmHg. In addition, CAMELOT and ACTION compared long-acting dihydropyridine calcium channel blockers to placebo.",
"   </p>",
"   <p>",
"    Some, but not all, of these trials demonstrated benefit from active therapy. However, patients treated with active therapy also had lower attained blood pressures, which provided another mechanism other than angiotensin inhibition to explain any observed benefits. Some support for the attained blood pressure being most important came from the CAMELOT trial, in which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    produced similar outcomes that were nonsignificantly better than placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29737/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following provides a brief summary of the results of the major trials. In the ACCORD BP trial described above, an attained systolic pressure of 119 mmHg provided no significant cardiovascular benefit and more drug-induced side effects compared to an attained systolic pressure of 134 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29737/abstract/6\">",
"     6",
"    </a>",
"    ]. This finding is not inconsistent with the following trials that suggest that an attained systolic pressure between 130 and 134 mmHg may provide better cardiovascular outcomes than an attained systolic pressure between 135 and 139 mmHg.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Trials demonstrating benefit",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant benefit was demonstrated with active therapy compared to placebo in the following trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       HOPE trial",
"      </strong>",
"      &mdash; The HOPE trial evaluated 9297 patients over the age of 55 who were at high risk due to prior cardiovascular disease",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diabetes mellitus with one other coronary risk factor: at 4.5 years, cardiovascular mortality occurred in 8.1 percent and nonfatal MI in 4.8 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?29/2/29737/abstract/10\">",
"       10",
"      </a>",
"      ]. The mean BP at entry was",
"      <span class=\"nowrap\">",
"       139/79",
"      </span>",
"      mmHg. The patients were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/37/24152?source=see_link\">",
"       ramipril",
"      </a>",
"      (10 mg once daily) or placebo, given before sleep.",
"      <br/>",
"      <br/>",
"      The primary endpoint was any cardiovascular event (cardiovascular death, MI, or stroke). The trial was prematurely terminated after a 4.5-year follow-up because ramipril therapy was associated with the following significant benefits:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A reduction in the primary endpoint (14.0 versus 17.8 percent for placebo, relative risk [RR] 0.78, 95% CI 0.70-0.86) (",
"      <a class=\"graphic graphic_figure graphicRef74077 \" href=\"UTD.htm?31/51/32573\">",
"       figure 2",
"      </a>",
"      ) and in each of the individual components of the primary endpoint, including cardiovascular mortality (6.1 versus 8.1 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/2/29737/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A reduction in nonfatal MI (5.6 versus 7.2 percent) and stroke (3.1 versus 4.5 percent) that was independent of other therapies, including beta blockers, lipid lowering agents, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?29/2/29737/abstract/11,12\">",
"       11,12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      These benefits were seen in all subgroups, including women and men and patients with diabetes [",
"      <a class=\"abstract\" href=\"UTD.htm?29/2/29737/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=see_link\">",
"       \"Treatment of hypertension in patients with diabetes mellitus\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The benefit of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/37/24152?source=see_link\">",
"       ramipril",
"      </a>",
"      in the HOPE trial was initially thought to be independent of its antihypertensive activity, as the difference between the two groups during the course of the trial was only",
"      <span class=\"nowrap\">",
"       3.3/1.4",
"      </span>",
"      mmHg (average",
"      <span class=\"nowrap\">",
"       135/76",
"      </span>",
"      mmHg with ramipril) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/2/29737/abstract/15\">",
"       15",
"      </a>",
"      ]. However, the actual difference in BP was probably substantially greater. Ramipril was given before bedtime and the office BP was measured about 10 to 18 hours later. In a subset of 38 patients with peripheral artery disease, ambulatory monitoring was performed at baseline and at one year [",
"      <a class=\"abstract\" href=\"UTD.htm?29/2/29737/abstract/16\">",
"       16",
"      </a>",
"      ]. The 24-hour ambulatory pressure was significantly reduced with ramipril, largely due to a more prominent fall in BP during the night",
"      <span class=\"nowrap\">",
"       (17/8",
"      </span>",
"      mmHg compared to placebo).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       EUROPA trial",
"      </strong>",
"      &mdash; The EUROPA trial of 13,655 patients with stable coronary heart disease and no heart failure was similar in design to HOPE except that the patients were at lower risk, with lower rates of hypertension (27 versus 47 percent), diabetes, and cerebrovascular and peripheral artery disease [",
"      <a class=\"abstract\" href=\"UTD.htm?29/2/29737/abstract/17\">",
"       17",
"      </a>",
"      ]. The mean BP at entry was",
"      <span class=\"nowrap\">",
"       137/82",
"      </span>",
"      mmHg and only 27 percent had a history of hypertension.",
"      <br/>",
"      <br/>",
"      The patients were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/32/22024?source=see_link\">",
"       perindopril",
"      </a>",
"      (8 mg once daily) or placebo. The primary endpoint was cardiovascular death, MI, or cardiac arrest. At a mean of 4.2 years, there was a significant reduction in the primary endpoint with perindopril therapy (8 versus 10 percent, relative risk reduction 20 percent, 95% CI 9-29 percent). There was at least a trend toward a similar benefit in each of the components of the primary endpoint, and the effect was consistent in all predefined subgroups [",
"      <a class=\"abstract\" href=\"UTD.htm?29/2/29737/abstract/18,19\">",
"       18,19",
"      </a>",
"      ]. Perindopril therapy was associated with a BP of approximately",
"      <span class=\"nowrap\">",
"       128/78",
"      </span>",
"      mmHg, a value that was a mean of",
"      <span class=\"nowrap\">",
"       5/2",
"      </span>",
"      mmHg lower than seen with placebo.",
"     </li>",
"     <li>",
"      <strong>",
"       CAMELOT trial",
"      </strong>",
"      &mdash; The CAMELOT trial compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"       amlodipine",
"      </a>",
"      (10",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"       enalapril",
"      </a>",
"      (20",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      to placebo in 1991 patients with known coronary disease [",
"      <a class=\"abstract\" href=\"UTD.htm?29/2/29737/abstract/9\">",
"       9",
"      </a>",
"      ]. The primary endpoint was a composite of cardiovascular death and cardiovascular events. The mean baseline BP was",
"      <span class=\"nowrap\">",
"       129/78",
"      </span>",
"      mmHg and both amlodipine and enalapril produced greater average reductions in BP than placebo",
"      <span class=\"nowrap\">",
"       (4.8/2.5",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       4.9/2.4",
"      </span>",
"      versus",
"      <span class=\"nowrap\">",
"       0.7/0.6",
"      </span>",
"      mmHg). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=see_link&amp;anchor=H3#H3\">",
"       \"Choice of therapy in primary (essential) hypertension: Recommendations\", section on 'Importance of attained blood pressure'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Most of the events comprising the primary endpoint were due to coronary revascularization or hospitalization for angina, and only these components were significantly reduced by amlodipine (an antianginal drug) compared to enalapril and placebo. There was a nonsignificant difference in the rate of \"hard\" cardiovascular endpoints (all-cause mortality, nonfatal MI, or stroke) with amlodipine or enalapril compared to placebo (hazard ratio 0.70 and 0.71, respectively, compared to placebo, 95% CI 0.41-1.21). A benefit this large, if real, would be clinically important. However, the upper limit of the confidence interval indicates the possibility of harm.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Trials showing no benefit",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following trials showed no benefit from active therapy compared to placebo even though lower blood pressures were attained.",
"    <strong>",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       PEACE trial",
"      </strong>",
"      &mdash; In the PEACE trial, 8290 patients with stable coronary disease were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/41/12952?source=see_link\">",
"       trandolapril",
"      </a>",
"      (4 mg daily) or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?29/2/29737/abstract/20\">",
"       20",
"      </a>",
"      ]. The patients were at lower cardiovascular risk and were more likely to have been treated with blood pressure and lipid-lowering therapy than the HOPE and EUROPA cohorts. The mean baseline BP in the PEACE trial was",
"      <span class=\"nowrap\">",
"       133/78",
"      </span>",
"      mmHg. The primary endpoint was a composite of cardiovascular death, nonfatal MI, or revascularization. At 4.8 years, there was no difference in the incidence of the primary endpoint with trandolapril compared to placebo (21.9 versus 22.5 percent, hazard ratio 0.96; 95% CI 0.88-1.06) even though there was a greater reduction in mean BP with trandolapril",
"      <span class=\"nowrap\">",
"       (4.4/3.6",
"      </span>",
"      versus",
"      <span class=\"nowrap\">",
"       1.4/2.4",
"      </span>",
"      mmHg in the placebo group, mean difference",
"      <span class=\"nowrap\">",
"       3.0/1.2",
"      </span>",
"      mmHg).",
"      <br/>",
"      <br/>",
"      The lack of benefit of trandolapril in PEACE may have been due in part to a lower average baseline BP than in HOPE or EUROPA and more aggressive baseline management of other aspects of coronary risk (such as coronary revascularization and lipid lowering) that may have mitigated the benefit of further BP reduction. The net effect was that the rate of cardiovascular death, nonfatal myocardial infarction, or stroke in the placebo group in PEACE was lower than in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/37/24152?source=see_link\">",
"       ramipril",
"      </a>",
"      and placebo groups in HOPE and in the placebo group in EUROPA and the rate of all-cause mortality in PEACE was similar to that of an age- and sex-matched cohort from the general population.",
"     </li>",
"     <li>",
"      <strong>",
"       TRANSCEND trial",
"      </strong>",
"      &mdash; The TRANSCEND trial randomly assigned 5926 high-risk patients who were similar to those in HOPE but did not tolerate ACE inhibitors to either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/38/27239?source=see_link\">",
"       telmisartan",
"      </a>",
"      80",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      or placebo; the mean baseline blood pressure was",
"      <span class=\"nowrap\">",
"       141/82",
"      </span>",
"      mmHg [",
"      <a class=\"abstract\" href=\"UTD.htm?29/2/29737/abstract/21\">",
"       21",
"      </a>",
"      ]. At a median follow-up of 56 months, the mean blood pressure was",
"      <span class=\"nowrap\">",
"       4.0/2.2",
"      </span>",
"      mmHg lower in the telmisartan group. Despite this, there was no statistically-significant difference between the two groups in the primary composite outcome of cardiovascular death, myocardial infarction, stroke, or hospitalization for heart failure (15.7 versus 17.0 percent, hazard ratio 0.92, 95% CI 0.81-1.05). Compared to HOPE, there was a significantly higher rate of use of statins, beta blockers, and antiplatelet agents in TRANSCEND.",
"     </li>",
"     <li>",
"      <strong>",
"       NAVIGATOR trial",
"      </strong>",
"      &mdash; In the NAVIGATOR trial, 9306 patients with impaired glucose tolerance and either established cardiovascular disease (24 percent) or one or more risk factors for cardiovascular disease were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/4/31815?source=see_link\">",
"       valsartan",
"      </a>",
"      (160",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?29/2/29737/abstract/22\">",
"       22",
"      </a>",
"      ]. In addition, all patients participated in a lifestyle intervention program. The mean blood pressure at baseline was",
"      <span class=\"nowrap\">",
"       140/83",
"      </span>",
"      mmHg. After a median follow-up of five years, there was no significant difference in the incidence of either an extended composite outcome of death from cardiovascular causes, nonfatal MI, nonfatal stroke, hospitalization for heart failure, arterial revascularization, or hospitalization for unstable angina (14.5 versus 14.8 percent respectively) or a core composite outcome that excluded unstable angina and revascularization (8.1 percent in both groups). The mean blood pressure decreased significantly more in the valsartan group",
"      <span class=\"nowrap\">",
"       (6.3/4.4",
"      </span>",
"      versus",
"      <span class=\"nowrap\">",
"       3.8/3.0",
"      </span>",
"      mmHg).",
"     </li>",
"     <li>",
"      <strong>",
"       ACTION trial",
"      </strong>",
"      &mdash; In the ACTION trial, 7665 patients with chronic stable angina (52 percent had a prior MI) were randomly assigned to long-acting",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      60 mg daily or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?29/2/29737/abstract/23\">",
"       23",
"      </a>",
"      ]. The mean baseline blood pressure of",
"      <span class=\"nowrap\">",
"       137/80",
"      </span>",
"      mmHg, and at study end, was significantly lower in the nifedipine group",
"      <span class=\"nowrap\">",
"       (130/75",
"      </span>",
"      versus",
"      <span class=\"nowrap\">",
"       136/78",
"      </span>",
"      mmHg). The primary endpoint was survival free of major cardiovascular events, including death of any cause, acute MI, refractory angina, new overt heart failure, debilitating stroke, and peripheral revascularization. At a mean follow-up of 4.9 years, nifedipine therapy had no effect on the incidence of the primary endpoint (4.60 versus 4.75 percent per year, hazard ratio 0.97) or all-cause mortality alone (1.64 versus 1.53 percent per year, hazard ratio). Nifedipine did reduce the need for coronary angiography and interventions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Meta-analyses",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2009 meta-analysis focused on seven trials that limited therapy to either an ACE inhibitor or an angiotensin receptor blocker to placebo in patients with ischemic heart disease and preserved left ventricular systolic function [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29737/abstract/24\">",
"     24",
"    </a>",
"    ]. Six trials of ACE inhibitor therapy (including HOPE, EUROPA, CAMELOT, and PEACE) significantly reduced both total mortality (risk ratio 0.87, 95% CI 0.81-0.94) and nonfatal MI (risk ratio 0.83, 95% CI 0.73-0.94).",
"   </p>",
"   <p>",
"    A limitation to this meta-analysis is that it does not distinguish between angiotensin inhibition and lower attained blood pressures as the mechanism of benefit. This limitation was overcome in a 2011 meta-analysis that included 25 placebo-controlled trials with more than 63,000 patients in which active treatment consisted of all major classes of antihypertensive drugs, including ACE inhibitors, angiotensin receptor blockers, beta blockers, calcium channel blockers, diuretics, or combination therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29737/abstract/25\">",
"     25",
"    </a>",
"    ]. Drug therapy significantly lowered the risks of all-cause mortality and MI to the same degree as in the earlier meta-analysis (pooled relative risks 0.87, 95% CI 0.80-0.95 and 0.80, 95% CI 0.69-0.93 respectively), suggesting that there was no specific benefit from therapy with angiotensin inhibitors compared with other antihypertensive drugs. The absolute risk reductions in all-cause mortality and MI were 14 and 13 per 1000 persons treated.",
"   </p>",
"   <p>",
"    Based upon these observations, we do",
"    <strong>",
"     not",
"    </strong>",
"    recommend the",
"    <strong>",
"     preferential",
"    </strong>",
"    use of ACE inhibitors or angiotensin receptor blockers to lower blood pressure in patients with cardiovascular disease unless there is a specific indication such as heart failure, prior MI, or proteinuric chronic kidney disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Are lower blood pressures harmful?",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a blood pressure threshold for all patients below which tissue perfusion is reduced to vital organs. As long as the blood pressure is lowered gradually, this threshold does not appear to occur at current blood pressure goals. The ACCORD BP trial of patients with type 2 diabetes who had cardiovascular disease or at least two additional risk factors for cardiovascular disease found that the aggregate cardiovascular outcomes at 4.7 years were similar in patients with attained systolic pressures of 119 and 134 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29737/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'ACCORD BP trial'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Coronary heart disease without heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with coronary heart disease without heart failure, it is possible that a lower limit exists for desirable diastolic pressure because much of coronary filling occurs during diastole. Observations from the Framingham study and a post hoc analysis from the INVEST trial suggested an increase in risk for patients with cardiovascular disease at a diastolic pressure below 70 to 75 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29737/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20218?source=see_link&amp;anchor=H13#H13\">",
"     \"Choice of therapy in essential hypertension: Clinical trials\", section on 'INVEST trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other analyses from placebo-controlled trials of hypertension found a similar J-shaped curve for diastolic and systolic pressures in both treated and untreated groups and for both cardiovascular and noncardiovascular mortality (",
"    <a class=\"graphic graphic_figure graphicRef73430 graphicRef80901 \" href=\"UTD.htm?16/9/16531\">",
"     figure 3A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29737/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. These findings indicate that the worse outcomes at lower pressures are independent of antihypertensive therapy as long as the BP is lowered slowly. This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33417?source=see_link&amp;anchor=H8#H8\">",
"     \"What is goal blood pressure in the treatment of hypertension?\", section on 'J-shaped diastolic curve'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33417?source=see_link&amp;anchor=H14#H14\">",
"     \"What is goal blood pressure in the treatment of hypertension?\", section on 'J-shaped systolic curve'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with heart failure (HF) due to systolic dysfunction, many experts consider the goal of therapy to be the lowest blood pressure that is not associated with symptoms of hypotension or evidence of hypoperfusion (eg, worsening prerenal azotemia). In some patients with severe HF, this may be a systolic pressure as low as 90 mmHg.",
"   </p>",
"   <p>",
"    Most patients with systolic HF are treated with inhibition of the renin-angiotensin system (eg, angiotensin converting enzyme inhibitors or angiotensin II receptor blockers), beta blockers, and, in selected patients, an aldosterone antagonist. These agents have favorable effects on survival in HF that are independent of their effects on blood pressure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29031?source=see_link\">",
"     \"Treatment of hypertension in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Isolated systolic hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are no convincing data, there may be a threshold diastolic BP below which adverse cardiovascular outcomes might increase in elderly patients with isolated systolic hypertension. When treating such patients, we and others (including JNC 7 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29737/abstract/5\">",
"     5",
"    </a>",
"    ]) suggest a minimum posttreatment diastolic pressure of 60 mmHg overall or perhaps 65 mmHg in patients with known coronary artery disease unless symptoms that could be attributable to hypoperfusion occur at higher pressures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/27/25018?source=see_link&amp;anchor=H20#H20\">",
"     \"Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension\", section on 'Goal blood pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Prior stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of lowering the BP with antihypertensive therapy has been evaluated in patients with a prior stroke, many of whom have a history of prior hypertension. This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17305?source=see_link\">",
"     \"Antihypertensive therapy to prevent recurrent stroke or transient ischemic attack\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     GOAL BLOOD PRESSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regardless of the goal BP, blood-pressure reduction should be gradual in all patients in the absence of a hypertensive emergency. In addition, patients with isolated systolic hypertension or stenotic arterial lesions (carotid or coronary) may be at increased risk for ischemic manifestations at lower blood pressure goals. Thus, such patients should be monitored carefully for possible signs of hypoperfusion, such as angina or neurologic dysfunction, and for elevations in serum creatinine, which are more likely to occur in patients with bilateral renal artery stenosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/27/25018?source=see_link&amp;anchor=H20#H20\">",
"     \"Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension\", section on 'Goal blood pressure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/54/8040?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of bilateral atherosclerotic renal artery stenosis\", section on 'Medical therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antihypertensive therapy should be accompanied by management of other risk factors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Patients with known atherosclerotic cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;As many of the relevant trials included patients with atherosclerotic cardiovascular disease (CVD) other than coronary heart disease, such as peripheral arterial or cerebrovascular disease, our recommendations are for all patients with atherosclerotic CVD.",
"   </p>",
"   <p>",
"    The 2003 JNC 7 report recommended a goal BP of less than",
"    <span class=\"nowrap\">",
"     140/90",
"    </span>",
"    mmHg in patients with coronary heart disease (CHD), similar to that in the general hypertensive population [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29737/abstract/5\">",
"     5",
"    </a>",
"    ]. In contrast, guidelines published in 2007 by the American Heart Association and the European Society of",
"    <span class=\"nowrap\">",
"     Hypertension/European",
"    </span>",
"    Society of Cardiology set a goal of less than",
"    <span class=\"nowrap\">",
"     130/80",
"    </span>",
"    mmHg for patients with atherosclerotic CVD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29737/abstract/2,31,32\">",
"     2,31,32",
"    </a>",
"    ]. All of these guidelines were published before the ACCORD BP trial.",
"   </p>",
"   <p>",
"    The trials presented above assessed composite endpoints and showed",
"    <strong>",
"     no",
"    </strong>",
"    compelling evidence supporting a goal of less than",
"    <span class=\"nowrap\">",
"     130/80",
"    </span>",
"    mmHg in patients with atherosclerotic CVD. ACCORD BP can be interpreted as showing that there is no benefit (considering the composite endpoint) to lowering the systolic blood pressure to less than 120 mmHg compared to a mean attained systolic blood pressure of 134 mmHg in patients with type 2 diabetes and prior CVD or CVD risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29737/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'ACCORD BP trial'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The meta-analysis of the placebo-controlled trials that assessed the value of adding a fixed dose of an angiotensin inhibitor provides some support for administering additional antihypertensive therapy in patients with a baseline blood pressure of 130 to 140 mmHg. However, the evidence has to be considered to be weak, since the trials were not performed to assess goal blood pressure and the addition of the results from NAVIGATOR and from ACTION (which evaluated long-acting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    ) might make the benefit not statistically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29737/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Placebo-controlled trials with a mean baseline BP less than 140/90 mmHg'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H532809390\">",
"    <span class=\"h3\">",
"     Patients with acute coronary syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the patients with coronary artery disease enrolled in the trials discussed above were clinically stable. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Clinical trials'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    An attempt was made to evaluate the optimal blood pressure after an acute coronary syndrome in a post hoc analysis of the PROVE IT-TIMI 22 trial, in which over 4000 patients were randomly assigned to two different statin strategies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29737/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33656?source=see_link\">",
"     \"Cholesterol lowering after an acute coronary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The relationship between blood pressure (both systolic and diastolic) and the primary composite outcome (all cause mortality, myocardial infarction, unstable angina, revascularization at 30 days, or stroke) exhibited a J- or U-shaped curve association, with the event rate being lowest in the blood pressure range of 130 to 140 mmHg systolic and 80 to 90 mmHg diastolic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33417?source=see_link&amp;anchor=H8#H8\">",
"     \"What is goal blood pressure in the treatment of hypertension?\", section on 'J-shaped diastolic curve'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33417?source=see_link&amp;anchor=H14#H14\">",
"     \"What is goal blood pressure in the treatment of hypertension?\", section on 'J-shaped systolic curve'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H271902655\">",
"    <span class=\"h3\">",
"     Stroke as an outcome of interest",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stroke was not a primary endpoint in any of the above trials, but many evaluated it as a prespecified secondary outcome. The most important data come from the meta-analyses of placebo controlled trials cited above and the ACCORD BP trial. As noted by the following observations, stroke risk appears to fall progressively at least to attained systolic pressures below 120 to 126 mmHg; in contrast, coronary risk does not improve and may increase at these lower attained systolic pressures, while mortality was not changed [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29737/abstract/6,30,34-37\">",
"     6,30,34-37",
"    </a>",
"    ]. In these trials, the mean attained systolic pressure in the treated groups was mostly above 130 mmHg. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Meta-analyses'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the meta-analysis of trials comparing all classes of antihypertensive therapy to placebo, there was a significant reduction in the risk of stroke with active therapy (pooled relative risk 0.77, 95% CI 0.69-0.98) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/2/29737/abstract/25\">",
"       25",
"      </a>",
"      ]. These findings are the same as those in an earlier meta-analysis of trials comparing angiotensin inhibitors to placebo, in which the risk ratio for stroke was 0.79 (95% CI 0.67-0.93) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/2/29737/abstract/24\">",
"       24",
"      </a>",
"      ]. These risk ratios are similar to those for nonfatal cardiovascular events. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Meta-analyses'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In ACCORD BP, the patients assigned to a goal blood pressure of less than 120 mmHg (mean attained systolic pressure 119 versus 134 mmHg in the group assigned to a goal of less than 140 mmHg) had a significantly lower annual rate of stroke (0.32 versus 0.53",
"      <span class=\"nowrap\">",
"       percent/year,",
"      </span>",
"      hazard ratio 0.59, 95% CI 0.39-0.89), with no significant difference in coronary events (hazard ratio 0.94, 95% CI 0.79-1.12) or cardiovascular death (hazard ratio 1.07, 95% CI 0.85-1.35) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/2/29737/abstract/6\">",
"       6",
"      </a>",
"      ]. The number of patients that needed to be treated to prevent one stroke in five years was 89. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'ACCORD BP trial'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Similar findings at attained blood pressures below 130 mmHg were noted in post hoc analyses of nonrandomized groups (less reliable data) in the ONTARGET and PROGRESS trials [",
"      <a class=\"abstract\" href=\"UTD.htm?29/2/29737/abstract/35-37\">",
"       35-37",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The ONTARGET trial randomly assigned over 25,000 patients with atherosclerotic disease to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/37/24152?source=see_link\">",
"       ramipril",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/38/27239?source=see_link\">",
"       telmisartan",
"      </a>",
"      , or both. There was a progressive reduction in stroke risk at attained systolic pressures of 121 compared to 130 mmHg or higher; in contrast, there was an increase in myocardial infarction risk at attained systolic pressures below 126 mmHg and cardiovascular mortality was unchanged or increased at attained systolic pressures below 130 mmHg [",
"      <a class=\"abstract\" href=\"UTD.htm?29/2/29737/abstract/36\">",
"       36",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20218?source=see_link&amp;anchor=H16#H16\">",
"       \"Choice of therapy in essential hypertension: Clinical trials\", section on 'ONTARGET trial'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The PROGRESS trial compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/32/22024?source=see_link\">",
"       perindopril",
"      </a>",
"      with or without adding",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35846?source=see_link\">",
"       indapamide",
"      </a>",
"      (a thiazide diuretic) to placebo in patients with a prior stroke. There was a progressive trend toward lower rates of recurrent stroke at lower systolic pressures down to below 120 mmHg [",
"      <a class=\"abstract\" href=\"UTD.htm?29/2/29737/abstract/37\">",
"       37",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17305?source=see_link&amp;anchor=H4#H4\">",
"       \"Antihypertensive therapy to prevent recurrent stroke or transient ischemic attack\", section on 'PROGRESS trial'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88155274\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is difficult to reach a confident conclusion about the optimal goal blood pressure in patients with atherosclerotic cardiovascular disease from the above observations. The meta-analysis of trials of angiotensin inhibitors versus placebo suggests benefit for both stroke and coronary disease at systolic pressures below 135 mmHg and perhaps below 130 mmHg compared to 135 to 139 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29737/abstract/24\">",
"     24",
"    </a>",
"    ]. The ACCORD BP trial of patients with type 2 diabetes who had either established or were at high risk for atherosclerotic cardiovascular disease found no overall cardiovascular benefit from an attained systolic pressure of 119 compared to 134 mmHg, but did find a significant reduction in stroke at a systolic pressure below 120 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29737/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon these observations, we propose the following approach in patients with atherosclerotic cardiovascular disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend a goal blood pressure of less than",
"      <span class=\"nowrap\">",
"       140/90",
"      </span>",
"      mmHg compared with higher pressures in all patients.",
"     </li>",
"     <li>",
"      We suggest (a weaker recommendation) an attempt to lower the systolic pressure below 130 to 135 mmHg if it can be achieved without producing significant side effects.",
"     </li>",
"     <li>",
"      For patients who fulfill the entry criteria in ACCORD BP (type 2 diabetes plus either cardiovascular disease or at least two additional risk factors for cardiovascular disease), the authors and reviewers of this topic suggest that the risks and burdens of aiming for a goal systolic pressure of less than 120 mmHg (more side effects, extra patient visits, and increased cost) plus the lack of experience of almost all physicians in attaining such a goal may be too great a burden to achieve the small reduction in stroke that may be attained (absolute benefit 1 in 89 patients at five years). However, such a goal may be considered in highly motivated patients who would accept more aggressive antihypertensive therapy to further reduce their risk of stroke.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Patients with risk factors for atherosclerotic cardiovascular events",
"    </span>",
"    &nbsp;&mdash;&nbsp;A separate issue related to goal blood pressure is whether the recommendations in the preceding section on patients with atherosclerotic cardiovascular disease apply to patients who are at risk (eg, smoker, hyperlipidemia) but do not have documented disease or diabetes. No studies have been performed to assess goal blood pressure in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29737/abstract/2\">",
"     2",
"    </a>",
"    ] and, given the weak evidence supporting a goal systolic pressure of less than 130 to 135 mmHg in patients who already have cardiovascular disease, we suggest a goal blood pressure equivalent to that in the general hypertensive population (less than",
"    <span class=\"nowrap\">",
"     140/90",
"    </span>",
"    mmHg) in patients at increased cardiovascular risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33417?source=see_link\">",
"     \"What is goal blood pressure in the treatment of hypertension?\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Patients with diabetes mellitus or chronic kidney disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with diabetes mellitus and chronic kidney disease are also at increased cardiovascular risk. Issues related to goal blood pressure in these disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\", section on 'Goal blood pressure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link&amp;anchor=H24#H24\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Blood pressure goal'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trials of antihypertensive therapy in patients with different levels of risk for a cardiovascular event have shown benefit, particularly in individuals with atherosclerotic cardiovascular (CVD) disease or those at very high risk, such as patients with diabetes or chronic kidney disease. The higher the starting blood pressure, the more likely benefit from treatment will be seen. For patients with hypertension, the minimum goal of therapy (less than",
"    <span class=\"nowrap\">",
"     140/90",
"    </span>",
"    mmHg) is well established. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33417?source=see_link\">",
"     \"What is goal blood pressure in the treatment of hypertension?\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, whether there is benefit from a lower goal blood pressure (less than 130 to 135 mmHg systolic) for those with atherosclerotic CVD (coronary artery disease, peripheral artery disease, abdominal aortic aneurysm,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cerebrovascular disease) has not been well defined.",
"   </p>",
"   <p>",
"    For hypertensive patients with established atherosclerotic CVD (see",
"    <a class=\"local\" href=\"#H16\">",
"     'Patients with known atherosclerotic cardiovascular disease'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend antihypertensive therapy to lower the blood pressure to less than",
"      <span class=\"nowrap\">",
"       140/90",
"      </span>",
"      mmHg compared with higher pressures in all patients (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest an attempt to lower the systolic pressure below 130 to 135 mmHg if it can be achieved without producing significant side effects (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with established atherosclerotic CVD and a systolic blood pressure between 135 and 139 mmHg (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Placebo-controlled trials with a mean baseline BP less than 140/90 mmHg'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest an attempt to lower the systolic pressure below 130 to 135 mmHg if it can be achieved without producing significant side effects (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients who fulfill the entry criteria in ACCORD BP (systolic blood pressure around 140 mmHg and type 2 diabetes plus either cardiovascular disease or at least two additional risk factors for cardiovascular disease):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients should be managed in a manner similar to that for hypertensive patients with established CVD, as presented directly above The authors and reviewers of this topic believe that the risks and burdens of aiming for a goal systolic pressure of less than 120 mmHg (more side effects, extra patient visits, and increased cost) plus the lack of experience of almost all physicians in attaining such a goal may be too great a burden to achieve the small reduction in stroke that may be attained (absolute benefit 1 in 89 patients at five years). However, such a goal may be considered in highly motivated patients who would accept more aggressive antihypertensive therapy to further reduce their risk of stroke. (See",
"      <a class=\"local\" href=\"#H271902655\">",
"       'Stroke as an outcome of interest'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For hypertensive patients at high risk for atherosclerotic CVD who do not have diabetes (see",
"    <a class=\"local\" href=\"#H17\">",
"     'Patients with risk factors for atherosclerotic cardiovascular events'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend a goal blood pressure less than",
"      <span class=\"nowrap\">",
"       140/90",
"      </span>",
"      mmHg compared to higher values, similar to that in the general hypertensive population (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Patients with risk factors for atherosclerotic cardiovascular events'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29737/abstract/1\">",
"      Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29737/abstract/2\">",
"      Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28:1462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29737/abstract/3\">",
"      Mancia G, Parati G, Borghi C, et al. Hypertension prevalence, awareness, control and association with metabolic abnormalities in the San Marino population: the SMOOTH study. J Hypertens 2006; 24:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29737/abstract/4\">",
"      Jackson R, Lawes CM, Bennett DA, et al. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet 2005; 365:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29737/abstract/5\">",
"      Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29737/abstract/6\">",
"      ACCORD Study Group, Cushman WC, Evans GW, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29737/abstract/7\">",
"      Verdecchia P, Staessen JA, Angeli F, et al. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet 2009; 374:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29737/abstract/8\">",
"      Cooper-DeHoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010; 304:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29737/abstract/9\">",
"      Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292:2217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29737/abstract/10\">",
"      Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29737/abstract/11\">",
"      Dagenais GR, Yusuf S, Bourassa MG, et al. Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study. Circulation 2001; 104:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29737/abstract/12\">",
"      Bosch J, Yusuf S, Pogue J, et al. Use of ramipril in preventing stroke: double blind randomised trial. BMJ 2002; 324:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29737/abstract/13\">",
"      Lonn E, Roccaforte R, Yi Q, et al. Effect of long-term therapy with ramipril in high-risk women. J Am Coll Cardiol 2002; 40:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29737/abstract/14\">",
"      Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29737/abstract/15\">",
"      Sleight P, Yusuf S, Pogue J, et al. Blood-pressure reduction and cardiovascular risk in HOPE study. Lancet 2001; 358:2130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29737/abstract/16\">",
"      Svensson P, de Faire U, Sleight P, et al. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. Hypertension 2001; 38:E28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29737/abstract/17\">",
"      Fox KM, EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29737/abstract/18\">",
"      Daly CA, Fox KM, Remme WJ, et al. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. Eur Heart J 2005; 26:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29737/abstract/19\">",
"      Brugts JJ, Boersma E, Chonchol M, et al. The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patients with stable coronary artery disease are not modified by mild to moderate renal insufficiency: insights from the EUROPA trial. J Am Coll Cardiol 2007; 50:2148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29737/abstract/20\">",
"      Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351:2058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29737/abstract/21\">",
"      Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, Yusuf S, Teo K, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008; 372:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29737/abstract/22\">",
"      NAVIGATOR Study Group, McMurray JJ, Holman RR, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010; 362:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29737/abstract/23\">",
"      Poole-Wilson PA, Lubsen J, Kirwan BA, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 2004; 364:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29737/abstract/24\">",
"      Baker WL, Coleman CI, Kluger J, et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart disease. Ann Intern Med 2009; 151:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29737/abstract/25\">",
"      Thompson AM, Hu T, Eshelbrenner CL, et al. Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis. JAMA 2011; 305:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29737/abstract/26\">",
"      D'Agostino RB, Belanger AJ, Kannel WB, Cruickshank JM. Relation of low diastolic blood pressure to coronary heart disease death in presence of myocardial infarction: the Framingham Study. BMJ 1991; 303:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29737/abstract/27\">",
"      Messerli FH, Mancia G, Conti CR, et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006; 144:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29737/abstract/28\">",
"      Boutitie F, Gueyffier F, Pocock S, et al. J-shaped relationship between blood pressure and mortality in hypertensive patients: new insights from a meta-analysis of individual-patient data. Ann Intern Med 2002; 136:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29737/abstract/29\">",
"      Staessen J, Bulpitt C, Clement D, et al. Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. BMJ 1989; 298:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29737/abstract/30\">",
"      Bangalore S, Messerli FH, Wun CC, et al. J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. Eur Heart J 2010; 31:2897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29737/abstract/31\">",
"      Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007; 115:2761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29737/abstract/32\">",
"      Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur Heart J 2007; 28:2375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29737/abstract/33\">",
"      Bangalore S, Qin J, Sloan S, et al. What is the optimal blood pressure in patients after acute coronary syndromes?: Relationship of blood pressure and cardiovascular events in the PRavastatin OR atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction (PROVE IT-TIMI) 22 trial. Circulation 2010; 122:2142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29737/abstract/34\">",
"      Chrysant SG, Chrysant GS. Effectiveness of lowering blood pressure to prevent stroke versus to prevent coronary events. Am J Cardiol 2010; 106:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29737/abstract/35\">",
"      Mancia G. Effects of intensive blood pressure control in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Circulation 2010; 122:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29737/abstract/36\">",
"      Sleight P, Redon J, Verdecchia P, et al. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens 2009; 27:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29737/abstract/37\">",
"      Arima H, Chalmers J, Woodward M, et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens 2006; 24:1201.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3843 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.96.59.103-1E13E97D75-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_2_29737=[""].join("\n");
var outline_f29_2_29737=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Trials comparing blood pressure goals",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - ACCORD BP trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Cardio-Sis trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H271901243\">",
"      - INVEST trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Placebo-controlled trials with a mean baseline BP less than 140/90 mmHg",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Trials demonstrating benefit",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Trials showing no benefit",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Meta-analyses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Are lower blood pressures harmful?",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Coronary heart disease without heart failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Heart failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Isolated systolic hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Prior stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      GOAL BLOOD PRESSURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Patients with known atherosclerotic cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H532809390\">",
"      - Patients with acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H271902655\">",
"      - Stroke as an outcome of interest",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H88155274\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Patients with risk factors for atherosclerotic cardiovascular events",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Patients with diabetes mellitus or chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3843\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3843|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/31/25086\" title=\"figure 1\">",
"      Number of risk factors and CVD risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/51/32573\" title=\"figure 2\">",
"      Ramipril in high risk patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/38/19055\" title=\"figure 3A\">",
"      J curve diastolic HTN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/58/35759\" title=\"figure 3B\">",
"      J curve systolic HTN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3843|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/25/18844\" title=\"table 1\">",
"      Components cardiovascular risk",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17305?source=related_link\">",
"      Antihypertensive therapy to prevent recurrent stroke or transient ischemic attack",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37685?source=related_link\">",
"      Cardiovascular risks of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20218?source=related_link\">",
"      Choice of therapy in essential hypertension: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=related_link\">",
"      Choice of therapy in primary (essential) hypertension: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33656?source=related_link\">",
"      Cholesterol lowering after an acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/54/8040?source=related_link\">",
"      Treatment of bilateral atherosclerotic renal artery stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=related_link\">",
"      Treatment of hypertension in patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29031?source=related_link\">",
"      Treatment of hypertension in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/27/25018?source=related_link\">",
"      Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33417?source=related_link\">",
"      What is goal blood pressure in the treatment of hypertension?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_2_29738="Cytomegalovirus infection in renal transplant recipients";
var content_f29_2_29738=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cytomegalovirus infection in renal transplant recipients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/2/29738/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/2/29738/contributors\">",
"     John Vella, MD, FACP, FRCP, FASN",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/2/29738/contributors\">",
"     William M Bennett, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/2/29738/contributors\">",
"     Daniel C Brennan, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/2/29738/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/2/29738/contributors\">",
"     Barbara Murphy, MB, BAO, BCh, FRCPI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/2/29738/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/2/29738/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/2/29738/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/2/29738/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytomegalovirus (CMV) is one of the most important infections in renal transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. Exposure to the virus, as indicated by the presence of detectable IgG anti-CMV antibodies in the plasma, increases with age in the general population and is present in more than two-thirds of donors and recipients prior to transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/1\">",
"     1",
"    </a>",
"    ]. It is therefore common for the donor",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    recipient to be CMV-positive at the time of transplantation.",
"   </p>",
"   <p>",
"    CMV can be transmitted from the donor either by blood transfusion or by the transplanted kidney; the concurrent administration of immunosuppressive drugs to prevent rejection further increases the risk of clinically relevant CMV disease, with induction therapy principally being associated with an increased risk of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Thus, both the recipient and the donor are routinely tested for anti-CMV antibodies prior to transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31718?source=see_link\">",
"     \"Evaluation for infection before solid organ transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CMV is also a significant underlying cause of morbidity and mortality in the renal transplant setting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      This was shown in a study using data from the US Renal Data System in which donor and recipient CMV sero-status was available for over 17,000 deceased donor renal transplant recipients [",
"      <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/8\">",
"       8",
"      </a>",
"      ]. Based upon a multivariate analysis, CMV-positive patients had significantly higher incidence of CMV disease, allograft loss, and overall costs compared with CMV-negative recipients.",
"     </li>",
"     <li>",
"      The impact of CMV on overall mortality was examined in a prospective, single center study of almost 500 patients who did not receive induction therapy or CMV prophylaxis [",
"      <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/9\">",
"       9",
"      </a>",
"      ]. Patients were monitored by weekly CMV pp65 antigenemia for 100 days and followed for a median length of time of 66 months. Despite the absence of induction therapy and maintenance immunosuppressive therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil, and low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      , CMV-antigenemia was detectable in over 60 percent of patients in the first 100 days after transplant. Compared to those without CMV, CMV disease was associated with a relative risk of overall mortality of 2.5, and importantly, asymptomatic CMV infection was associated with a relative risk of overall mortality of 2.9.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It should be noted that many deceased donors receive numerous blood transfusions before the retrieval of organs. Under such circumstances, it should be presumed that one or more of the units of blood were CMV positive and the recipient will require prophylaxis even if the donor and recipient are CMV negative serologically.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CMV INFECTION VERSUS DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is an important distinction between CMV infection and CMV disease. Detection of virus via culture, molecular techniques or changes in serology defines CMV infection. Infection is considered to be present if one or more of the following findings is noted: seroconversion with the appearance of anti-CMV IgM antibodies; a fourfold increase in preexisting anti-CMV IgG titers; detection of CMV antigens in infected cells; detection of CMV-DNAemia by molecular techniques;",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    isolation of the virus by culture of the throat, buffy coat, or urine. Of note, the widespread availability of CMV PCR testing has rendered serology, antigen and culture based testing obsolete.",
"   </p>",
"   <p>",
"    CMV disease, in comparison, requires clinical signs and symptoms, such as fever, leukopenia, or organ involvement (including hepatitis, pneumonitis, pancreatitis, colitis, meningoencephalitis, and rarely myocarditis) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/1,2,10\">",
"     1,2,10",
"    </a>",
"    ]. CMV chorioretinitis, relatively common in patients with the acquired immunodeficiency syndrome (AIDS), is a rare feature of CMV disease in transplant recipients. However, progressive chorioretinitis, when it occurs, can become clinically apparent several months after transplantation, even in patients without previous evidence of symptomatic infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37688?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of AIDS-related cytomegalovirus retinitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The total burden of CMV viral particles in the host may correlate with clinical evidence of disease, disease severity, or response to therapy as illustrated by the following [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The number of CMV particles, as determined by quantitative polymerase chain reaction (PCR), and its correlation with clinical illness was analyzed as part of a study of 25 renal and 95 cardiac transplant recipients [",
"      <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/11\">",
"       11",
"      </a>",
"      ]. All patients with CMV DNA levels of &ge;500",
"      <span class=\"nowrap\">",
"       copies/&micro;g",
"      </span>",
"      of total DNA in peripheral blood had clinical evidence of disease, although some with lower viral burdens were also symptomatic.",
"     </li>",
"     <li>",
"      In another report, the initial CMV viral load and the rate of increase of virus in the blood correlated with the risk of developing CMV disease in renal, liver, and bone marrow transplant recipients [",
"      <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since PCR results may vary significantly by laboratory, the general application of this technique requires further standardization and study. Quantitative CMV levels are lower in plasma compared to whole blood or buffy coat samples. Thus, it is difficult to interpret quantitative results among studies with different sample sources. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/12/44230?source=see_link\">",
"     \"Viral load testing for cytomegalovirus in solid organ transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OVERVIEW OF PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Previously, treatment was only administered once CMV disease occurred. This resulted in an overall incidence of CMV disease of approximately 20 to 60 percent. Subsequently, preventive strategies have been developed that have significantly lowered the incidence of CMV disease, which is approximately five percent with modern approaches [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Preemptive strategy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Currently, there are two principal approaches in helping prevent CMV disease in patients undergoing solid organ transplantation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prophylactic strategy involves the administration of antiviral agents to patients at increased risk of developing CMV infection.",
"     </li>",
"     <li>",
"      A preemptive strategy involves periodic monitoring for viremia, principally using polymerase chain reaction (PCR), to permit prompt treatment after the detection of very early systemic infection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is unclear which preventive strategy is preferred [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/17\">",
"     17",
"    </a>",
"    ]. A number of meta-analyses of randomized trials of these and other strategies have been performed [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 2006 systematic review evaluated ten trials involving 476 solid organ recipients, of which six were preemptive therapy versus placebo or standard therapy (treatment once CMV disease occurred), three were preemptive versus prophylactic therapy, and one was oral versus intravenous preemptive therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/18\">",
"       18",
"      </a>",
"      ]. No difference was observed with preemptive versus prophylaxis therapy in the risks of CMV disease (RR of 0.42, 95% CI 0.07-2.65) or mortality (RR of 1.86, 95% CI 0.61-5.72). Most of these data were derived from one study [",
"      <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/21\">",
"       21",
"      </a>",
"      ]. Oral and intravenous preemptive therapy were also associated with similar risks of disease. By comparison, preemptive therapy, compared with placebo or standard therapy, significantly reduced the risk of CMV disease.",
"     </li>",
"     <li>",
"      A 2006 meta-analysis of 17 trials (with the comparator being placebo or no treatment) involving 1980 kidney and liver transplant recipients found that CMV organ disease was significantly reduced with both prophylaxis (odds ratio of 0.20, 95% CI 0.13-0.31) and preemptive (odds ratio of 0.28, 95% CI 0.11-0.69) strategies [",
"      <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/19\">",
"       19",
"      </a>",
"      ]. Acute rejection was also significantly reduced with both. Only the prophylactic approach resulted in decreased bacterial and fungal infections and mortality.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whether a prophylactic or preemptive strategy is best requires additional comparative trials, which are ongoing. One significant drawback of the preemptive approach is that success requires extreme vigilance. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'CMV status and prophylactic therapy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H25\">",
"     'Preemptive strategy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     OVERVIEW OF AGENTS USED FOR PROPHYLACTIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence and risk of severe CMV disease as well as the approach to management are determined by the CMV status, defined serologically, of both the donor and the recipient (see below). A number of different drugs and routes of administration have been used.",
"   </p>",
"   <p>",
"    A 2005 meta-analysis of 19 trials (with the comparator being placebo or no treatment) involving 1981 solid-organ transplant recipients found that antiviral prophylaxis significantly lowered the risk of CMV disease, CMV infection, and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/20\">",
"     20",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     Ganciclovir",
"    </a>",
"    was superior to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    , while oral ganciclovir was similarly effective as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    and intravenous ganciclovir.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Valganciclovir",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     Valganciclovir",
"    </a>",
"    has now supplanted",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    and CMV hyperimmune globulin as the prophylactic therapy of choice for CMV infection",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    disease among transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     \"Ganciclovir: Drug information\"",
"    </a>",
"    .) Prior to a discussion of the risk of disease and patient management based upon CMV serologic status, it is useful to review the evidence supporting the efficacy of valganciclovir among transplant recipients.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     Valganciclovir",
"    </a>",
"    is a valyl-ester prodrug of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    and has a bioavailability of nearly 70 percent (compared to 7 percent for oral ganciclovir) and at doses of 450 to 900 mg produces serum ganciclovir levels that are similar to that measured with intravenous administration of ganciclovir administered at 2.5 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37688?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of AIDS-related cytomegalovirus retinitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The results of the phase III PV 16000 international, double-dummy, double-blinded trial of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    versus oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    for the prevention of CMV in solid organ transplant recipients have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/24\">",
"     24",
"    </a>",
"    ]. In this study, 364 CMV",
"    <span class=\"nowrap\">",
"     D+/R-",
"    </span>",
"    solid organ transplant recipients (including 120 renal transplant recipients) were randomly assigned at a 2:1 ratio to receive oral valganciclovir 900 mg per day or oral ganciclovir 1000 mg TID with dose adjustments for renal insufficiency. Treatment was administered for 100 days as prophylaxis for CMV, with study medication being initiated within 10 days of transplant surgery. All patients with CMV disease had a positive determination of CMV in blood or tissue. During prophylaxis, only 0.8 and 1.6 percent of patients in the valganciclovir and ganciclovir groups developed CMV disease, respectively. This study therefore demonstrated that valganciclovir and oral ganciclovir have similar efficacy and reaffirmed that a period of intravenous ganciclovir is unnecessary when an appropriate oral agent such as valganciclovir or ganciclovir is used.",
"   </p>",
"   <p>",
"    However, as reported in other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/25\">",
"     25",
"    </a>",
"    ], CMV disease was common after prophylaxis, with some variation in incidence based upon how data were analyzed [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/24\">",
"     24",
"    </a>",
"    ]. Results were evaluated as either \"investigator-treated CMV disease\" or on an \"intention-to-treat\" basis. The latter was based upon an \"adjudicated determination of CMV disease\" as determined by a retrospective, independent, external review committee mandated by the FDA. The FDA definition was very strict, resulting in an under-determination of CMV-disease.",
"   </p>",
"   <p>",
"    At six months, CMV disease according to the adjudicated determination occurred in 12 and 15 percent in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    and oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    groups, respectively; according to the investigator-treated determination, by comparison, disease occurred in 23 and 22 percent, respectively. In kidney transplant recipients, the intention to treat incidence of disease was 6 and 23 percent in the valganciclovir and oral ganciclovir arms, respectively; in the investigator-treated determination, the incidence was 20 and 21 percent, respectively. The greater incidences reported in the investigator-treated determination are more consistent with historic reports and clinical experience.",
"   </p>",
"   <p>",
"    During the PV16000 study, plasma was obtained at routine intervals and retrospectively analyzed for CMV by PCR. Levels below 400 copies per milliliter, although possibly positive qualitatively, were below the level of quantitation and reported as negative. During prophylaxis, 2.5 and 10.4 percent of those randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    and oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    were viremic, respectively. By 12 months, approximately 50 percent had become viremic in plasma. The incidence of viremia may have been greater if buffy coats had been sampled as leukocytes are a reservoir for CMV.",
"   </p>",
"   <p>",
"    A subsequent systematic review evaluated the ability of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    to prevent posttransplant CMV disease in solid organ transplants, including kidney transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/26\">",
"     26",
"    </a>",
"    ]. Late-onset CMV disease (greater than 90 days posttransplant) was common among those who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    prophylaxis (9 and 18 percent in",
"    <span class=\"nowrap\">",
"     D+/R-",
"    </span>",
"    and all patients, respectively) but was not observed in those administered valganciclovir preemptive therapy.",
"   </p>",
"   <p>",
"    A multicenter trial (IMPACT trial) compared 200 days versus 100 days of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    prophylaxis (900 mg daily) among 326 high risk",
"    <span class=\"nowrap\">",
"     (D+/R-)",
"    </span>",
"    renal transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/27\">",
"     27",
"    </a>",
"    ]. At 12 months, fewer patients in the 200-day group developed CMV disease compared with those in the 100-day group (16 versus 37 percent, respectively). There was no difference in the rates of acute rejection or adverse side effects.",
"   </p>",
"   <p>",
"    Overall, these results suggest that a duration for CMV prophylaxis of 100 days may be insufficient for CMV D+R- transplant recipients. Most programs now routinely provide prophylaxis for up to 200 days for such patients.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     Valganciclovir",
"    </a>",
"    prophylaxis may be relatively less likely to induce resistance than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    (see next section).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Drug resistant CMV",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     Ganciclovir",
"    </a>",
"    -resistant CMV, although well-known among HIV-infected patients, has previously only been published as isolated case reports among transplant recipients. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     \"Ganciclovir: Drug information\"",
"    </a>",
"    .) However, such isolates have emerged among the transplant population and may be more common in seronegative recipients of seropositive organs. In one study of 240 recipients of liver, kidney, or pancreas transplants, ganciclovir-resistant CMV disease developed in 5 of 67 (7 percent) seronegative recipients of CMV-positive organs compared to none of 173 seropositive recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/28\">",
"     28",
"    </a>",
"    ]. Ganciclovir resistance was also more common among those who received the most intense immunosuppressive regimen",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    were administered prolonged ganciclovir prophylactic therapy. These findings support the hypothesis that the possibility of selecting a mutant virus is enhanced among patients with higher viral titers who are exposed to lengthy treatment on inadequate concentrations of active drug.",
"   </p>",
"   <p>",
"    In the PV16000 trial, for example, three cases (2 percent) of those administered oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    developed ganciclovir resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/24\">",
"     24",
"    </a>",
"    ]. By comparison, none of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    patients developed resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Other antiviral agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several additional agents have been evaluated or are currently undergoing investigation as possible anti-CMV agents among solid-organ recipients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     CMV hyperimmune globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMV hyperimmune globulin is a product prepared from human serum that contains a high titer of anti-CMV antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/29\">",
"     29",
"    </a>",
"    ]. Initially developed in the 1980s, it was licensed for the prophylactic therapy of CMV disease, although it sometimes was also used in the rescue therapy of tissue invasive disease. The infusions are typically commenced within 72 hours of engraftment, and are usually continued in the outpatient department for four months. The following protocol is recommended: 150",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    within 72 hours; 100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    at two, four, six, and eight weeks; and 50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    at 12 and 16 weeks after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of this regimen was proven by a multicenter trial, performed before the availability of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    , which showed that hyperimmune globulin had the following effects when compared to no therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      It decreased incidence of CMV disease &mdash; 20 versus 60 percent.",
"     </li>",
"     <li>",
"      It did not alter the incidence of viral isolation or seroconversion, indicating that its main effect was to prevent clinically evident infection.",
"     </li>",
"     <li>",
"      It reduced the incidence of fungal or parasitic superinfection &mdash; 0 versus 20 percent.",
"     </li>",
"     <li>",
"      It diminished incidence of marked leukopenia, a marker of severe infection &mdash; 4 versus 37 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The last two findings probably reflect a reduction in the immunosuppressive effects of CMV disease induced by the hyperimmune globulin rather than a general enhancement of the immune system with the preparation. As mentioned above,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    has supplanted CMV hyperimmune globulin for preventing CMV disease in at risk patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Valacyclovir",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited evidence suggests that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    may also help prevent CMV disease among high-risk renal transplant patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/15,31,32\">",
"     15,31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a multicenter prospective study, 408 CMV-positive renal allograft recipients and 208 CMV-negative recipients of a renal allograft from a positive donor were randomized to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      (2 gm four times daily) or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/32\">",
"       32",
"      </a>",
"      ]. At six months, active therapy significantly reduced the incidence of disease among both seronegative (16 versus 45 percent for placebo) and seropositive recipients (1 versus 6 percent). Valacyclovir also decreased the incidence of acute rejection among seronegative patients (26 versus 52 percent versus placebo, p = 0.001).",
"     </li>",
"     <li>",
"      In another study, 70 renal transplant recipients at risk for CMV",
"      <span class=\"nowrap\">",
"       (D+/R-,",
"      </span>",
"      <span class=\"nowrap\">",
"       D+/R+,",
"      </span>",
"      <span class=\"nowrap\">",
"       D-/R+)",
"      </span>",
"      were randomly assigned to three-month prophylaxis with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      (2 g four times daily) or preemptive therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"       valganciclovir",
"      </a>",
"      (900 mg twice daily for a minimum of 14 days) for CMV DNAemia &ge;2000",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      by quantitative PCR in whole blood assessed weekly for 16 weeks and at 5, 6, 9, and 12 months [",
"      <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/15\">",
"       15",
"      </a>",
"      ]. The 12-month incidence of CMV DNAemia was higher in the preemptive group (92 versus 59 percent), while the incidence of CMV disease was the same (6 versus 9 percent). The onset of CMV DNAemia was delayed in the valacyclovir group (37 versus 187 days), with breakthrough CMV DNAemia in 9 percent of the valacyclovir group and in 47 percent after discontinuation of valacyclovir. Over 12 months, a significantly higher rate of biopsy-proven acute rejection was observed in the preemptive group (36 versus 15 percent). Thirty-two percent required discontinuation for side effects including hallucinations, confusion, neutropenia, and leukopenia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      However, another study that reported outcomes at four years suggested that allograft survival was better with preemptive therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/15,33\">",
"       15,33",
"      </a>",
"      ]. In this study, 70 patients were randomly assigned to receive preemptive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"       valganciclovir",
"      </a>",
"      (900 mg twice daily for two to three weeks upon on detection of viremia) or prophylactic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      (2 grams four times daily for three months) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/15\">",
"       15",
"      </a>",
"      ]. Although the incidence of CMV disease was not different between groups at 12 months, there was a trend toward increased fibrosis and tubular atrophy at three years among patients who received prophylactic valacyclovir compared with preemptive valganciclovir (38 versus 19 percent) and the four-year graft survival was worse among patients who received valacyclovir (74 versus 92 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/33\">",
"       33",
"      </a>",
"      ]. The mechanism underlying the decreased graft survival with prophylactic valacyclovir may have been related to the increased expression of profibrotic genes associated with post-prophylactic CMV viremia [",
"      <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/34\">",
"       34",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      This result is in contrast to an earlier study that suggested superior long-term allograft survival associated with prophylactic oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      compared with preemptive therapy with intravenous ganciclovir. This was shown in a study of 148 kidney allograft recipients randomly assigned to oral ganciclovir prophylaxis or preemptive therapy in which intravenous ganciclovir was administered to those with &ge;400 CMV DNA",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/35\">",
"       35",
"      </a>",
"      ]. Compared with preemptive therapy, prophylaxis was associated with significantly higher long-term allograft survival (uncensored for death) at four years (92 versus 78 percent); there was no difference when graft survival was censored for death.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    study is also in contrast to a randomized study that compared preemptive to prophylactic therapy among 115 kidney transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/36\">",
"     36",
"    </a>",
"    ]. In this study, one and four year graft outcomes did not differ between groups but death was more common in the prophylaxis group at four years.",
"   </p>",
"   <p>",
"    Since",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    (even in high concentrations) has limited activity against CMV, the mechanism of action for these surprising results remains unclear. Although promising, further study is required to properly assess the role for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    in this setting.",
"   </p>",
"   <p>",
"    It should be noted that cases of thrombotic thrombocytopenic",
"    <span class=\"nowrap\">",
"     purpura/hemolytic",
"    </span>",
"    uremic syndrome",
"    <span class=\"nowrap\">",
"     (TTP/HUS),",
"    </span>",
"    including some fatalities, have been reported during clinical trials in patients with advanced HIV disease as well as bone marrow and kidney transplant recipients, who were given high dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    (8",
"    <span class=\"nowrap\">",
"     g/day).",
"    </span>",
"    The relationship to valacyclovir is unclear.",
"   </p>",
"   <p>",
"    Therefore, it is currently recommended that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     Valacyclovir",
"    </a>",
"    be used with caution and at reduced doses in patients with renal impairment, elderly patients, or in patients receiving concomitant nephrotoxic agents as the risk of renal dysfunction and neurotoxicity may be increased [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30003?source=see_link\">",
"     \"Valacyclovir: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Leflunomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"     Leflunomide",
"    </a>",
"    is a pyrimidine synthesis inhibitor and immunosuppressive agent that is currently utilized for the treatment of rheumatoid arthritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/59/10169?source=see_link\">",
"     \"Leflunomide in the treatment of rheumatoid arthritis\"",
"    </a>",
"    .) Given its immunosuppressive properties, it has also been used in experimental and clinical transplantation. Leflunomide prevents CMV and herpes simplex virus type I replication by interfering with virion assembly [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/38\">",
"     38",
"    </a>",
"    ], and may therefore eventually assume a role in the management of CMV in transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/38-42\">",
"     38-42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Acyclovir",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    as prophylaxis in CMV infection has been compared to other antiviral agents, particularly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    , in many of the studies previously cited. A three month course of high-dose acyclovir (800 mg four times per day, with modification of dosage for impaired renal allograft function) after transplantation has also been utilized. In one randomized, placebo-controlled trial, for example, symptomatic CMV disease developed in only one of six CMV-negative recipients who received a graft from a CMV-positive donor versus all seven such patients who were treated with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/43\">",
"     43",
"    </a>",
"    ]. However, these results have not been confirmed [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/44\">",
"     44",
"    </a>",
"    ]. This is not surprising because acyclovir does not have in vitro activity against CMV at clinically achievable concentrations. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     \"Acyclovir: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Maribavir",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maribavir is a DNA synthesis inhibitor with the potential for prevention and treatment of human CMV infections related to transplants (including solid organ and hematopoietic stem cells), congenital transmission, and in patients with HIV infection. Maribavir is a benzimidazole nucleoside that prevents viral DNA synthesis and capsid nuclear egress. It is therefore potentially useful for CMV resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    . However, the clinical trial for its prophylaxis use has been discontinued based on lack of efficacy (",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/\">",
"     clinicaltrials.gov",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     CMV STATUS AND PROPHYLACTIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following provides an overview of general clinical practice guidelines and a review of some of the data concerning the prevention of cytomegalovirus disease after transplantation among different combinations of",
"    <span class=\"nowrap\">",
"     donor/recipient",
"    </span>",
"    CMV status [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CMV-negative recipients of kidneys from CMV-negative donors have the lowest incidence of CMV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. When infection does occur in these patients, it may be caused by false seronegativity in the donor or recipient, community exposure, or perioperative transfusion of leukocyte-containing blood. The use of leukocyte-poor blood substantially decreases the risk of virus transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/48\">",
"     48",
"    </a>",
"    ]. By comparison, there is a high risk of infection",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    disease when the donor or recipient or both is CMV-positive [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/24,45,48\">",
"     24,45,48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     CMV-positive donor, CMV-negative recipient",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, approximately 70 to 90 percent of CMV-positive donor, CMV-negative recipients developed \"primary\" CMV infection when prophylaxis was not administered. Furthermore, 50 to 80 percent developed CMV disease and roughly 30 percent will develop pneumonitis, a major contributor to morbidity and mortality. In the absence of prophylactic therapy, the mortality rate was 15 percent. For unclear reasons, the rate of primary infection has decreased to 50 percent even in the absence of prophylaxis and despite the use of lymphocyte depleting therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Previously, none of the available prophylactic regimens reliably prevented CMV infection in these patients, but they may have decreased the severity of CMV disease. Because of these difficulties, some centers had previously avoided the placement of CMV-positive kidneys into CMV-negative recipients. However, the advent of effective prophylactic and rescue therapies with the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    has largely led to the abandonment of such a policy.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     Valganciclovir",
"    </a>",
"    is the treatment of choice as prophylaxis.",
"   </p>",
"   <p>",
"    The previously described PV 16000 trial demonstrated that a period of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    is not necessary for prevention of CMV disease in high-risk solid organ transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the setting of acute graft rejection, a treatment option is the concurrent administration of prophylactic intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    with antirejection treatment (consisting of either high dose steroids, or antilymphocyte therapy), which is similar to regimens in bone marrow and liver recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/49\">",
"     49",
"    </a>",
"    ]. The availability of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    has obviated the need for intravenous ganciclovir in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     CMV-negative donor, CMV-positive recipient",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transplant recipients in this setting may have reactivation of latent CMV infection due to the administration of immunosuppressive drugs. CMV infection",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    disease develop in up to 20 percent of cases (not treated with anti-lymphocyte therapy), although progression to pneumonitis is rare. Some groups use prophylactic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    therapy in this population. This is especially true when lymphocyte depleting agents are used for induction therapy or treatment of rejection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     CMV-positive donor, CMV-positive recipient",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seropositive recipients of CMV-positive kidneys are at risk for both reactivation of latent virus and superinfection with a new viral strain. The worst graft and patient survival at three years post-transplantation is observed among the group in which the donor and recipient are both positive [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. Although the reason is unclear, this enhanced risk of disease may be due to the presence of multiple CMV virotypes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reactivation of different viruses. We currently administer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    to such patients since oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    use is associated with a much higher pill burden and is essentially unavailable.",
"   </p>",
"   <p>",
"    It is important to note that historically, reactivation was particularly common when OKT3 was included in the antirejection protocol [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. In one study, for example, the incidence of CMV disease in seropositive recipients was 59 percent in patients treated with OKT3 versus only 21 percent in those not treated with OKT3 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/52\">",
"     52",
"    </a>",
"    ]. OKT3 is no longer available, but it is important to remember that the incidence of CMV disease is increased with any lymphocyte depleting agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     CMV-negative donor, CMV-negative recipient",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the low prevalence of disease in this patient population, independent of type of immunosuppressive therapy, no treatment with antiviral prophylaxis therapy has been recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/45\">",
"     45",
"    </a>",
"    ]. However, one study showed that the incidence of disease in the D-R- population approaches 10 percent when antilymphocyte induction therapy is used with only",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    for herpes prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/48\">",
"     48",
"    </a>",
"    ]. We use acyclovir, 200 to 400 mg twice daily for prophylaxis against herpes simplex virus (HSV) 1, 2, 3, and 4, but not HSV-5, CMV.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Duration of prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal duration of prophylaxis is unknown. In the PV 16000 trial of D+R- patients, approximately 55 percent of patients had detectable viremia and up to 25 percent developed CMV after 100 days of either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    or oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/24\">",
"     24",
"    </a>",
"    ]. Most institutions use approximately three months of prophylaxis.",
"   </p>",
"   <p>",
"    By comparison, at some transplant centers, a longer or variable duration of prophylaxis has been used according to the CMV-serostatus of the donor and recipient [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/27,48,54\">",
"     27,48,54",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a multicenter trial, 326 D+R- patients were randomly assigned to prophylaxis with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"       valganciclovir",
"      </a>",
"      (900",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      for either 200 or 100 days [",
"      <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/27\">",
"       27",
"      </a>",
"      ]. Compared with 100 days of therapy, prophylactic therapy for 200 days was associated with a significantly lower incidence of confirmed CMV disease (16 versus 37 percent) and confirmed CMV viremia (37 versus 41 percent) at 12 months post-transplant. This study is noteworthy for the late incidence of asymptomatic CMV viremia which, at four years after transplantation, was associated with an increased risk of death compared with those without CMV viremia [",
"      <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another center, prophylaxis, including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      , was prescribed for 90 days in D-R+ cases and for 180 days in D+R- and D+R+ cases. D-R- cases did not receive CMV-disease prophylaxis [",
"      <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/48\">",
"       48",
"      </a>",
"      ]. The incidence of CMV disease and effect on patient and allograft survival stratified by CMV-serostatus with this specific strategy was evaluated in 470 patients transplanted between August, 1996 and December, 2000 [",
"      <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/48\">",
"       48",
"      </a>",
"      ]. There was a significant association of disease with donor CMV-seropositivity when the recipient was CMV seronegative, as disease occurred in 4.1 and 22.2 percent of D-R- and D+R- pairings, respectively. By comparison, donor CMV-serostatus was not significantly associated with CMV-disease incidence when the recipient was CMV-seropositive (5.2 and 9.2 percent incidence in D+R+ and D-R+ pairings, respectively). The apparently counterintuitive ordering of CMV-disease incidence in D+R+ and D-R+ cases may be due to the longer prophylaxis period in D+R+ cases, with three months given for D-R+ cases and six months for D+R+ cases. All CMV-disease occurred after prophylaxis ended. Despite the relatively mild degree of disease severity, which was promptly detected and treated, the presence of disease was significantly associated with poorer graft survival (57 and 79 percent in patients with and without CMV-disease).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another center routinely uses a 24 week course of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    in patients at high risk of CMV disease, particularly D+R- recipients who received thymoglobulin induction therapy plus maintenance immunosuppressive therapy. In a study from this center, the group that received a 24 week regimen, compared with a historic control group administered a 12 week course, had a markedly lower rate of CMV infection (31 versus 7 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/54\">",
"     54",
"    </a>",
"    ]. Similar findings were reported in another study [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     CMV status and HLA-DR matching",
"    </span>",
"    &nbsp;&mdash;&nbsp;The previous retrospective review also found that the degree of HLA-DR matching had a significant effect upon the development of CMV disease and allograft survival [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/48\">",
"     48",
"    </a>",
"    ]. The efficacy of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    was assessed among",
"    <span class=\"nowrap\">",
"     donor-positive/recipient-positive,",
"    </span>",
"    <span class=\"nowrap\">",
"     donor-positive/recipient-negative,",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     donor-negative/recipient-positive",
"    </span>",
"    combinations, in which the number of HLA-DR matches varied. CMV disease occurred most frequently in",
"    <span class=\"nowrap\">",
"     donor-positive/recipient-negative",
"    </span>",
"    recipients with zero HLA-DR matches. In addition, allograft survival at five years was significantly decreased among those with CMV disease and zero matches compared to patients with CMV disease and one or two HLA-DR matches (16 versus 76 percent, respectively). These results suggest that, to enhance allograft survival, consideration should be given to HLA-DR matching plus CMV status in the allocation of kidneys.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Approach using a prophylactic strategy",
"    </span>",
"    &nbsp;&mdash;&nbsp;With a prophylactic strategy, we currently administer oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    to all patients other than seronegative recipients of seronegative grafts. Most transplant centers administer such therapy for a total duration of 100 days. When a lymphocyte-depleting therapy (ATGAM&reg;, Thymoglobulin&reg;, OKT3, Campath) is administered in a quadruple immunosuppressive regimen and a preemptive approach is not used, we recommend that prophylaxis be extended to six to nine months for",
"    <span class=\"nowrap\">",
"     D+/R-",
"    </span>",
"    patients. Many centers also extend prophylactic therapy to 200 days for",
"    <span class=\"nowrap\">",
"     D+/R-",
"    </span>",
"    patients, independent of induction therapy.",
"   </p>",
"   <p>",
"    The choice of which agent to use depends upon the renal function of the patient and the relative affordability of each of the agents [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/10\">",
"     10",
"    </a>",
"    ]. In general, we prefer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    (if there are no contraindications) because of the reduced pill burden, increased likelihood of compliance with once a day administration, and the potential for a decreased incidence of drug resistance. However, valganciclovir is",
"    <strong>",
"     contraindicated",
"    </strong>",
"    when the patient is on dialysis or has an estimated creatinine clearance of less than 10",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     \"Valganciclovir: Drug information\"",
"    </a>",
"    .) Since oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    is available generically, it may also be more affordable than valganciclovir. It is now known that even six months of oral valganciclovir prophylaxis will not prevent CMV",
"    <span class=\"nowrap\">",
"     infection/disease",
"    </span>",
"    in high risk patients",
"    <span class=\"nowrap\">",
"     (D+/R-).",
"    </span>",
"    In one report, almost 50 percent of such patients developed CMV viremia within a mean of 107 days after prophylaxis ended [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/56\">",
"     56",
"    </a>",
"    ]. In this report, most of the individuals were symptomatic with evidence of tissue invasive disease. Furthermore, relapses after the end of treatment commonly occurred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     PREEMPTIVE STRATEGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A preemptive strategy is based upon the idea that periodic PCR monitoring of whole blood for CMV DNAemia allows the detection of very early systemic infection. This permits prompt treatment, which may limit morbidity and mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relative effectiveness of a preemptive strategy versus other approaches has been evaluated in several studies. A 2006 systematic review evaluated ten trials involving 476 patients, of which six were preemptive therapy versus placebo or standard therapy (treatment once CMV disease occurred), three were preemptive versus prophylactic therapy, and one was oral versus intravenous preemptive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/18\">",
"     18",
"    </a>",
"    ]. No difference was observed with preemptive versus prophylaxis therapy in the risks of CMV disease (RR of 0.42, 95% CI 0.07-2.65) or mortality (RR of 1.86, 95% CI 0.61-5.72). However, most of these data were derived from one study [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/21\">",
"     21",
"    </a>",
"    ]. Oral and intravenous preemptive therapy were also associated with similar risks of disease. By comparison, preemptive therapy, compared with placebo or standard therapy, significantly reduced the risk of CMV disease.",
"   </p>",
"   <p>",
"    Two subsequent studies found that preemptive and prophylactic strategies were similarly effective, at least in the short term, in preventing CMV disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. In one report, 98 at risk kidney transplant recipients",
"    <span class=\"nowrap\">",
"     (D+/R-,",
"    </span>",
"    <span class=\"nowrap\">",
"     D+/R+,",
"    </span>",
"    D-R+) were randomly assigned to prophylaxis (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    , 900",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for 100 days) or preemptive therapy (valganciclovir, 900 mg twice per day for at least 21 days for CMV DNAemia as defined by levels greater than 2000",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    by PCR) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/16\">",
"     16",
"    </a>",
"    ]. Doses of valganciclovir were adjusted for renal function. All patients who developed CMV DNAemia were treated with valganciclovir, which was continued until the PCR assay became negative.",
"   </p>",
"   <p>",
"    The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A similar incidence of symptomatic infection (eg, disease) was reported in both arms (overall four percent). There were no deaths.",
"     </li>",
"     <li>",
"      CMV DNAemia was significantly more likely in the preemptive group (59 versus 29 percent for the prophylactic arm). However, the late onset of CMV DNAemia (greater than 100 days) was significantly more likely with prophylaxis therapy (24 versus zero percent).",
"     </li>",
"     <li>",
"      Although not statistically significant, high risk",
"      <span class=\"nowrap\">",
"       D+/R-",
"      </span>",
"      patients may be more likely to have disease with prophylactic therapy; symptomatic infection was observed in four patients in the prophylactic arm (3",
"      <span class=\"nowrap\">",
"       D+/R-",
"      </span>",
"      and one",
"      <span class=\"nowrap\">",
"       D+/R+)",
"      </span>",
"      versus only one in the preemptive arm",
"      <span class=\"nowrap\">",
"       (D+/R-).",
"      </span>",
"      Time of onset of disease occurred later than 100 days in all patients with symptomatic disease in the prophylactic arm, but at day 62 in the one patient treated preemptively.",
"     </li>",
"     <li>",
"      Both approaches were associated with similar overall costs, minimal side effects, and low rates of adverse outcomes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the incidence of CMV disease is similar, at least in the short term, with either preemptive or prophylactic strategies with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    (approximately 5 percent). This incidence is significantly lower than that observed during the period in which treatment was only administered once CMV disease occurred (20 to 60 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Approach using preemptive strategy",
"    </span>",
"    &nbsp;&mdash;&nbsp;With a preemptive strategy, we monitor whole blood quantitative CMV-PCR weekly for 12 to 16 weeks post-surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/12/44230?source=see_link\">",
"     \"Viral load testing for cytomegalovirus in solid organ transplant recipients\"",
"    </a>",
"    .) In patients in whom the CMV-PCR becomes positive, which is reliably quantitative above 2000",
"    <span class=\"nowrap\">",
"     copies/mL,",
"    </span>",
"    we use the following approach, which varies in part upon the severity of the infection:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In all cases of quantifiable CMV-viremia, we recommend that the antimetabolite (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      ) be discontinued (if being administered), at least until viremia clears. The severity of the CMV and the risk for rejection dictate whether to restart the antimetabolite.",
"     </li>",
"     <li>",
"      Asymptomatic or only mild disease is treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"       valganciclovir",
"      </a>",
"      for a minimum of 21 days or longer if necessary to clear viremia.",
"     </li>",
"     <li>",
"      Invasive disease is treated with intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      . However, during a period in which there was a lack of availability of intravenous ganciclovir, we successfully treated these patients with oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"       valganciclovir",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Weekly quantitative PCRs should be obtained during treatment to determine an adequate response. If the quantitative PCR level does not decrease by 50 percent in two weeks, viral resistance or lack of recipient immunocompetence should be suspected. In this setting, the dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"       valganciclovir",
"      </a>",
"      can then be increased or the patient switched to intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      to overcome relative resistance. Consideration should also be given for treatment with hyperimmune CMV globulin for patients with suspected CMV immunocompetence. We recommend that treatment should continue for one week beyond the finding of a negative quantitative CMV PCR.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We consider secondary prophylaxis for an additional three months after this initial treatment, particularly in those at high-risk for recurrence (ie,",
"    <span class=\"nowrap\">",
"     D+/R-",
"    </span>",
"    or 2DR HLA mismatched patients).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal strategy to control CMV is based in part upon the institution and available resources. Additional studies are ongoing concerning whether a prophylactic or preemptive strategy is best [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/57\">",
"     57",
"    </a>",
"    ]. One significant drawback of the preemptive approach is that success requires extreme vigilance.",
"   </p>",
"   <p>",
"    Although one study showed that overall costs and control were similar between a prophylactic or preemptive approach, a preemptive approach is difficult to accomplish logistically outside of a clinical trial. As mentioned above, there is accumulating evidence that prophylaxis is associated with better outcomes than preemptive or deferred therapy. Because of this, our current recommendation is to provide prophylaxis with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    for 6 to 12 months in the",
"    <span class=\"nowrap\">",
"     D+/R-",
"    </span>",
"    patients and for 3 months for",
"    <span class=\"nowrap\">",
"     D+/R+",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     D-/R+",
"    </span>",
"    patients who receive lymphocyte-depleting induction or rejection therapy. This is consistent with the 2010 International Consensus Guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     CMV DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic CMV infections typically occur one to four months after transplantation if prophylaxis is not used or one to four months after discontinuation of prophylaxis, although cases may develop later. Thus, the onset of disease usually follows the period of maximal immunosuppression for the prevention and treatment of acute rejection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/56/32649?source=see_link\">",
"     \"Induction immunosuppressive therapy in renal transplantation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/52/4938?source=see_link\">",
"     \"Acute renal allograft rejection: Treatment\"",
"    </a>",
"    .) As noted above, however, the risk of reactivation is increased in seropositive recipients treated with lymphocyte depleting therapy. One of the cardinal features of CMV disease among patients administered",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    is the development of marked leukopenia, a complication which usually requires the temporary discontinuation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reduction of immunosuppressive medications.",
"   </p>",
"   <p>",
"    However, leukopenia may not be as prominent a feature of CMV disease as it used to be because",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil (MMF, CellCept) is preferred to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    in most immunosuppressive regimens and prophylactic antiviral therapy is extremely effective:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      , the incidence of leukopenia with MMF may be lower because of its relatively selective action on the purine salvage pathway upon which proliferating lymphocytes are particularly dependent.",
"     </li>",
"     <li>",
"      The incidence of tissue invasive CMV disease appears to be decreasing with the current practice of administering",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"       valganciclovir",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      to most patients as prophylactic therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, as the immune system may be directly suppressed because of CMV infection, it is prudent to modify the immunosuppressive regimen as required. We have no fixed protocol for this clinical situation since the degree of immunosuppression may significantly vary by individual. Nevertheless, the antimetabolite utilized, either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or MMF, is usually permanently discontinued.",
"   </p>",
"   <p>",
"    The most common presentation of CMV disease is a mononucleosis-like syndrome with fever, malaise, myalgias, and arthralgias, usually associated with leukopenia and mild (5 to 10 percent) atypical lymphocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/47\">",
"     47",
"    </a>",
"    ]. A mild elevation in serum aminotransferase concentrations also may be seen. With the use of MMF, however, invasive CMV disease can occur in the absence of fever and leukopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Interstitial pneumonitis and ulcerations in the esophagus and colon are particularly troublesome and cause major morbidity. As an example, gastrointestinal bleeding among renal transplant recipients is commonly caused by erosions due to CMV. In this setting, invasive disease is usually confirmed with endoscopic biopsy. By comparison, encephalopathy and chorioretinitis are unusual in renal transplant recipients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Techniques for detecting CMV have improved dramatically. Interpretation of results may be problematic, however, because of the broad spectrum of clinical disease with which the virus is associated (ranging from asymptomatic viral shedding to fulminant infection). The implications of positive identification of CMV in blood or tissue depend largely upon the clinical context and the source of the specimen [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/60\">",
"     60",
"    </a>",
"    ]. The diagnosis of CMV infection and disease is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/25/8597?source=see_link\">",
"     \"Diagnosis of cytomegalovirus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/12/44230?source=see_link\">",
"     \"Viral load testing for cytomegalovirus in solid organ transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy of CMV disease varies with the severity of the clinical manifestations. The mononucleosis-like syndrome may resolve without the administration of antiviral drugs. A reduction in the overall level of immunotherapy is often recommended. As an example, lymphocyte depleting agents should be discontinued and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil should be given in reduced dosage or discontinued. Reduced immunotherapy is particularly necessary when there is evidence of tissue invasive disease and organ involvement (including chorioretinitis). Whether",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    should be discontinued in this setting remains controversial. We usually do",
"    <strong>",
"     not",
"    </strong>",
"    discontinue cyclosporine or tacrolimus unless there is evidence of life-threatening infection (see above). Corticosteroids are generally continued to prevent possible adrenal insufficiency.",
"   </p>",
"   <p>",
"    Uncontrolled trials suggest that patients with organ involvement may benefit from a two to three week course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/2,61-63\">",
"     2,61-63",
"    </a>",
"    ]. Hyperimmune globulin (Cytogam) may also be added to the treatment regimen in those with organ involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/64\">",
"     64",
"    </a>",
"    ]. Prior to initiating this regimen, however, potential causes other than CMV disease need to be excluded. As an example, CMV infection may be associated with Pneumocystis carinii pneumonia, which should also be treated [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/1,61\">",
"     1,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The usual dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    is 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every 12 hours in patients with normal renal allograft function [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. Although we and others recommend that dose reductions should be made in those with renal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/10\">",
"     10",
"    </a>",
"    ], some evidence suggests that lower doses increase the likelihood of recurrent CMV disease in renal transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/65\">",
"     65",
"    </a>",
"    ]. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     \"Ganciclovir: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most frequent side effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    is leukopenia, which is usually reversible after reducing the dose or stopping the medication. A mild elevation in the plasma creatinine concentration also may be seen, although the role of ganciclovir in this complication is uncertain. Crystal-induced acute renal failure, as seen with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    , appears to be a rare event with ganciclovir. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/2/34857?source=see_link\">",
"     \"Crystal-induced acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     Valganciclovir",
"    </a>",
"    has been used to treat CMV-associated retinitis in AIDS patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/66\">",
"     66",
"    </a>",
"    ]. Based on the excellent bioavailability of valganciclovir and pharmacokinetics, it may be useful for treatment of CMV disease in kidney transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. The effectiveness of valganciclovir was best evaluated in the VICTOR study [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/68\">",
"     68",
"    </a>",
"    ]. In this noninferiority trial, 321 solid organ recipients (74 percent kidney transplant patients) with CMV disease were randomly assigned to oral valganciclovir (900 mg twice daily for 21 days) or intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    twice daily for 21 days), which was followed in both arms by valganciclovir (900 mg daily until day 49). Doses were adjusted based upon kidney function. Both agents were similarly effective in suppressing viremia at 21 days (77 and 80 percent) and 49 days (85 and 84 percent). Side effects were also comparable. Follow-up at one year also found that outcomes were similar in both treatment arms [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the results from the VICTOR study are intriguing, symptomatic patients with high viral loads and tissue-invasive disease should continue to be treated initially with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    until a response to therapy has been documented by clinical improvement and a decrease in viral load because of the risk of relatively resistant CMV [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/23,70\">",
"     23,70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The VICTOR study also suggested the importance of treating for at least one week beyond a negative CMV-PCR, and to administer secondary prophylaxis at prophylactic doses for at least one month after CMV-PCR negativity is achieved. In the VICTOR study, discontinuation of the anti-metabolite component was associated with more rapid clearing of the virus but not late eradication. However it was unclear from this study whether the antimetabolite was ever reintroduced [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Our experience is that discontinuation of the anti-metabolite,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, is essential for virus eradication when",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    is used for treatment of CMV disease. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     \"Valganciclovir: Drug information\"",
"    </a>",
"    .) In general we do not reintroduce the antimetabolite as we believe that CMV-viremia is a sign of excessive immunosuppression. Cytomegalovirus infection may be immunosuppressive and after clearance of viremia, the patient may be at risk for rejection. For patients who are at increased risk for rejection after clearance of CMV, the antimetabolite is reintroduced at a dose lower than that which was used when the patient developed CMV. We recommend viral monitoring with weekly CMV-PCRs for four weeks to make sure CMV has not reactivated on this lower dose. If CMV recurs, we discontinue the antimetabolite indefinitely, and re-treat the patient as above. If CMV reactivation does not occur we continue the antimetabolite at the reduced dose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     CMV-INDUCED RENAL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the most controversial issues regarding CMV infection in renal transplantation is whether the virus itself can cause allograft dysfunction. Renal function may deteriorate in patients with CMV infection but factors such as decreased renal perfusion, acute tubular necrosis, and transplant rejection may be more important than a direct viral effect on the kidney. There are reports describing the occurrence of a CMV-induced transplant glomerulopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. However, the frequency and clinical significance of this lesion are uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/2,29,74\">",
"     2,29,74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some insight into the possible presence of CMV nephropathy was provided by a study in thirteen biopsy samples that were available for analysis from patients suspected of CMV disease, in whom a buffy coat CMV-PCR had drawn within two to five days of a renal allograft biopsy for an elevated serum creatinine concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/75\">",
"     75",
"    </a>",
"    ]. All were evaluated for CMV pathologically by light microscopy, immunohistochemistry, in situ hybridization and tissue PCR. Qualitative and quantitative buffy coat CMV-PCR were positive in 10 (77 percent) patients, with tissue CMV-PCR being positive in five (50 percent) biopsies, including two with CMV inclusions and three with no inclusions. All five biopsies with acute rejection were associated with CMV viraemia and two of the five with allograft CMV inclusions. Thus, the use of sensitive techniques provides some evidence that CMV nephropathy may be much more common than previously reported.",
"   </p>",
"   <p>",
"    It has also been suggested that CMV infection is an independent risk factor for the development of rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/76\">",
"     76",
"    </a>",
"    ]. How this might occur is not known, but the net effect is that prevention of CMV infection using the modalities described above may diminish the incidence of rejection and lead to improved allograft survival.",
"   </p>",
"   <p>",
"    Infection with CMV has also been implicated by some studies in the development of coronary artery narrowing. A similar relationship has been reported between transplant renal artery stenosis and CMV infection. As an example, the correlation between CMV infection and renal artery stenosis was evaluated in a series of over 900 renal transplant recipients, 75 of whom were diagnosed with renal artery stenosis via angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/77\">",
"     77",
"    </a>",
"    ]. Patients with stenosis were paired with a control individual matched for age, sex, year of transplant, and number of grafts, but without renal artery disease. Definitive evidence of CMV infection was significantly associated with stenosis (36 versus 12 control patients, p&lt;0.001).",
"   </p>",
"   <p>",
"    In addition, CMV has been associated with thrombotic microangiopathy",
"    <span class=\"nowrap\">",
"     (HUS/TTP)",
"    </span>",
"    in solid organ and bone marrow transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]; the disorder may respond to immunoglobulin infusion [",
"    <a class=\"abstract\" href=\"UTD.htm?29/2/29738/abstract/80,81\">",
"     80,81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/10/19618?source=see_link\">",
"       \"Patient information: Cytomegalovirus (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H835998629\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cytomegalovirus (CMV) is a significant cause of morbidity and mortality in renal transplant recipients. CMV is present in more than two-thirds of donors and recipients prior to transplantation and can be transmitted from the donor by the transplanted kidney; the concurrent administration of immunosuppressive drugs to prevent rejection increases the risk of clinically relevant CMV disease. Both the recipient and the donor are routinely tested for anti-CMV antibodies prior to transplantation. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is an important distinction between CMV infection and CMV disease. Detection of virus defines CMV infection. CMV disease requires clinical signs and symptoms. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'CMV infection versus disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The incidence of CMV disease in the transplant recipient may be lowered by either prophylactic or preventive strategies. A prophylactic strategy involves the administration of antiviral agents to patients at increased risk of developing CMV infection. A preemptive strategy involves periodic monitoring for viremia to permit prompt treatment after the detection of early systemic infection. It is unclear which preventive strategy is more effective. The preemptive approach requires extreme vigilance. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Overview of prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If a prophylactic strategy is used, we suggest oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"       valganciclovir",
"      </a>",
"      for all patients except seronegative recipients of seronegative grafts. Most transplant centers administer such therapy for a total duration of 100 days, extending to 180 days in high risk (CMV",
"      <span class=\"nowrap\">",
"       D+/R-)",
"      </span>",
"      recipients. When a lymphocyte-depleting therapy is administered in a quadruple immunosuppressive regimen, prophylaxis should be extended to six to nine months for seronegative recipients of a kidney from a seropositive donor. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Approach using a prophylactic strategy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If a preemptive strategy is used, whole blood quantitative CMV-PCR should be monitored weekly for 12 to 16 weeks post-surgery. In patients in whom the CMV-PCR becomes positive, we use the following approach (see",
"      <a class=\"local\" href=\"#H27\">",
"       'Approach using preemptive strategy'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For all patients who are on an antimetabolite such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      and have a quantifiable CMV-viremia, we recommend that the antimetabolite be discontinued at least until viremia clears. The severity of the CMV and the risk for rejection dictate when to restart the antimetabolite. If the antimetabolite is reintroduced, serial CMV-PCR monitoring should be done.",
"     </li>",
"     <li>",
"      Patients who are asymptomatic or have only mild disease should be treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"       valganciclovir",
"      </a>",
"      for a minimum of 21 days or longer if necessary to clear viremia.",
"     </li>",
"     <li>",
"      Patients with invasive disease should be treated initially with intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Weekly quantitative PCRs should be obtained during treatment to determine an adequate response. If the quantitative PCR level does not decrease by 50 percent in two weeks, viral resistance or lack of recipient immunocompetence should be suspected. In this setting, the dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"       valganciclovir",
"      </a>",
"      can then be increased or the patient switched to intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      to overcome relative resistance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptomatic CMV infections typically occur one to four months after transplantation if prophylaxis is not used or one to four months after discontinuation of prophylaxis. Symptoms include fever, malaise, myalgias, and arthralgias, usually associated with leukopenia and mild atypical lymphocytosis. A mild elevation in serum aminotransferase concentrations also may be seen. A cardinal feature of CMV disease among patients is the development of marked leukopenia. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'CMV disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Therapy of CMV disease varies with the severity of the clinical manifestations and often involves a reduction in the overall level of immunotherapy with or without antiviral therapy. We usually do",
"      <strong>",
"       not",
"      </strong>",
"      discontinue",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      unless there is evidence of life-threatening infection. The discontinuation of the anti-metabolite,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil, is essential for virus eradication when",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"       valganciclovir",
"      </a>",
"      is used for treatment of CMV disease. (See",
"      <a class=\"local\" href=\"#H34\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/1\">",
"      Rubin RH. Infectious disease complications of renal transplantation. Kidney Int 1993; 44:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/2\">",
"      Farrugia E, Schwab TR. Management and prevention of cytomegalovirus infection after renal transplantation. Mayo Clin Proc 1992; 67:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/3\">",
"      Brennan DC. Cytomegalovirus in renal transplantation. J Am Soc Nephrol 2001; 12:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/4\">",
"      Smith SR, Butterly DW, Alexander BD, Greenberg A. Viral infections after renal transplantation. Am J Kidney Dis 2001; 37:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/5\">",
"      Kotton CN, Fishman JA. Viral infection in the renal transplant recipient. J Am Soc Nephrol 2005; 16:1758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/6\">",
"      B&uuml;chler M, Hurault de Ligny B, Madec C, et al. Induction therapy by anti-thymocyte globulin (rabbit) in renal transplantation: a 1-yr follow-up of safety and efficacy. Clin Transplant 2003; 17:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/7\">",
"      Burke GW 3rd, Kaufman DB, Millis JM, et al. Prospective, randomized trial of the effect of antibody induction in simultaneous pancreas and kidney transplantation: three-year results. Transplantation 2004; 77:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/8\">",
"      Schnitzler MA, Lowell JA, Hardinger KL, et al. The association of cytomegalovirus sero-pairing with outcomes and costs following cadaveric renal transplantation prior to the introduction of oral ganciclovir CMV prophylaxis. Am J Transplant 2003; 3:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/9\">",
"      Sagedal S, Hartmann A, Nordal KP, et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 2004; 66:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/10\">",
"      Preiksaitis JK, Brennan DC, Fishman J, Allen U. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 2005; 5:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/11\">",
"      Toyoda M, Carlos JB, Galera OA, et al. Correlation of cytomegalovirus DNA levels with response to antiviral therapy in cardiac and renal allograft recipients. Transplantation 1997; 63:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/12\">",
"      Roberts TC, Brennan DC, Buller RS, et al. Quantitative polymerase chain reaction to predict occurrence of symptomatic cytomegalovirus infection and assess response to ganciclovir therapy in renal transplant recipients. J Infect Dis 1998; 178:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/13\">",
"      Ferreira-Gonzalez A, Fisher RA, Weymouth LA, et al. Clinical utility of a quantitative polymerase chain reaction for diagnosis of cytomegalovirus disease in solid organ transplant patients. Transplantation 1999; 68:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/14\">",
"      Emery VC, Sabin CA, Cope AV, et al. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000; 355:2032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/15\">",
"      Reischig T, Jindra P, Hes O, et al. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant 2008; 8:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/16\">",
"      Khoury JA, Storch GA, Bohl DL, et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006; 6:2134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/17\">",
"      The American Society of Transplantation Infectious Disease Guidelines. Am J Transplant 2009; 9(Suppl 4):S8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/18\">",
"      Strippoli GF, Hodson EM, Jones C, Craig JC. Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients. Transplantation 2006; 81:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/19\">",
"      Kalil AC, Levitsky J, Lyden E, et al. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005; 143:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/20\">",
"      Hodson EM, Jones CA, Webster AC, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 2005; 365:2105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/21\">",
"      Jung C, Engelmann E, Borner K, Offermann G. Preemptive oral ganciclovir therapy versus prophylaxis to prevent symptomatic cytomegalovirus infection after kidney transplantation. Transplant Proc 2001; 33:3621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/22\">",
"      Pescovitz MD, Rabkin J, Merion RM, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000; 44:2811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/23\">",
"      Chamberlain CE, Penzak SR, Alfaro RM, et al. Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients. Am J Transplant 2008; 8:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/24\">",
"      Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/25\">",
"      Brennan DC, Garlock KA, Singer GG, et al. Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients. Transplantation 1997; 64:1843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/26\">",
"      Sun HY, Wagener MM, Singh N. Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: a systematic review. Am J Transplant 2008; 8:2111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/27\">",
"      Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010; 10:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/28\">",
"      Limaye AP, Corey L, Koelle DM, et al. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000; 356:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/29\">",
"      Snydman DR, Rubin RH, Werner BG. New developments in cytomegalovirus prevention and management. Am J Kidney Dis 1993; 21:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/30\">",
"      Snydman DR, Werner BG, Heinze-Lacey B, et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med 1987; 317:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/31\">",
"      Kuypers DR, Vanrenterghem YF. Prophylaxis of cytomegalovirus infection in renal transplantation: new data for an old problem. Nephrol Dial Transplant 1999; 14:2304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/32\">",
"      Lowance D, Neumayer HH, Legendre CM, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999; 340:1462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/33\">",
"      Reischig T, Hribova P, Jindra P, et al. Long-term outcomes of pre-emptive valganciclovir compared with valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation. J Am Soc Nephrol 2012; 23:1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/34\">",
"      Santos RD, Brennan DC. Randomized trial of pre-emptive or prophylactic valganciclovir therapy for prevention of cytomegalovirus infection in renal transplantation. J Am Soc Nephrol 2012; 23:1446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/35\">",
"      Kliem V, Fricke L, Wollbrink T, et al. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant 2008; 8:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/36\">",
"      Spinner ML, Saab G, Casabar E, et al. Impact of prophylactic versus preemptive valganciclovir on long-term renal allograft outcomes. Transplantation 2010; 90:412.",
"     </a>",
"    </li>",
"    <li>",
"     Valacyclovir: Package Insert.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/38\">",
"      Knight DA, Hejmanowski AQ, Dierksheide JE, et al. Inhibition of herpes simplex virus type 1 by the experimental immunosuppressive agent leflunomide. Transplantation 2001; 71:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/39\">",
"      Waldman WJ, Knight DA, Blinder L, et al. Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide. Intervirology 1999; 42:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/40\">",
"      Waldman WJ, Knight DA, Lurain NS, et al. Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide. Transplantation 1999; 68:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/41\">",
"      John GT, Manivannan J, Chandy S, et al. Leflunomide therapy for cytomegalovirus disease in renal allograft recepients. Transplantation 2004; 77:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/42\">",
"      Chong AS, Zeng H, Knight DA, et al. Concurrent antiviral and immunosuppressive activities of leflunomide in vivo. Am J Transplant 2006; 6:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/43\">",
"      Balfour HH Jr, Chace BA, Stapleton JT, et al. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 1989; 320:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/44\">",
"      Kletzmayr J, Kotzmann H, Popow-Kraupp T, et al. Impact of high-dose oral acyclovir prophylaxis on cytomegalovirus (CMV) disease in CMV high-risk renal transplant recipients. J Am Soc Nephrol 1996; 7:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/45\">",
"      Jassal SV, Roscoe JM, Zaltzman JS, et al. Clinical practice guidelines: prevention of cytomegalovirus disease after renal transplantation. J Am Soc Nephrol 1998; 9:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/46\">",
"      Kudlacz E, Perry B, Sawyer P, et al. The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models. Am J Transplant 2004; 4:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/47\">",
"      Winston DJ, Wirin D, Shaked A, Busuttil RW. Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet 1995; 346:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/48\">",
"      Schnitzler MA, Lowell JA, Hmiel SP, et al. Cytomegalovirus disease after prophylaxis with oral ganciclovir in renal transplantation: the importance of HLA-DR matching. J Am Soc Nephrol 2003; 14:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/49\">",
"      Goodrich JM, Bowden RA, Fisher L, et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993; 118:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/50\">",
"      Schnitzler MA, Woodward RS, Brennan DC, et al. The effects of cytomegalovirus serology on graft and recipient survival in cadaveric renal transplantation: implications for organ allocation. Am J Kidney Dis 1997; 29:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/51\">",
"      Schnitzler MA, Woodward RS, Brennan DC, et al. Impact of cytomegalovirus serology on graft survival in living related kidney transplantation: implications for donor selection. Surgery 1997; 121:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/52\">",
"      Hibberd PL, Tolkoff-Rubin NE, Cosimi AB, et al. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3. Transplantation 1992; 53:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/53\">",
"      Oh CS, Stratta RJ, Fox BC, et al. Increased infections associated with the use of OKT3 for treatment of steroid-resistant rejection in renal transplantation. Transplantation 1988; 45:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/54\">",
"      Doyle AM, Warburton KM, Goral S, et al. 24-week oral ganciclovir prophylaxis in kidney recipients is associated with reduced symptomatic cytomegalovirus disease compared to a 12-week course. Transplantation 2006; 81:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/55\">",
"      Akalin E, Bromberg JS, Sehgal V, et al. Decreased incidence of cytomegalovirus infection in thymoglobulin-treated transplant patients with 6 months of valganciclovir prophylaxis. Am J Transplant 2004; 4:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/56\">",
"      Helanter&auml; I, Lautenschlager I, Koskinen P. Prospective follow-up of primary CMV infections after 6 months of valganciclovir prophylaxis in renal transplant recipients. Nephrol Dial Transplant 2009; 24:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/57\">",
"      Geddes CC, Church CC, Collidge T, et al. Management of cytomegalovirus infection by weekly surveillance after renal transplant: analysis of cost, rejection and renal function. Nephrol Dial Transplant 2003; 18:1891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/58\">",
"      Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/59\">",
"      Moreso F, Ser&oacute;n D, Morales JM, et al. Incidence of leukopenia and cytomegalovirus disease in kidney transplants treated with mycophenolate mofetil combined with low cyclosporine and steroid doses. Clin Transplant 1998; 12:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/60\">",
"      Shelhamer JH, Gill VJ, Quinn TC, et al. The laboratory evaluation of opportunistic pulmonary infections. Ann Intern Med 1996; 124:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/61\">",
"      Stoffel M, Gianello P, Squifflet JP, et al. Effect of 9-(2-hydroxy-1-[hydroxymethyl] ethoxymethyl) guanine (DHPG) on cytomegalovirus pneumonitis after renal transplantation. Transplantation 1988; 46:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/62\">",
"      Harbison MA, De Girolami PC, Jenkins RL, Hammer SM. Ganciclovir therapy of severe cytomegalovirus infections in solid-organ transplant recipients. Transplantation 1988; 46:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/63\">",
"      Snydman DR. Ganciclovir therapy for cytomegalovirus disease associated with renal transplants. Rev Infect Dis 1988; 10 Suppl 3:S554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/64\">",
"      Waid TH, McKeown JW. Cytomegalovirus hyperimmune globulin for CMV disease refractory to ganciclovir in renal transplantation. Transplant Proc 1995; 27:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/65\">",
"      Brennan DC, Garlock KA, Lippmann BA, et al. Control of cytomegalovirus-associated morbidity in renal transplant patients using intensive monitoring and either preemptive or deferred therapy. J Am Soc Nephrol 1997; 8:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/66\">",
"      Martin DF, Sierra-Madero J, Walmsley S, et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med 2002; 346:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/67\">",
"      Babel N, Gabdrakhmanova L, Juergensen JS, et al. Treatment of cytomegalovirus disease with valganciclovir in renal transplant recipients: a single center experience. Transplantation 2004; 78:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/68\">",
"      Asberg A, Humar A, Rollag H, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007; 7:2106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/69\">",
"      Asberg A, Humar A, Jardine AG, et al. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant 2009; 9:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/70\">",
"      Avery RK. Valganciclovir versus IV ganciclovir for therapy of cytomegalovirus viremia: has victory been achieved? Am J Transplant 2007; 7:2062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/71\">",
"      Asberg A, Jardine AG, Bignamini AA, et al. Effects of the intensity of immunosuppressive therapy on outcome of treatment for CMV disease in organ transplant recipients. Am J Transplant 2010; 10:1881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/72\">",
"      Richardson WP, Colvin RB, Cheeseman SH, et al. Glomerulopathy associated with cytomegalovirus viremia in renal allografts. N Engl J Med 1981; 305:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/73\">",
"      Herrera GA, Alexander RW, Cooley CF, et al. Cytomegalovirus glomerulopathy: a controversial lesion. Kidney Int 1986; 29:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/74\">",
"      Birk PE, Chavers BM. Does cytomegalovirus cause glomerular injury in renal allograft recipients? J Am Soc Nephrol 1997; 8:1801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/75\">",
"      Liapis H, Storch GA, Hill DA, et al. CMV infection of the renal allograft is much more common than the pathology indicates: a retrospective analysis of qualitative and quantitative buffy coat CMV-PCR, renal biopsy pathology and tissue CMV-PCR. Nephrol Dial Transplant 2003; 18:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/76\">",
"      Pouteil-Noble C, Ecochard R, Landrivon G, et al. Cytomegalovirus infection--an etiological factor for rejection? A prospective study in 242 renal transplant patients. Transplantation 1993; 55:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/77\">",
"      Pouria S, State OI, Wong W, Hendry BM. CMV infection is associated with transplant renal artery stenosis. QJM 1998; 91:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/78\">",
"      Miller BW, Hmiel SP, Schnitzler MA, Brennan DC. Cyclosporine as cause of thrombotic microangiopathy after renal transplantation. Am J Kidney Dis 1997; 29:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/79\">",
"      Tschuchnigg M, Bradstock KF, Koutts J, et al. A case of thrombotic thrombocytopenic purpura following allogeneic bone marrow transplantation. Bone Marrow Transplant 1990; 5:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/80\">",
"      Jeejeebhoy FM, Zaltzman JS. Thrombotic microangiopathy in association with cytomegalovirus infection in a renal transplant patient: a new treatment strategy. Transplantation 1998; 65:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/2/29738/abstract/81\">",
"      Hochstetler LA, Flanigan MJ, Lager DJ. Transplant-associated thrombotic microangiopathy: the role of IgG administration as initial therapy. Am J Kidney Dis 1994; 23:444.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7300 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-210.101.131.232-2A3F076F4F-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_2_29738=[""].join("\n");
var outline_f29_2_29738=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H835998629\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CMV INFECTION VERSUS DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OVERVIEW OF PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      OVERVIEW OF AGENTS USED FOR PROPHYLACTIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Valganciclovir",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Drug resistant CMV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Other antiviral agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - CMV hyperimmune globulin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Valacyclovir",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Leflunomide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Acyclovir",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Maribavir",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      CMV STATUS AND PROPHYLACTIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      CMV-positive donor, CMV-negative recipient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      CMV-negative donor, CMV-positive recipient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      CMV-positive donor, CMV-positive recipient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      CMV-negative donor, CMV-negative recipient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Duration of prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      CMV status and HLA-DR matching",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Approach using a prophylactic strategy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      PREEMPTIVE STRATEGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Approach using preemptive strategy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      CMV DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      CMV-INDUCED RENAL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H835998629\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/52/4938?source=related_link\">",
"      Acute renal allograft rejection: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=related_link\">",
"      Acyclovir: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/2/34857?source=related_link\">",
"      Crystal-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/25/8597?source=related_link\">",
"      Diagnosis of cytomegalovirus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31718?source=related_link\">",
"      Evaluation for infection before solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=related_link\">",
"      Ganciclovir: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/56/32649?source=related_link\">",
"      Induction immunosuppressive therapy in renal transplantation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/59/10169?source=related_link\">",
"      Leflunomide in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37688?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of AIDS-related cytomegalovirus retinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/10/19618?source=related_link\">",
"      Patient information: Cytomegalovirus (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30003?source=related_link\">",
"      Valacyclovir: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=related_link\">",
"      Valganciclovir: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/12/44230?source=related_link\">",
"      Viral load testing for cytomegalovirus in solid organ transplant recipients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_2_29739="Echinococcal cyst features";
var content_f29_2_29739=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F81405&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F81405&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cyst characteristics of the four echinococcal species",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Species",
"      </td>",
"      <td class=\"subtitle1\">",
"       Larval form in humans",
"      </td>",
"      <td class=\"subtitle1\">",
"       Cyst components",
"      </td>",
"      <td class=\"subtitle1\">",
"       Cyst growth",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       E. granulosus",
"      </td>",
"      <td>",
"       Cystic, unilocular, expansile",
"      </td>",
"      <td>",
"       Metacestode has an internal germinative layer (endocyst) surrounded by a parasite-derived acellular laminated layer (exocyst), which in turn is surrounded by a host-derived adventitial layer (pericyst).",
"      </td>",
"      <td>",
"       Cells bud internally within the cystic cavity, then vacuolate and become \"brood\" capsules. Protoscolices develop within the brood capsules.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       E. multilocularis",
"      </td>",
"      <td>",
"       Multilocular, infiltrative",
"      </td>",
"      <td>",
"       Very thin laminated layer only and no pericyst, which enables tissue invasion.",
"      </td>",
"      <td>",
"       Germinative layer of the metacestode proliferates within cyst and exogenously to infiltrate host tissue. Cells from the germinative layer can detach and metastasize to other organs.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       E. vogeli and E. oligarthus",
"      </td>",
"      <td>",
"       Polycystic, expansile",
"      </td>",
"      <td>",
"       Large cysts with multiple vesicles are separated by septa lined by germinative epithelium. Externally, the cyst is surrounded by fibrous tissue.",
"      </td>",
"      <td>",
"       Brood capsules bud internally from the germinative epithelium. An expansile and infiltrative polycystic metacestode mass develops.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_2_29739=[""].join("\n");
var outline_f29_2_29739=null;
var title_f29_2_29740="ACC AHA AVR in aortic stenosis";
var content_f29_2_29740=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68344&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68344&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA Guideline Summary: Indications for aortic valve replacement (AVR) in aortic stenosis (AS)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or general agreement that AVR is indicated in patients with AS in the following settings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Symptomatic severe AS.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Severe AS in patients undergoing coronary artery bypass graft surgery or surgery on the aorta or other heart valves.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Severe AS with a left ventricular ejection fraction less than 50 percent.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIa - The weight of evidence or opinion is in favor of the usefulness of AVR in patients with AS in the following setting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Moderate AS in patients undergoing coronary artery bypass graft surgery or surgery on the aorta or other heart valves.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIb - The weight of evidence or opinion is less well established for the usefulness of AVR in patients with AS in the following settings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Severe AS in asymptomatic patients who have an abnormal response to exercise such as the development of symptoms or hypotension.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Severe AS in asymptomatic patients with a high likelihood of rapid progression (as determined by age, valve calcification, and coronary heart disease).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Severe AS in asymptomatic patients in whom surgery might be delayed at the time of symptom onset.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Mild AS in patients undergoing coronary artery bypass graft surgery in whom there is evidence, such as moderate to severe valve calcification, that progression may be rapid.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Extremely severe AS (aortic valve area less than 0.6 cm",
"        <sup>",
"         2",
"        </sup>",
"        , mean gradient greater than 60 mmHg, and aortic jet velocity greater than 5.0 m/sec) in asymptomatic patients in whom the expected operative mortality is 1 percent or less.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class III - There is evidence and/or general agreement that AVR for AS is not useful in in the following settings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; For the prevention of sudden cardiac death in asymptomatic patients who have none of the class IIa or IIb findings.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_2_29740=[""].join("\n");
var outline_f29_2_29740=null;
var title_f29_2_29741="LVEF predicts six-month mortality after STEMI";
var content_f29_2_29741=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75743&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75743&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 507px\">",
"   <div class=\"ttl\">",
"    LVEF predicts six-month mortality after STEMI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 487px; height: 310px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a study of 1194 patients with an acute ST segment elevation myocardial infarction (STEMI) treated with thrombolysis, the resting left ventricular (LV) ejection fraction (LVEF) measured by radionuclide angiography (RNA) was a powerful predictor of six-month mortality. The highest risk group was those with a LVEF &lt;30 percent.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Burns RJ, Gibbons RJ,&nbsp;Yi Q, et al. J Am Coll Cardiol 2002; 39:30.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_2_29741=[""].join("\n");
var outline_f29_2_29741=null;
var title_f29_2_29742="MICs for other yeasts";
var content_f29_2_29742=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F71985&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F71985&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    In vitro susceptibility of non-candidal yeasts to systemically active antifungal agents determined by CLSI M27-A3 broth microdilution methods",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Organism",
"      </td>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Antifungal agent",
"      </td>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       No. tested",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"3\">",
"       MIC, &micro;g/ml",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Range",
"      </td>",
"      <td class=\"subtitle2\">",
"       50 percent*",
"      </td>",
"      <td class=\"subtitle2\">",
"       90 percent*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"6\">",
"       <em>",
"        Cryptococcus neoformans",
"       </em>",
"      </td>",
"      <td>",
"       Amphotericin B&bull;",
"      </td>",
"      <td>",
"       661",
"      </td>",
"      <td>",
"       0.03-32",
"      </td>",
"      <td>",
"       0.5",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Flucytosine",
"      </td>",
"      <td>",
"       1614",
"      </td>",
"      <td>",
"       0.06-128",
"      </td>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       8",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fluconazole",
"      </td>",
"      <td>",
"       1615",
"      </td>",
"      <td>",
"       0.007-64",
"      </td>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       8",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Itraconazole",
"      </td>",
"      <td>",
"       1615",
"      </td>",
"      <td>",
"       0.007-64",
"      </td>",
"      <td>",
"       0.25",
"      </td>",
"      <td>",
"       4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Posaconazole",
"      </td>",
"      <td>",
"       1437",
"      </td>",
"      <td>",
"       0.007-2",
"      </td>",
"      <td>",
"       0.12",
"      </td>",
"      <td>",
"       0.25",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Voriconazole",
"      </td>",
"      <td>",
"       1608",
"      </td>",
"      <td>",
"       0.007-2",
"      </td>",
"      <td>",
"       0.06",
"      </td>",
"      <td>",
"       0.12",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"5\">",
"       <em>",
"        Trichosporon asahii",
"       </em>",
"      </td>",
"      <td>",
"       Amphotericin B&bull;",
"      </td>",
"      <td>",
"       43",
"      </td>",
"      <td>",
"       1-8",
"      </td>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fluconazole",
"      </td>",
"      <td>",
"       43",
"      </td>",
"      <td>",
"       0.25-16",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       8",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Itraconazole",
"      </td>",
"      <td>",
"       43",
"      </td>",
"      <td>",
"       0.06-4",
"      </td>",
"      <td>",
"       0.5",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Posaconazole",
"      </td>",
"      <td>",
"       24",
"      </td>",
"      <td>",
"       0.06-&gt;16",
"      </td>",
"      <td>",
"       0.12",
"      </td>",
"      <td>",
"       N/A",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Voriconazole",
"      </td>",
"      <td>",
"       10",
"      </td>",
"      <td>",
"       0.25-2",
"      </td>",
"      <td>",
"       0.5",
"      </td>",
"      <td>",
"       2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"5\">",
"       Other",
"       <em>",
"        Trichosporon",
"       </em>",
"       spp",
"      </td>",
"      <td>",
"       Amphotericin B&bull;",
"      </td>",
"      <td>",
"       15",
"      </td>",
"      <td>",
"       0.06-1",
"      </td>",
"      <td>",
"       0.25",
"      </td>",
"      <td>",
"       N/A",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fluconazole",
"      </td>",
"      <td>",
"       15",
"      </td>",
"      <td>",
"       0.5-4",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       N/A",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Itraconazole",
"      </td>",
"      <td>",
"       15",
"      </td>",
"      <td>",
"       0.03-0.5",
"      </td>",
"      <td>",
"       0.12",
"      </td>",
"      <td>",
"       N/A",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Posaconazole",
"      </td>",
"      <td>",
"       15",
"      </td>",
"      <td>",
"       0.03-0.5",
"      </td>",
"      <td>",
"       0.12",
"      </td>",
"      <td>",
"       N/A",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Voriconazole",
"      </td>",
"      <td>",
"       15",
"      </td>",
"      <td>",
"       0.03-0.25",
"      </td>",
"      <td>",
"       0.06",
"      </td>",
"      <td>",
"       N/A",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"6\">",
"       <em>",
"        Rhodotorula",
"       </em>",
"       spp.",
"      </td>",
"      <td>",
"       Amphotericin B&bull;",
"      </td>",
"      <td>",
"       64",
"      </td>",
"      <td>",
"       0.5-2",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Flucytosine",
"      </td>",
"      <td>",
"       64",
"      </td>",
"      <td>",
"       0.06-0.5",
"      </td>",
"      <td>",
"       0.12",
"      </td>",
"      <td>",
"       0.25",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fluconazole",
"      </td>",
"      <td>",
"       64",
"      </td>",
"      <td>",
"       32-&gt;64",
"      </td>",
"      <td>",
"       &gt;64",
"      </td>",
"      <td>",
"       &gt;64",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Itraconazole",
"      </td>",
"      <td>",
"       64",
"      </td>",
"      <td>",
"       0.5-16",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       16",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Posaconazole",
"      </td>",
"      <td>",
"       64",
"      </td>",
"      <td>",
"       0.5-16",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Voriconazole",
"      </td>",
"      <td>",
"       64",
"      </td>",
"      <td>",
"       0.25-16",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"6\">",
"       <em>",
"        Saccharomyces cerevisiae",
"       </em>",
"      </td>",
"      <td>",
"       Amphotericin B&bull;",
"      </td>",
"      <td>",
"       74",
"      </td>",
"      <td>",
"       0.12-2",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Flucytosine",
"      </td>",
"      <td>",
"       74",
"      </td>",
"      <td>",
"       0.25-32",
"      </td>",
"      <td>",
"       0.25",
"      </td>",
"      <td>",
"       0.25",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fluconazole",
"      </td>",
"      <td>",
"       74",
"      </td>",
"      <td>",
"       0.12-16",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       8",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Itraconazole",
"      </td>",
"      <td>",
"       74",
"      </td>",
"      <td>",
"       0.015-1",
"      </td>",
"      <td>",
"       0.5",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Posaconazole",
"      </td>",
"      <td>",
"       22",
"      </td>",
"      <td>",
"       0.12-1",
"      </td>",
"      <td>",
"       0.5",
"      </td>",
"      <td>",
"       0.5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Voriconazole",
"      </td>",
"      <td>",
"       17",
"      </td>",
"      <td>",
"       0.007-0.5",
"      </td>",
"      <td>",
"       0.06",
"      </td>",
"      <td>",
"       0.12",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"6\">",
"       <em>",
"        Blastoschizomyces capitatus",
"       </em>",
"      </td>",
"      <td>",
"       Amphotericin B&bull;",
"      </td>",
"      <td>",
"       23",
"      </td>",
"      <td>",
"       0.06-0.25",
"      </td>",
"      <td>",
"       0.12",
"      </td>",
"      <td>",
"       0.12",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Flucytosine",
"      </td>",
"      <td>",
"       23",
"      </td>",
"      <td>",
"       0.12-16",
"      </td>",
"      <td>",
"       0.12",
"      </td>",
"      <td>",
"       4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fluconazole",
"      </td>",
"      <td>",
"       23",
"      </td>",
"      <td>",
"       1-32",
"      </td>",
"      <td>",
"       8",
"      </td>",
"      <td>",
"       8",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Itraconazole",
"      </td>",
"      <td>",
"       23",
"      </td>",
"      <td>",
"       0.3-0.5",
"      </td>",
"      <td>",
"       0.12",
"      </td>",
"      <td>",
"       0.25",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Posaconazole",
"      </td>",
"      <td>",
"       25",
"      </td>",
"      <td>",
"       N/A",
"      </td>",
"      <td>",
"       0.12",
"      </td>",
"      <td>",
"       0.25",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Voriconazole",
"      </td>",
"      <td>",
"       23",
"      </td>",
"      <td>",
"       0.03-0.5",
"      </td>",
"      <td>",
"       0.25",
"      </td>",
"      <td>",
"       0.25",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CLSI: Clinical and Laboratory Standards Institute.",
"     <br>",
"      * 50 percent and 90 percent; MIC encompassing 50 percent and 90 percent of isolates tested, respectively.",
"      <br>",
"       &bull; Amphotericin B MICs determined by Etest.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     1. Pfaller, MA. Antifungal susceptibility testing methods. Curr Drug Targets 2005; 6:929.",
"     <br>",
"      2. Pfaller, MA, Boyken, L, Hollis, RJ, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008; 46:150.",
"      <br>",
"       3. Pfaller, MA, Messer, SA, Boyken, L, et al. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J Clin Microbiol 2005; 43:2163.",
"       <br>",
"        4. Arikan, S, Hascelik, G. Comparison of NCCLS microdilution method and Etest in antifungal susceptibility testing of clinical Trichosporon asahii isolates. Diagn Microbiol Infect Dis 2002; 43:107.",
"        <br>",
"         5. Paphitou, NI, Ostrosky-Zeichner, L, Paetznick, VL, et al. In vitro antifungal susceptibilities of Trichosporon species. Antimicrob Agents Chemother 2002; 46:1144.",
"         <br>",
"          6. Serena, C, Marine, M, Pastor, FJ, et al. In vitro antifungal susceptibilities of uncommon basidiomycetous yeasts. Antimicrob Agents Chemother 2004; 48:2724.",
"          <br>",
"           7. Asada, N, Uryu, H, Koseki, M, et al. Successful treatment of breakthrough Trichosporon asahii fungemia with voriconazole in a patient with acute myeloid leukemia. Clin Infect Dis 2006; 43:e39.",
"           <br>",
"            8. Diekema, DJ, Petroelje, B, Hollis, RJ, Pfaller, MA, Activities of available and investigational antifungal agents against Rhodotorula species. J Clin Microbiol 2005; 43:476.",
"            <br>",
"             9. Zerva, L, Hollis, RJ, Pfaller, MA. In vitro susceptibility testing and DNA typing of Saccharomyces cerevisiae clinical isolates. J Clin Microbiol 1996; 34:3031.",
"             <br>",
"              10. Pfaller, MA, Messer, S, Jones, RN. Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae. Antimicrob Agents Chemother 1997; 41:233.",
"              <br>",
"               11. Swinne, D, Watelle, M, Nolard, N. In vitro activities of voriconazole, fluconazole, itraconazole, and amphotericin B against non Candida albicans yeast isolates. Rev Iberoam Micol 2005; 22:24.",
"               <br>",
"                12. Pfaller, MA, Diekema, DJ, Merz, WG. Infections due to emerging non-Candida, non-Cryptococcus opportunistic yeast pathogens. Curr Fungal Infect Reports 2007; 1:53.",
"               </br>",
"              </br>",
"             </br>",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_2_29742=[""].join("\n");
var outline_f29_2_29742=null;
var title_f29_2_29743="Decision tree axial SpA primary";
var content_f29_2_29743=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F80964&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F80964&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Approach to the diagnosis of axial spondyloarthropathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 431px; height: 535px; background-image: url(data:image/gif;base64,R0lGODlhrwEXAsQAAP///4CAgH9/fz8/P7+/vwAAAO/v7y8vL8/Pz9/f35+fn19fX09PTx8fH6+vr29vb4+Pjw8PD8DAwEBAQODg4KCgoGBgYNDQ0LCwsDAwMCAgIHBwcFBQUJCQkBAQEAAAACH5BAAAAAAALAAAAACvARcCAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJgxQBjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOOFIo0Eg0Cq6ytrq+wsbKztLW2t7i5uru8vb6/wMECDRKnMxIDxsp0A8XLL8jP0m7N0y3R1tln1dop2N3gYNzhJd/k51nj6ADm6+5S6ujtIgkQAgoGAA8INQj5KAgezNj3IiANfywUCEzQ6gvBFAoUkDDALyIAhDMMLBjAzwXGEslKOFjVEWACEQYY/5QkEe/cPAcHFBAQwADAAAI1Hp4gEDLGzRc8aehEYeBAPgIHCCg98rNGUxSrSBiMSrCAjAUQAPxrMXSEVRIPGBBQ8NREhJ4IerJ05m5ehJMobUJgwOCkUotkF5xMoEDAgKwAFJxEwOAviaAG/ArIJ0AEvsBwRQygyeBo4QX//C5AgFjASgEOBggMPGCy45OgBywwcU9E0BMKHNDNrProWImhGTi4WHg3gNSrEzRY0HgEX78SfzNMkGBj8smzARC4zHjBRn58fzcWTKDAPQhwFaxsPkCicOKHqSfOt16wvtK+v3qdGFh2ZccLGkRegBMk23XtIGWCaAZAsJoAETwQUf9lBDQgXQMEGKCfTQQI5w9griWDngCr3WRABBLJJ1ljc110koH6rIaAA0EdsBoJBezGQFYRAsCARD8VINGNJRwwAgFn6QWSQCU+0FhovyUYm1F8JXBAAgbkuCM+B0DQn2sN+JMlAAVMJlyEPJpWIgInHlgZAhFIl0xUNyVQAAEBNfbhVgBAmBKVVkpVJgAQJGPYT7tJeJKINukWmWh81mSjAw9gSMBoa73DjlpqDohTUFHZ2B9Hr/10EwSQHpZMmiKkuUpfKlHalFUFMnDAqFvxZJ0JXwXF0ACqUMilCJmO0JMB+UDgI0v9WRUBK1ZlqtsIfa5i2ldsXpkhr419lZb/azWtqtVcr2onmVJrNpYjPQ4q8KII10qXrbTbuhrSAi5+K90DA0SAE6GtNmCUrrt+eNGwkg34nzyUJkAqsZVm2tRNneJ0U6+i7iqCVdNVVl5xvhYLQJUGBCVidw0kB2OGwu0WrcQQ23QCodq+qRROCl/J4cuDUsvvjyFFVWtIQWnLMabFMRyurvLdeMBKr/XM7s8hOfDmtzDxMy4K6GmrwFkDFHCowJLOY5pWOF46NJ8CSViprgw7eFHEy04nQrzCsgtoTQXkQ5ZNyXE2gIQiTyxCowICUPW9NrM0AkKBZwyAbHKh6+1vL3LWwD/8QCuubzi/XfkIETCW1dxc2j20/79AE/1Pg5QC0Plvn7NbN2kAfDnhw2UnJTGzI4SJE+PL6gNYc1y/M49Gr/4p9uPEH7Bbw7oK8Kqi06ZVWkc8ujlg8RU1oFoy0g/AIvcgwjiAi/nAOwAD4hL++Aj8iQDT+CvZhL1Wrh5QU6bEm6bAq8qjfGS3PzrLAYojH5iQT37TC4z2NvIb7fWvdD9x3mgagLkRGBAzN3PMAvfWv/1FKULPsx2h8jO+oGHPX+gaVmv807XU5YFQM0iAC0HCLiG8hgnCsUJZTlCUE7SEHPN4YQ4ecC4U7NCGMzTCAvoGjxpOpH/Ba0sSJUVFpgzMJVOsohaF8MNwBHGLYAxCF8Hxxf8wmpEHY+xGGc/IxhukURupEIYc50jHOt6iNHbMox73GAxiSIoRpAikIAdJyExMYAKFTKQiF0kKU7TxkSNoBCQnSUkWSLKSmMykBgrAyQJ4IJOghKQFOlkADoTylGesACk7gMpWbpECpLyAK2dJxQxwUgO0zKU7NsBJC+jyl+TAACcrAMxidoOTjjSmMp8xgQws85nLCMAGoElNRVwAA9XMpja3yc1uevOb4PylBBhJznIK8orhDEcAJsPHdrozGAMIQDrdEQCMUVEA8pwnOuq5RXzqc5/2lJQ//0kOfmpxoAQFh0GriNCEamOh98ynQx8a0AQoJTIlQE4WnbBRsMT/DygsaOhEpwFRNR0xMDUxAAx3cNIXrDQFLWXBRkU60meU9HGxoctJ8Gg98qgkdn0pD2HqIh0HXCc0LyKLac7TmIr1RzwQGMkIFgMjsoyGXt5DyUYe8MHFYQioyPkbfHgFVsNkVKI1lcZNFcZVFFknQlZJAD8Q4KAGRUgVBTrQAOQaPh7V6EZFsZJwmDM7VSDlUgCbGE5mtDitTCgmi0sLARwQAaRlSUL8CNSEKGanCZGApmk1xlqDdrxMfcVcWTvbT0rnv9j5JVc/sQevWocfwTFxZ/OqF5wS+5ctRcxbj9Ltrpj3WbSGVhmjlRdrrULEmjFvudQqmbciWJyTlQpN/7TKUNQodEOb6ItOZ1vFdsdF3Kka97inSK6uoJtV6z13bJYLXNV2g4BhceRmwwioxBolgNpF6C1akSEBhEWn1xytv1oRoWrZBVr0IqKkCmhAyNYL34to7wEUC8lqK+wt86Fvcd1y3gDlRY/XlaBL5CvK+Wz3vr3+BF6xEqCcQki48vLqvA5+sH6/YK4gdJcGDc5xIW76Bc/+4MczCLKQB0HkdSh5yYFoMjqeDOU/SPkcVK5yH65MjixreQ9cXsJSWjBmLHj5y3lY5zt1gUdbtHnNu4gnmg0xTnNy4pCGRKSdP4HOOc/ykpbEsZ8HvQJAF1rQhE60CQytAkYr+tElcP80CiQNaUhTetGIrnSiLx3pTGt60JwmQag/PedRi8DUpNYyqlGdaiiv2tOtVkGd90zrWtu6E4h0AatjHWk93/rXwA52I/qMaV7PYNcjRbaxAaBshzab188maLRbPW19VpvU105ntjW9bXB229KwPu63Hz3ubpZ70+EO7bkJvW5tttvP765mvNE87znMWtiCxDO+B0nsTNZbDgHw9b4HTvCApxuS/45DwrOxcLUe/MEPR3jE2dhwN1Tc4bm8uBo22clPupLjnPR4KzWehlF20pSuNDknUT7yiQ9ClZ1kpSthzkmZt7wbsOykLF2Zc07u/ObdsGUBcElLoRPdlSRPAy//C+BLWi696Uh3+SCEWQBi0pLqVo96OJCpS67/WeqDaOYvxU7LpKdBmr9Ee9nBLohr/tLta1+23E/N9rlX2ex236bGC853fI8AkH0PPK2Tefa618A7cE684u0onzgu/vGQ54Uf16Dxl2ay8R1t4xvDUHlaYt6VmwdD52f5+VaG/gujd2XpUXl6L6S+las/Zeu78HpUxj6Us+dC7eV6OIyyQEGHMwFzeMzEEhjkMBdZiO+Nf5/simAeCOgIRVhAGPBKRQDg+cLxYWr8fCRj+ilIyUdt0m8x7B7ABrN+CtwGVEKhacdASFkM5P9bX1XKIi2VrfMnNSAAI3lA45c7DnA1/+p3ZJmHAv83Mh61K1MBf+nCQpRneDQAQxwiOFlBGFn1G+cTP3vlGgIgIkWBHodhVPe1OBsIVDPBG4ahEV8DHJLhJZ8VGqMhAMuRGJNRHdcROxvxU0gRVr9RKRc1HKDRH5P1NtZ3ezZRga+RF75HAEWEEgiGMMYRVHnTG7xSg1vFGLVRVBsBM4ZFAjl1H3chEUwoHQNUHmKVgTqCKJCxK9mBRwiAMVTVPhCoBrUnAqrgI04CJZ9SEysyEZQiH1EShwHlFxSRJrJhAMLRMRGAPhZSIBuDE0bCJVMiOPxBJzFiI1nRJTS4IWZyiLEzV3WlH5g1XOESWJOlYb4BGvvnNf88YVHJoAAMojYj8ADSggDOUQIfglENoiVk8iRdxYlOghtxYoIaKFflkhQYhSglgiAKIosdM4pQsiWaNSiLRVsZZokghFiuESqSUX6cJ4EzsFLdwQ/Nohj7Ix4lkIIKaFvrUzg3wQDEMQzgIgKgcjiqwCHJYDnv6DeVIh8HYyqkFRgbkY3eko3WpR855IGtmDoMwx/JIBaSsRJqURrLJzgB9RqrcI7PkkIkcCyrkCwEdDZSKJIiIJE2oTc2E1z2IjFKY4o4tRpLZH91WHhM8FLQwh8XNS+58iMBBZClIWF9EzN/8TIdkzMYc1hKsTneIn+4JR9Q+Tg30VwweZAJkz7/9rgAjeKTDWkpeOMnmyItajEddMg+Txheq6CTFeKSauEyS2FaJKk4uxIz36KRoHE0RDMt5DU2qoNdNBkpEXiTKFArk4MuCIEkxvGEFFiIcmIqiqKISaM2/lBZjsOPUaiAW1k0y3M/jWkTu+FeIYGXCHk5KCFhW2ERJzYCrvggyXCPZkMCQkICCfAAUDQrJmBgkkM5ErOLAWZW/ACXiaM4jJMprllXoRmH/rVf2JgwkJJfiRlFNrkEODkC+zM+DvA+eEkC+0IaXTKUhehAvkGb4wOLU/U8/1JCreUkJTgx44NB8tE9vwmeFiYaFCNjflM67yMCWskSy4eEC/N98AJF/9S5Yx0jHV1SGn0DJOgZGPyzGwVUPFBSP5zpjwjKEvODPwG6PPapYq5yL+3pfTWWDOqJHSb2G8WXe1twhzXQFzJAf0FgeUZgZE64Mqp5gCmwnTGQgEAQU0XQYyiRWL4CjqInjjIAozIAWTDgokBgpEPgoxZ2kUgoAzBRgCqgoz/Ao0TgWUVRQUHKBioKSlGKSSiqBV96eTUKekKKekQaA0w6SWFaSWOaBWWKSW9KSXGKBXNaSXU6SXd6BZUXeYAaqLbQePkoqIZ6qJNnh2sKA4LnCfrWqJzwd5C6CY86qZhAeGiAd2egqYnAqYbgqWQAqp+6qOsgquZHqvSEqudgqv9fAHKelHGqWlCxSgcqV0qweqvaQHMFYHNaF3fa0HMF8HO9+nXgYHS6xKpRNqt08HTHqqzdgKxegHXNiqvHVACYCnTECg5kR63D+lDTNK2+2g1wx63Ymnd+6qwPha7mSgPQamXquq4y0K5+IK92R698YK89cG+Bl6bR9K4k5a9SoGaH+gpyVqoAa1MHCwVh1gRnhlwJ67B6sLBM0LCi9bAVG7HwFwUUm14Wy7EYmwUbqwj4GrEdywQSuwQh26klq7Ifa2Yr66UvewgjuwNENnyucbMlwHsm0DFKsRUj8Rg8u5QnkLIQR651QGS98hUwxACrs475CCHzElyulZYuRLT/Mhuzo9qyGYUxSpuzw1F8dpmasFl8v4G10ZmteIC07PSB/sgsD8A465gUocGLtPggUGG2mYq3TKa3RIC0atm12skPq1MaydAgzoIxRSGWZFu2qWq0dIC0XNu2sXOg4fNbKvWjCVq3Z9W44XoHkDsft0M27gM902JhCcZEaHi3nIu2nrtjScueCJqdqlNgWIOXCEK4/NAgKmC1Wdu5dnCySsC7Q8a3yaq1ViC8hDCzaUu8QgC8SYC8e+u4c+C8SAC9gqC8nsu8QUC9R2C9xeu7R5uxUOC9gIC9v6u9QMC9RkC+7iq9ALe2A8sKBbtP6Ltl9esD+ioKlUoK/Aqx4Puv/2l3v2AmwHJKwAPsvv0awAjsvwtcSeZLBQ98vg3sseDKugxnwBErcMHWv0eLwVYQwXWQv7+Wa8nrweUgbPsLbBz8SCD8AxE8bJZqZyQ8wctbBi3MAzcMcCbcvDvMbD3sAzmscD/swj0cxDlgxG+AxEdswq4qcnzQxDScvWNQqyzHB1QcxRIsBrrKq3uwxVjcwWMArMK6B2L8xY+7w8YKCGn8v/O6w8wKCG/MxvZLBtIKCHUsx/faw14HCHtsweXbw9sKCIHsx+0bqt8aZYeMxwdMBuMKCI1MyG0MryI7xEBMyZK8vZaMw5l8yZU8vJx8tZ5cAxUQw4yUdexAyoq0wv9ptsk6MG0TMI/xC2cLMAGiBr+x3E7zW7QlbAMT4ER2QAC0HEniKwfs2wZKjAOu7Mt1AMyiNsxxUMwwG8o00Mt9wMzCzAfQHJi7XAPUzAfWfGrODAfZrKjSPAPdvAffzGzh/AbjfLbXy3bnrAfprL5o0M55W84yEM8FSg8BiAIKMbWZUg8QQKVC8M+3GczgfJtwYbMqYNAo8LMEHQTAxxqsTMT4HAPxvDHJAbUuUBRHkRRLUTIRFtE7cEMoeRgIrc60okLD7NHrZ4v00r3F4dKbO8kXDQMZrbuyqBUbURyhkYFTlRzddY/uOIU+iIGriIUEooEYNFld2EACgBMydND/zUwrrREVNkhVn1V8zXFb60iCHZEb2CETjYGBWcGCxRGGOwWDLFrTLLvN01xDWvlYkugZk5Md2hlAqnEiM2hPvYhZexiMXgJZDlCMSOIXyMiga2kT4DXP+lU3PhIVntgjIqEa7KK7n7U32JWIiwgkjnhZWWE7k0ggbnWJb8MaGozKoMDBx3wDybyzEXCB+bgRBpMnIDECwMInPiIhD0Cbfo2UHFktHsk5yPI4Bskrl53SN5UsfdEYAXnb5MJVO2s7n0Va8rgKEPIaRG1hVEth75g6ApDaqo1rEdfaNvDaXqmUcOJaAPSX7QgnC1BBdjkzO4lbXvEyMDOS3RXV66jc/4+dYDoDuu5tVRhVFMVHlFbSs2HrGiC93hv23RRdw4xa0cgMz070Ex/SEWRyEpdrOOjy0VKhubjZILr5FbypiL5p3GYIm03o387nnG1Duiqzjjlo4EPbmTSBEuRptxeR4Y7z4Jc548Ul4S9g3jWA3jSUQiWknkjKPv2BnR2xg/GjoCPGoNZ5Oy0WoQdgPypuE2jYQ/1d1WL7IWWNuyVQlrL5m1izng105frAPzv+G+ZZX+j54CMqHWdpzxBc3hTu2hauA1OdozZaAyuE0mJeA4HeouvsRsun51OAbEbOrn+uA0Qk6ESwPzvh4jdQ6YpOBPsZ4VI84Tf9AhmNB46Nzf99ngKQnupHPunorOl64OgBy+ej7gKlfgenvgeyHgWrXustcOu/DOt5sOsKS+twbc7KTAe5HuusfgK9fuz5DMu37E6zXMvT/k65fMYxEOnHxnajDGwpXGumLMLjHQqqbMPGHr2h2uwKLOrQPqSfHGjbzu7xWsT0/sXcXu/oHu+HNu++nqL3rsjF9u5qyu+Nlu7vvO8GP2kI/71jkO/4HvBFbu8Lz/D+TvCuJ/Hd2gIQ7+4PHwDkvm/nbkzPru5jIAEoL3gzPE8ln/BU1PGLPPH//qwav8oXb/LvAPMke/MuLyk6b/Me3/M5X/NErmtE3+8vf/RZLPPJK97lXmtC+vP/Rc/xSu8NT4/C4Sb1oc70cmdqWr/0Rl+vWV/12h70xub1ZD+9DQ9tYy9ta59qUIwCcQ9Oc68CdZ9qV4wCeQ9Oe68CfZ9qXowCgQ9Og68ChZ9qZYwCiQ9Oi68Cjd9qa4wCkQ9Ok68ClZ9qcYwCmQ9Om68CnZ9qd4wCoQ9Oo68Cpd9qfTyY1vpPqb8Crd9qg4wCsQ9Os68CtZ9qaldoiaxtu29JvR9rj4wCwQ9Ow68CxV/xyJ/8yr/8zN/8xhbyVx/9kzrypyz90k/9RSCw17793G9H2b7tttz94o8L318F9FxTVnv+3UDs8broOZb+7u9k6Kv+EwX/k8T+2x7/6GX//5AEAkIAkKV5oqm6smYgtLE807V947m+n+L+8oLCIXHmKyIBwCSz6XxCU8fcMmq9DqdYW3Xr/YKf2ls3bD6Pz6qyuu1+m9I1NryelNfp9j1fPNLpESSQJAyyGCwMIMw8LEYhGCAhPAThwen1ZWpW/lHBpBQckAh8rixAAESuDBCQsN68xpCSNCIRDHBuBhIQqE6C1cZAbhKrWMroFQgoAMwaCAwIqBI2LAjwjo4mXFfDDEAwMBhCL0TyKjBTW6cmfjoMDDgAwAskKAwKvC+QPA88pJf4hI2Ag0Stbo0aUA4AAgbR2CmcFqdTn2SkGshD2CQWCo4sgpnwWGzPsRjJDP+ImrVOwL4SKCEQmAWgAIkC0RAcgDnvgQEI+x7AeNcswj+XOVsdaAUUQQMD9gAsWNDrVQFmDJgBBaAAlwmazWBAS8AUAMKsQiNAQsUAlQNHPSjySUZC6C1oqCB+EniwoCJ9JLY+TNANQIJE6V4RCNeKbLh6WvENYIBA8Lpmhka+KdlC7rJZEUp8DtlKplev8xYjxhWBlACaMkUzbEAqUYIIOr+6auXVszmuJXaD/UQT4WpSNBs86AWVgYPLb3WVOuHVJ9kGvRoMSgogK/BmA8RGsMpM+dWXrawbuHpacCHsCQ4kQNmKFTiGDszXXIzZjWYWclHOYpppueE2U00lxJL/2ky8YPMaggclxcsi2xyAi0xUjQKDVxr9lmGBw+FSAIOt9MRABJEosEAE+k0EnQo2VdhbbkzNFqKHpHm4zQCyncYQV4mdBkFeEEBASY+sKHCAAo6ItF9mcHERXVej8MgcYye8UiRhpSEoT48IfUPCIg66Io8BaIlZSCquGYkhbtoJZcKJUAV3IJh3LbJYhLRIOQqUdshFQFNkccUKARESsEh3OH4lmDyzKEjoaTKx9skriD3AY5NOttHfCnKlspqP8LhFoAEN+MPlXBV+iUt6BxzAQIEmOMAqTgMcUE+FShJWIQJuzoJTOL6RAAGqDNRpIEKvxgoAA7BSIkCFA0gU/9CfefR5IAAQ4KIRK2c6ssicKwmX4aEkrBMPCXMKgAorOLmCQJzavRuJUOpqw2mn186Aib40qJIiGJ6aASpUUhXayq25bntsst0tUCGyANSKS60HLPSKtAxvh7F1p1V8wCIV5/cvGvwik63JNCiAKrUDo+yGv5qogt3KxBCcwsw3Z5IzGDv3gSqvPGvi8wlAE22H0V4gnbTTWyxdAiYOkFIqCpNd8UsmIBlpTMxtNP202FBETYIeDzBAwFYsnhABsS8KweEXm8L2wDvLeO1iCwmMWG0K6Nig5g6IKKIC4MNc7TcKIIlJipcqYH21Q0V/7Z/KA6LoQDgBL2CzCYSXQ/+AMszUU09hA6SjgObipAJNUbc8E5BE0EjWDAnYNBSYAtCkk7uXuUNAGQy+3x7Ox/Mos0LZV+wMDWvOGaNyD58AvsMpqUS/ndW0bN8Ri7U6UJD0bqfQAOIskInF8npE1hyClNTnrAMP3FXCWhRPJqKi0QjWi3r+9OQnMNiKpLRzrhLUR14Gwg1aelIdSJjvPfFhhWDSYh4JGoCC8JHPdu4GkOdoonnRCd5fEJCYiOBGL4xBIT341orTpW510IMhYQbjkkTwZBb3aIZfHsMQh6ACMJZiEUcyt7m/dA56osMbOczhkIzxT4X2iMkP8UW77hmhcp9SWYkacIBIxIImZ2L/iChMsADmGEJAYvqRrBQ0J4QgRGAL+GCSlqStWSBHORohBbdIEQ0tPWhb0XAeIDnSNSlosWDSC8gg63E9AERALIOgToA8hDXqRKUXePQfMwBIHROgpzxHMQGv2gIp3YhnPeZzIHk6ySJp2dEV8JOV/Oh3ggTozyy4uOQ+MmmA7hAgAsjCIH1kpcAcrG+R6PLGYmiiALcNoADQS9GKFrhAjYDpIDaSlEbQEhoTECBTGvJQiU60x9kwaBvR0ZhUeKFOAslgeVagw6/80Yx29mIsAisRqyqJG35aKC8C+FXxWmUCgl7JI/AKCDMXeEpAEgIammJbig6ApjCGiowo8Epx/1qTCnD0s1y40UgfnVdHLGbxByqr3/9aoTn50aJ+ZOHTTFRhGna5S5sAgFO3uCIAHh3UXqqJxDr0xAuuiExQvhCUmOaRkUHZB6lsU14iwyBCLCUGKRAwAEL8OYuccDWg5voRLiJ1O7L2qARyO6VDmfkaR+GGbgTE6DPhIU3p5IdBO91qV0U6iz3icxDhBCoOkqmCzuHKUtOCxDcXOoppRUJalDDNxTKmU2FNTiO4rFbIFmGsyMDgWQegRDAT+5ddPUpiFGNVknAljwdgTDvxrOrPlDmrv+yoJigS67g0tNtmGIk3zcippOQUWeK6JJKpeCewmMlUhhwwXSxSgCqo8/+Kl1ppOzJdYJgYUlOtWMhIvS2uUsU0jDgVlrZHs20gscC5EwhsB3Lzgjyj0DyXFQ6SqUNVInDz2Ym1TCG4eI8iZlFZMOqUVrCy7Akq9h22dkdjqo0YaNNaLKFlbLFjFFMZO5QK0coqwP0lMAL+CwMOtfYA4dsVSmWhXhewF55XCPDLQAm9G8wXai/eQtjGxgS6/cuwPt5EfaHQ4yEXAcj6EjKS+1DkJxy5yVJG5o7NFuMp07fKzLsylrtsAyZ7mT9anqf0FHBIGWhtBudLRYt1ILgSrDkGhGuzCdTEOCeBOcxqeLIT9IASxaEAm29rQS28kuYiAC4Wd27B9QD9N1f/mizPejYDn5ugB7wlZCEEMUgzZHNUu4jJIV664mOWeA9m5E56+bAnYQwzF3hkRBCDuYcDFkMQikWmVMI7Xe3swbuGsA4brKj17R6HMy1H2Q3YCPKY7auyDuvSO2JpgFaSwjf0uGeDxbTPevRHnLSsoADyuF8ol9SUp5ACP0ii5VU05xSopuIoYolNda4jDUoyM074Ksb6GlmpfwM84AIfOMEL/m96GDzhCl+4wgfQbCOrzDcddU25BJ2bkkbjpATaEC7y6GiOIzQxtbkNW3sUScE4yxo/JeJiUhTN4iqIre6hNmaWJ4EA4DznOt85z3vu858DPeg5n8AEhG70oyM9/+kS0FtHfjOiD5E3YSxJJ1nE2SOOf9REgOa4xSkk1gSNpl3egAkvJPKKByxgECAiUF975BNb1vzh+sL5pHkccQThCeoH9BYvoIqA85ZVNzIyqlas5hVb4lRNv4yrl14hGJsJgJZOgY26cAlznbL1VPDmt9w5Rfe6b/mwi2GWrBgFDwXwvdqu7WyPJIsQ0YoXejBayIEJzCsDsyoWDGhJx3DlnFcwJVWXl1TJF3DmY4P+86B3tgoSMOgwNGSj+vJc3JPf+eVbbgVodwOx8eqk+O6n0vtRPvb7zOXyg178mCE/+pOQ7PZ3Wf0jYT/8icC+E8TZDAaw2ptrUD0k7F/SyP9fMdBf/QmBwXCP93zBL8jE/9VAyckXVxzaygwgMRSgAfJAMvTQDl2R8DBG2pQQBFCN7KDADj1F993aO/RaJ/EPNrzDvp3ACS0EKXgg4VBPifECX7xQItTOT13DU2xaLGxFZSBf3V0gBgLC5aTStsnLBc3cIOzINRhQh8FGHLGb6jDAu4XVwWjSQJ3bBx3UJO1Duo2SdmRFFMbEd4zFvOmTtXWVGlKbu1ke51kfEhYBqJySxrndkKSVHIEh23HFyVHb7l3EURUIDdrGVLkESH2dwsgGSwSehyyQy60d8ZVLdg0I5dShHQ4BHjbUYDUUpTTUuiDAN2FVcfHR2DHIFor/ImFIy/PtFSt+IqIsQizgCNqpXdRBHUbRoRFeHxJ64mkAnlNp1DzUon744ChIhJUQUA1BnuTxTXhliOLRRAJsVwH8FqSYCZp4ly2WS+UNRxm1nYFkxeL14qQdISdGCdzEFUGw2GpZCKwMUQlsFr2BE3/5xu6VAGz5HkKQGA3uCjN8UgmImFiRzMKMIo4E3wN4xemNoxjBA0OORAXqwi9i4Pv5X0sQyRXUTh2oAsqdo56lozrSAEbSgOdIwxUcXxsEn8hMpEXOH0zWn0mSpADKpAXeZPvRZE3yDEWGUE6i3/0hgQPWQP7FjQrAogwsmjCsJCEokfoAZSaMJE9uxuW0/0ArysL57SOd4QAsZmINKBk4oZXhQNo8QOUmUiUOJMNWUMJT+FALtRANZRoCBEtKBsQ7GIkQ/QU+9FAKBKEjqOCEoB5YEMbuoE5N9JANhqDa0IOMrZCmqc3ueFpddFfpuJAHwgDoOFou+GJaesKLtMJapJ4v+VK5bcc+yAsigqG4OQsqtNLVpZIUUEspUkwWCgZXCdM4CQoEKUoqmaE3TGYktFQYbssYEgU6uCG2qV0UScMo0cT9tIUT+KRURiX2gcotpF4rhpyszMkowNYfYp2OTFRbZc9pEOLKcUglepUX1khaieco8gMjFojFXR1DpRVNnJH7SGd1xgV/Jp9VEv9KdgqULg6IAESA+UgfocAVhEkiClzILZBdL6QnKo7TVxwKgxxjDT0KfMbiONKnm7SjtlCTImaBfwKKiaIjgNIPvHCQAASXeB3XPPRO1XCjh9FPdDVUd1jj9GRU5PFDNHaIRrgkcIBLUyFGGUlXV2SjQIhjwliTNtoJTd0aEkxnRaCoSF4OrizEszzLC/kKiR3YqMSDDtXoTGgpUUlMjnrIQFKJa9HCrgCpnbgNx3QHQqYVhU2MRxTkrDikk5oG7tnIK76MelDplb7BVHqmzmglE3zlDHSkfdZAjk0fE1RpfyYqGSxqEjSqUjro+Umqk+zoHRiqzIxql+3kpeJZqar/AaKiqtRkaqsyG1rCalUSGldqX57c0o0hQf81n66mgAHsDgmxwAQujq3umaqeAavC6syEpYWdYk/9xR8OpbTCF7XeUq6oDc2twKe2F5Eha8F8a5MFgvEoBazxAw4xhTUgQDrsqMZ02jW4oLmmgK8dpnf0mqsVXoSC10PgmrrEKwyaAKFizzkwwxAKVjR0FxayjjvIK0mE68887JDRAQbBSSrYTCkdCkycSWRRAoYkiSBUzReqwG6eSokZkzyYJhr+lXCam1OQjhe67ItUi4H+gwJkIVMJynVAIU8MJFPELB9U6h4oa6vSQSEdxAMMwIo41p0yg81gyDmNHIlSqMZt/2dazcJ7Ru00JmK4dSoJgKAxpp5ZZa2TRSzTlO3Y0MGD1soxyk0sMMVL1ec5uSKr+KVPnZg4WZw3LigMeB1u9G35WM2D5kbYJlhE0a3DyuqsblEKzEtMUIJ8nMkgOMW+7Qhq6AZZlBENSu5uSISQ/p1QQVKMeiOOUmOjbK4yxkEWFkuBaMmpDJ/Yni7Qni0WDC2qnk1s9YLEwMm0JADJVFsgNSTqACSuoJq23s6cBsU7hqk3QkWa2t7LPq89xsG0jOEnIAKsZISTim1Akm3iKq6iJsEc5cBGiuUXkC/6Be2Jfi+tFgFIFla1cKt0bmaYpW8ezO7TnOr69sz9zhP/Jv9N/uqv7HpvAFtZrc6UHQRgnfnqynCVL6gC1QyUS+jHZUJXohBkU7ZIZxIwCjDrfOwBA1KPtfZBWAZTS5xd2qxNsYjIWV2KNUSMI3wtVQ0wAY8rA3xMZibCQhDPdsgrqSmm4axOJPRDSmrmU7SQhLArKvywWkUmrtWOZvIQq8mlwkpuDgvVo9bQOsilWsEDFF6uS5CAbPCe4MZGJDjfVfqvkaUxz0zsBmnHc7LFZGibS1msNZ7sTilFxM0SndxTa+IPQvgSIhbLPvxmHBynHDYFdCrKuKFCyvLsPigyIk8DfpgmFxPAPlwKGsHZF30TGUPFXdRY3mjwBsNYChitgeT/5yQN0kOEU9KqjZIsAo1AIlI2EySBxnK4zzjOgnpghyz3F6Sep3WksrbcQtUqyDAHM8v5SEFx8Tw4H4mAgxdFgi1llydTitQ2wxr3mTavTNrOo1eM6NS509p+Cd7SIi0fiBpphYoYYisWc7ecM6R+wyquczVxHVpFyojOc9lV4VieFVlwmhnBgBftSEt48gKMGjbX7yVws8nQQeMqC5+UF0O4aLwlilAVqXeFaiBhV0bIymIARVcF1yegCjNkdKlQCjSCdIUinujq1Er76HKFhJfgVPnOw8ew1JKU0YaRcZKUQNqhLgihY0P/y+1GzOUKKoqgFkpERlKwnp2y6Tws/5aYjglk+aOvyISxbLJpQWrvwUdSmynG2MuCIRjxQZZXOwfJhGkzk8UKIxbDwJ38tEwDdNKuLES8iYnxWssMBzAA2wAWO2sdbOrNYNr5ZvBQk/J6mcHxNWsYDLbJ+HRQC7VIEvXcvWpid+8oY7ZfY/ax8rX+Io1yOMFSdvYDVvYdnraTAA0CJE88aWVjO0H8eh+WLfShpvb4sZc1aCvw2A5ZzAf/eMdd3yWrfUM4CNYTRUKqvRpgL4lONNFjqgI50OVkIjdZ6GBbM1GuDVltk2ppKwF7nYhLVpADQYxUGEC0dQUj70QAMYQYQhK4SXJIeFq08dJp2sfHSlJxStsa6v9PAhnb03A32Nz2+mVLPVHCS2kJRJGnTEyc92WTpAAUAHhcyhUibEASa4iRfHZncUU4o4AzLCNZgK/qgM+fbb01tTnIogjH002JpCgIWC0LOJzIPos2PImIXsH4Nv1zh4rVApkGKG43iWegkFugbXVnUtGcuBAVWLRJ3rW4LSkINoLXASdFTE9ee3WXovxWvZpQGUk5AXl4coOuj4l4shI506kA3G5LtKiWifWKIpCedJypQe0p7L2p71l4nO9pPanL6e0po0gW65H5mVMBoUvlZe/AY3v3DZQ5uHo3Z8+Aoi+6aX/2+kL6pOtYpX/vpWP6FTS6VRl6RdjWm9na1ej/Klfxcyrsjpe4kDstDqol9+QMAWnrQFLGwKKlh7ESwadD7KPb1muoipw8n6BUOJHUBVmwBr+qFS3Vwio9oPTANg1I+iooIkJlumYn9lVpSyamCPWxtYPMl7c7816aWhwkpvOAEXAvuw3vYL1ScaZVC9LiSzUOZhV5ibx7SWKw+7oSwl1IRZZpuuI2TyMFu9fOz3ZhLkF8RxzwXh9/jm9QkP50RSqtRC+ZNz268Xlw0npTB3qXgJnYzHDkJjHR8akUQsZvLHDdDgY3Aa9/Qe1eKj1F5D0xSMGPEbwYeHX4USn4bHIpUSmAqId5xi2TidEas041ODghrT0XF8bdrSuf/7L4Up+tU2qoc4HVC+2vl0LB11U0KRFXmCNToHTD3w7Qf3GL+5OBkMmD5q1O3fiyrUqGqmdgkTMrCO7b0pIrADy2k7K2+3jA3vt2acRYiP3nKNct8V7Q31FoebTK04pUhe5wGVSWx8HjvjF5+V1FywdE3/QEk30UuLzZ+npWephNwAMENBYVkgU0ueSOwINPfT4JfNHGJWiwvP6E+IoJwNZRr5ZYG1ScG0VTXy6KLbXuKgXunlYciHDVB/yscjoR7A7oiS8/qL4VhD6PYT2gIPoVDE2YuS9K/Lf1Z3+/jP8lbH+nU1r5m4T6y8z5oz/MNP+yKhOq6/q8LvAKNMT8Fv/B38EZCCCAQZTAiZQGwhjnC8fyTNf2jcNCkPf+DwQGeMGi8YhMygKCW2LRUCQVUuBApPQNIi5DZAAgNASPRgKgaCzOkGb2DT/t4vR6bGjP6/dMHAEc5rBw5TCwcKIwMOD2tEgQ9qjgwMBwZiAw8FD1QnAIAIEFGiOQQJq4CODwGAiAyYAlY9ikMBgG+OA2sApw4LL3azMHPByER3yMjNN38yc3kIAQIcUgReBCzfu40CTQlGkAcYiLBvjysBp9ySBTsJhgDUBdeDLgALGO4ECj25AN1hyviq4XAvQlIybsoMI7RBY6PLYsBgJFD2zJcVPgIoBSA8YgOKCxG4CBzbj/WIRRDs2BXgAeKBKR8QTHMQDMJOin4IACWLEIYBLQjMCXBhXp7fL5cE/CpAeNMX1qJ2INgCIBxOx2U183qty8PWoWE+CLlAYKuIkRM2urJuEeQDhBoMzZGLoMNCDxD4yAdUY5zYX6ZingYU4HG0YilQbXE1eBggSwzYuLcSJJgjnwaB6MNS8OOPDMDu7jbSMa3AWAwMW8BG9RHs17gkGuXVQOB25omw/u3LxzJJbxMULFqo0hHxggWyUDVJW/gvlIKSUaNwsqImjA0+qLBceTQy76ecABEeHovj5pQOeDCOPpnel9RDD8OIXn27/zF46vBZtm+KIlA0tImEHDK1l0/3JfEfIlmER9DNr32xvcHVBUDWko4gsMn2UYBIA0VIjEde892MOCJBbh4Im8Rahii/CZ6GIPKcY4GIs03ggVjDjWMOOOSdnoY5DJ6CgkDD0W2VR+SC4JDJFLHskkMUBGSeVtVc4A5ZV6TKlll0A4iWSWXtLB5ZhmBrOblmKemUWZbL5JUJpXrgnnEW7WySaYRdKJZzFK9tmnnkLyCagPdxbapaBBEoqoMot0A2mkkk5KaaWWXopppppuymmnnn4KqqYDyFklo43aIMEQqq7KaquuvgprrLLOSqusE0xQa6667sprr6pKcKappw67BKnEMinssccmq+yJzDbb6LPQJv8o7bR9VmstfNhme6YGBXxbgAfchmnsuMpaAG4BHJg7aLnsDltBuh286+O29FZJQboX3IujvfxGmcG3Gvx7o78EI7nBtxYcHKPBDAeJwbcVPNyiwxTv+C0FFzvr7sZsTpCBxyRaLLKLAWxQMoMkp3ziBRiwfN/KMM9Mscw03/yvzTjvzK7OPP9src9spupr0UYfjXTSSi9dK7DBdnxvAI+GSnXVVl+NddZaYzoqm0IH+yfQgCm6KNT0Hir2QWTXa/a7aKeNzNo7fm3m23Aj1Ha7Jdt9d5N5l7132H07JHe/f4/7Wwkj7uPjA9nFUNsLCZzheBhHGDDI4zWkNoN0qXT/ozknHMbp9eHc/vbTDTHtMdAwrdNQFSJSDAQbEAu8NboNlYcGwwMMEJDILhKZNUPhBZuebYQiKXBGAlUkskBYlJAywiBuSELJJQO0xkI9chRyyE2kwQB98wpg0honglyxkQJIEUDJKotkTw4qrSyQOSQjPcLNGARA8J6dwKARUhDfXE7RBARw7y3Ma4kiDLI6xsDABQXJxHYE0A8ZGI9GdBuT8rxikUkYIAEZScABEpCeR2CmJd54ADgwY5fJndAAAynANBSQHggITwEtEEMYGmANAhFkACuIQBgiIJubTI5AqLhHGK4hhb0UcS37005OCJCAcUgGBkA0ADVyKDx4/2BDNl4QwUD0EUPtoIQBDhhRAfTBgNZwoT2jQN7xAlc8EDaDjRKEQFF0cZ1u1MIyRoHAo1BRnNfFRn4pAIQiq6ILgLRBDm9pXQkxQRNI+gSEGQHITdDgCRQAAn5VHCAmm5AenfQlLlt4RARHcI8GsCQsYJjEJ0AkBztyUJfQ+mAVm2FJKu6PAJgpgRmdYxQBLKAEWFRjc8xjFIA8cjaLoaIl1SISTT6zk+WgBh3hMkowKBKbbliPL3TxmWOqcQakoSVkGiCeDOqAlyajp7Ii5JZ46CMRLBxBRjQDwwhgQZ3SLMFpUONMbxjkBX4szUmmOQIjAuQj9FDnJIh5AtKIxP8L1nRlGB7zQ8+ZRACVDONomvCZzySzIilc5wnSh42Y5NMkvMjOBhtmz2X9ZTlEDGktaLgImR4ACo/4iHj06MhIHAc0xQnPBCekj4LqAJ6gEYsAVpKL47CPO8jpn3i0wkl6DKAKDVjoCz4zVBco0jhdFRFkDlGX7qzwlVA4KmPEswAD2PKluLxpPfGIBF8IMUeCA8YnDfPKG/i1YjklFt9eQNX+PCV2CuHPYRKLptIBdnBja+zIPHuqx3LWDotVUQe9JNrR0qG0HNusapPC2s+69rWEA63KbIsoqW1tt7ztrW9/+6muPa1kRGOacY9rK1whd7nMXZXT6oZb2jLltK//pa50dXNdZFg3u1GJLneL9V3DhRcY2x3vG8o7OPSat0HeXa9612un9pr3vfBFkXzHS1+cFbe5rLoVf131XM7m92b7/a+BYRXg9N6XtgPubnUX/GAqNfhaEFbthMlU4dNlWMAbVsiF6/RhkXkLXOIq0oi/VWIF1zcJ6ALXuorU4m+9WMUrPkK8wDWvIt34WzmmcY2LkC9w7atIQf7WkH384yAErAADW9KSm8zhJBshYQVY2JKobOUoSzkIESvAxJbU5S9rectAyFiUzDzaEJcMZFRis4U73LeTSRhlbyZzEFxGJTzX2c58jpKa+wzo+AZ60GzjboEPfLQEUwDRjJ6V/8YcC2fETQ24WhPuCyQwBkpr2lMNSHBuI326whpGMBLwXJQG4OlC/RlPqR3SbkrtJVQvC9TJE/VgSG1qJska0txtddxenesl7XpYqwaxrTsbA1h3adihpXXQjp0jYMc61YAqNpymBA/FzAABuDTA+QBYAxIoVtoyYA1QOoeEynGODiu4AbOj5expAQkBxGOcDMRyggMABQLylAEECiA8DZKbfJ6BnydWh1ktPGJ3ceC2u6lNgQpYAMrQ7bXgtpFBBxhE463YyCAMhG+xuMB5mNjEGEJZvIG/IAIjwg4BzCKFNxriBJiz3050CAP4MQCIaKDcA+EyvTNgrxIj+EkXBv+RV+ehZjn5eTcGNrDkb73J2lMX3BxFYBeDuqCEIrjOSWgunGyLITXYQU0vjFgDXMcAo+YgBcBhcsNs9LMj55bJDFd4xtLIEIV4d2F5NHqIOKaikQAQKDhiAawLBGAC6UpXox9vq3j3Mmy2bChqZImFmNBiANyMAUcicIjF5JOPsFP516mI8IsEUpniDLjlafcVl0Tgf398BCHRXnjIsPEMzSBKtlECrKdHvfGQL/6rqC3gsNX1API8zgsy8gDOdJ4GQFyMLDuC8jomWzqHjU3Mn38RYjJTnTqYzf7SuT9N/hIMqQfl7JsBDgbQdCwBjvjE00XouYWNpu15gP+LkhH/3kNCp5cCNGcGADEeFBVRaWd6I8E9JlEAvtAYZYQCpXRWgIB3PsFSmAFQtodMfERKq4ALQZFvAfduL3ABHcABKZZ/DfMne3VLOTECqpQR15EJ0ycTO/dVR2RX+RQbZjVP2ycDNfcSckAhCWV2drVWLTFUGZgeyLFCDzBUPEdIE1GEV4Uhe7QSuDQSyNeC9QJtcYBvPqB2gyFYiwMHJ/iFgxKGcDCGJdKASRFZeaCGawiGDFKGWlKHdtgvbQhbcahrXsiHLoiHgChsgjiIFeOHD5GHV7KHiWgyi1hbQrhsiAiJIzNpm2Y1lnYCmKaJn5gpnXaJQXJoxpcrimaKxvdoMKPIiq3oiq8Ii7Eoi7NIi7Voi7eIi7moi7vIi73oi78IjMEojMNIjMVojMeIjBQTAgA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The figure shows an algorithmic approach to the diagnosis of spondyloarthropathy (SpA) in clinical practice. This approach was developed for the primary care physician or others with limited experience in evaluating patients for early inflammatory disease of the spine. Percentages in brackets indicate the probability of axial SpA before (pretest probability) and after a test has been performed (post-test probability).",
"    <div class=\"footnotes\">",
"     * Suspicions for SpA could be the presence of several other clinical features.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rudwaleit M, van der Heijde D, Khan MA, et al. How to diagnose axial spondyloarthritis early. Ann Rheum Dis 2004; 63:535. Copyright &copy; 2004 BMJ Publishing Group.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_2_29743=[""].join("\n");
var outline_f29_2_29743=null;
